Study ID: [REMOVED]
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, 
Tolerability, and Pharmacokinetics of TAK-510 in Healthy Subjects
Study Number: TAK-510-1001
Document Version and Date: Amendment 3; 21 April 2022
Certain information within this document has been redacted (ie, specific content is masked irreversibly 
from view with a black bar) to protect either personally identifiable information or company 
confidential i nformation. Clinical Study Protocol
TITLE PAGE
TAKEDA DEVELOPMENT CENTER AMERICAS, INC 
PROTOCOL
A Randomized, Double -Blind, Placebo -Controlled, Phase 1 Study to Evaluate the Safety, 
Tolerability, and Pharmacokinetics of TAK -510 in Healthy Subjects
Study Identifier: TAK-510-1001
Compound: TAK-510
Date: 21April 2022
Version Number: Amendment 3
Amendment History:
Date Amendment NumberAmendment Type (for regional 
Europe purposes only) Region
21April 2022 Amendment 3 Substantial Global
02 September 2021 Amendment 2 Substantial Global
19 May  2021 Amendment 1 Substantial Global
02 December 2020 Initial protocol Not applicable Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduc t of the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 2of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTABLE OF CONTENTS
1.0 STUDY SUMMARY ...................................................................................................... 9
1.1 Protocol  Amendment 3 Summary  of Changes .......................................................... 14
2.0 STUDY SCHEMATIC .................................................................................................. 21
3.0 SCHEDULE OF STUDY PR OCEDURES .................................................................... 22
3.1 Part 1 for SRD Cohorts 1 to 12 and 21 to 25 ............................................................ 22
3.2 Part 2 for MRD Cohorts 13 to 17 and 26 to 28: Screening Through Day 9, 
Follow-Up, and Early Terminat ion........................................................................... 25
3.2.1 Overall Schedule of Study  Procedures for Part 2 .............................................. 25
3.2.2 Part 2 for MRD Screening Through Day 1 Assessments .................................. 29
3.2.3 Part 2 for MRD Day s 2 to 4 Assessments ......................................................... 32
3.2.4 Part 2 for MRD Day  5 Through Day  9 Assessments, Follow -Up, and Early  
Terminat ion..................................................................................................... 34
3.3 Part 3 for Dose Titration and Redosing Cohorts 18 to 20: Screening Through Day  
15, Follow -Up, and Early Terminat ion..................................................................... 37
3.3.1 Overall Schedule of Study  Procedures for Part 3 .............................................. 37
3.3.2 Part 3 Screening Through Day 1 Assessments .................................................. 41
3.3.3 Part 3 Day s 2 to 6 Assessments ........................................................................ 44
3.3.4 Part 3 Day  7 and Day  8 Assessments ............................................................... 46
3.3.5 Part 3 Day  9 Through Day  15 Assessments, Follo w-Up, and Early 
Terminat ion..................................................................................................... 48
4.0 INTRODUCTION ......................................................................................................... 51
4.1 Background ............................................................................................................. 51
4.2 Rationale for the Proposed Study ............................................................................. 51
4.3 Benefit/Risk Profile .................................................................................................51
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 53
5.1 Study  Objectives ...................................................................................................... 53
5.1.1 Study  Primary  Object ive.................................................................................. 53
5.1.2 Study  Secondary  Object ives............................................................................. 54
5.1.3 Study  Expl oratory  Object ives.......................................................................... 54
5.2 Endpoints ................................................................................................................. 55
5.2.1 Primary Endpo int............................................................................................. 55
5.2.2 Secondary  Endpo ints....................................................................................... 55
5.2.3 Exploratory  Endpo ints..................................................................................... 56
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 56
6.1 Study  Design ........................................................................................................... 56
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 3 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL6.1.1 Overall Study Design .......................................................................................56
6.1.2 Part 1: SRD Cohorts 1 to 12 and 21 to 25 .........................................................59
6.1.3 Part 2: MRD Cohorts 13 to 17 and 26 to 28 .....................................................60
6.1.4 Part 3: Dose Titration a nd Redosing Cohorts 18 to 20...................................... 62
6.2 Stopping Rules .........................................................................................................64
6.2.1 Stopping Cr iteria for Individual Subjects .........................................................64
6.2.2 Criteria for Pr emature Termination or Suspension of the Study ........................64
6.3 Rationale for Study Design, Dose, and E ndpoints .................................................... 66
6.3.1 Rationale of St udy Desi gn ...............................................................................66
6.3.2 Rationale for Dose...........................................................................................66
6.3.2.1 FIH Starting Dose Consideration Based on Nonclinical Safety Study
Results,Experience...............................................................................................66
6.3.2.2 FIH Maximum Dose Consideration .........................................................68
6.3.2.3 FIH Proposed Dose Reg imen for the SR D Cohorts ..................................68
6.3.2.4 Rationale for Dosi ng Interva l...................................................................69
6.3.2.5 Rationale for Dose Titration and Redosing Af ter Washou t.......................69
6.3.3 Rationale for Endpoints ...................................................................................70
6.3.4 Critical Procedures Based on Study  Objectives: Timing of Procedures ............70
6.4 Procedure Modifications Permitted Within Protocol Parameters ..............................70
6.5 Study Beginning and End/Completion .....................................................................70
6.5.1 Definition of Begi nning of the Study ...............................................................70
6.5.2 Definition of E nd of the Study .........................................................................70
6.5.3 Definition of Study Discontinuation.................................................................71
6.5.4 Criteria for Pr emature Termination or Suspension of the Study ........................71
6.5.4.1 Criteria for Premature Termination or Suspension of Study .....................71
6.5.4.2 Procedures for Premature Terminati on or Suspension of the St udy..........71
6.5.5 Criteria for Pr emature Termination or Suspension of a Site ..............................71
6.5.5.1 Crite ria for Premature Termination or Suspension of a Site......................71
6.5.5.2 Procedures for Premature Terminati on or Suspension of a S ite................71
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS ..............72
7.1 Inclusion Criteria .....................................................................................................727.2 Exclusion Criteria ....................................................................................................73
7.3 Excluded and Allowed Concomitan t Medications, Supplements, and Di etary
Products ...................................................................................................................75
7.3.1 Concomitant Medications ................................................................................75Property of Takeda: For NiNon-Commercial Use Only and Subject..............
...............
r the SRthe 
l.............
on and on and
...........
sed on Sed on 
PermittPermi
End/CoEnd/C
BeginnBegin
n oof f EndEn
tioon on fto the Applicable Terms of Use600
.......6262
..............
...............
............
.............
...............
.............
onclinionclin
teria foeria fi
4.14.1 C
.5.4.2.5.4.2
.5.55.5
6
7.07.0ct to
TAK -510
Study ID TAK -510-1001 Page 4of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL7.3.2 Fruit Juice........................................................................................................ 75
7.3.3 Alcoho l............................................................................................................ 75
7.3.4 Caffeine ........................................................................................................... 75
7.3.5 Smoking .......................................................................................................... 75
7.4 Diet, Fl uid, Act ivity.................................................................................................76
7.4.1 Diet and Fluid .................................................................................................. 76
7.4.1.1 Part 1 ....................................................................................................... 76
7.4.1.2 Part 2 and 3 .............................................................................................. 76
7.4.2 Activity........................................................................................................... 76
7.5 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 76
7.6 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 77
7.7 Subject Replacement ................................................................................................ 77
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 78
8.1 Clinical Study  Drug .................................................................................................78
8.1.1 Clinical Study  Drug Labeling .......................................................................... 78
8.1.2 Clinical Study  Drug Inventory  and Storage ...................................................... 78
8.1.3 Clinical Study  Drug Blinding ........................................................................... 78
8.1.4 Randomization Code Creation and Storage ...................................................... 79
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure .................................79
8.1.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ............................. 79
8.2 Ancillary  Supplies ................................................................................................... 80
9.0 STUDY PROCEDURES ............................................................................................... 80
9.1 Administrative Procedures ....................................................................................... 80
9.1.1 Inform ed Consent Procedure ............................................................................ 80
9.1.1.1 Assignment of Screening and Rando mizat ion Numbers ........................... 80
9.1.1.2 Study  Drug Assignment ........................................................................... 81
9.1.2 Inclusio n and Exclusio n................................................................................... 81
9.1.3 Medical History /Dem ography .......................................................................... 81
9.1.4 Concomitant Medications ................................................................................ 81
9.2 Clinical Procedures and Assessments ....................................................................... 81
9.2.1 Full Physical Examinat ion............................................................................... 81
9.2.2 Height and Wei ght........................................................................................... 81
9.2.3 BMI ................................................................................................................. 81
9.2.4 Vital Signs....................................................................................................... 81
9.2.4.1 Follow-Up Safet y Moni toring .................................................................. 83
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 5of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL9.2.5 Glucose ........................................................................................................... 84
9.2.6 ECG Procedure ................................................................................................ 84
9.2.6.1 Screening and Safety ECGs ..................................................................... 84
9.2.6.2 Telemetry ................................................................................................ 84
9.2.7 Study  Drug Administration .............................................................................. 85
9.2.8 AE Monitoring ................................................................................................ 85
9.2.9 Laboratory  Procedures and Assessments .......................................................... 86
9.2.9.1 Hem atology............................................................................................. 86
9.2.9.2 Chemistry ................................................................................................ 86
9.2.9.3 Urinalysis ................................................................................................ 87
9.2.9.4 Diagnostic Screening ............................................................................... 87
9.2.10 PK, Immunogenicit y, Bi omarker, and DNA Samples ....................................... 87
9.2.10.1 PK Measurements .................................................................................... 88
9.2.10.2 Immunogenicit y (ADA) Measurements ................................................... 90
9.2.10.3 Biomarker Measurem ents........................................................................ 91
9.2.10.4 DNA Measurements ................................................................................ 91
9.3 Confinement ............................................................................................................ 92
9.3.1 Part 1 (SRD) .................................................................................................... 92
9.3.2 Part 2 (MRD) ................................................................................................... 92
9.3.3 Part 3 (Dose Titration and Redosing) ............................................................... 92
9.4 Childbearing Status and Methods of Contraception .................................................. 93
9.4.1 Women of Childbearing Potential .................................................................... 93
9.4.1.1 Definit ion of Women of Childbearing Potential ....................................... 93
9.4.2 Women of Nonchildbearing Potenti al.............................................................. 93
9.4.2.1 Contraception for Wo men of Nonchildbearing Potent ial.......................... 93
10.0 ADVERSE EVENTS .................................................................................................... 93
10.1 Definit ions and El ements of AEs ............................................................................. 93
10.1.1 SAEs ............................................................................................................... 95
10.1.2 AEs of Special Interest ..................................................................................... 96
10.2 AE Procedures ......................................................................................................... 96
10.2.1 Assigning Severit y/Intensit y of AEs ................................................................ 96
10.2.2 Assigning Causalit y of AEs ............................................................................. 96
10.2.3 Start Date ......................................................................................................... 97
10.2.4 EndDate .......................................................................................................... 97
10.2.5 Pattern of Adverse Event (Frequency) .............................................................. 97
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 6of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL10.2.6 Action Taken Wit h Study  Treatm ent................................................................ 97
10.2.7 Outcom e.......................................................................................................... 97
10.2.8 Collect ion and Reporti ng of AEs, SAEs, AESIs, and Abnormal LFTs ............. 98
10.2.8.1 Collect ion Peri od..................................................................................... 98
10.2.8.2 Reporting AEs ......................................................................................... 98
10.2.8 .3Reporting SAEs ....................................................................................... 99
10.2.8.4 Management of Specific AEs .................................................................100
10.2.8.5 Reporting of Abnormal LFTs .................................................................101
10.2.9 Safety Reporting to Invest igators, IRBs and/or IECs, and Regulatory 
Authori ties..................................................................................................... 101
11.0 STATISTICAL METHODS ........................................................................................ 101
11.1 Statistical and Analyt ical Plans .............................................................................. 101
11.1.1 Analysis Sets .................................................................................................102
11.1.1.1 Safety Analysis Set ................................................................................ 102
11.1.1.2 PK Analysis Set ..................................................................................... 102
11.1.1.3 Immunogenicit y Analysis Set................................................................ 102
11.1.2 Analysis of Demography  and Other Baseline Characterist ics......................... 102
11.1.3 PK Analysis ................................................................................................... 102
11.1.4 Safety Analysis .............................................................................................. 103
11.1.4.1 AEs ....................................................................................................... 103
11.1.4.2 Clinical Laboratory  Evaluat ions............................................................. 103
11.1.4.3 Vital Signs............................................................................................. 103
11.1.4.4 ECG ...................................................................................................... 104
11.1.4.5 Other Safet y Param eters ........................................................................ 104
11.1.5 Immunogenicit y Analysis .............................................................................. 104
11.1.6 Biomarker Analysis ....................................................................................... 105
11.2 Interim Analysis ................................ .................................................................... 105
11.3 Determinat ion of Sample Size ................................................................................ 105
12.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................. 105
12.1 Study -Site Moni toring Visit s................................................................................. 105
12.2 Protocol  Deviat ions................................................................................................ 106
12.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions.............................. 106
13.0 ETHICAL ASPECTS OF T HE STUDY ...................................................................... 106
13.1 IRB and/or IEC Approval ...................................................................................... 107
13.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion....................... 107
13.3 Subject Confidentialit y.......................................................................................... 109
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 7of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL13.4 Publicat ion, Di sclosure, and Clinical Study  Registrati on Policy ............................. 109
13.4.1 Publicat ion and Disclosure ............................................................................. 109
13.4.2 Clinical Study  Registrati on............................................................................ 109
13.4.3 Clinical Study  Resul ts Discl osure.................................................................. 110
13.5 Insurance and Co mpensation for Injury .................................................................. 110
14.0 ADMINISTRATIVE AND R EFERENCE INFORMATION ....................................... 110
14.1 Administrative Informat ion.................................................................................... 110
14.1.1 Study  Contact Informat ion............................................................................. 110
14.1.2 INVESTIGATOR AGREEMENT .................................................................111
14.1.3 Study -Related Responsibilit ies....................................................................... 112
14.1.4 List of Abbreviat ions..................................................................................... 112
15.0 DAT A HANDLING AND RE CORDKEEPING .......................................................... 114
15.1 Case Report Forms (Electronic and Paper) ............................................................. 114
15.2 Record Retention ................................................................................................... 114
16.0 REFERENCES ............................................................................................................ 115
17.0 APPENDICES ............................................................................................................. 117
LIST OF IN -TEXT TABLES
Table 3.a Part 1 for SRD Cohorts 1 to 12 and 21 to 25 ....................................................... 22
Table 3.b Part 2 f or MRD Cohorts 13 to 17 and 26 to 28: Screening Through Day 9, 
Follow-Up, and ET ............................................................................................ 25
Table 3.c Part 2 for MRD Screening Through Day 1 Assessments ..................................... 29
Table 3.d Part 2 for MRD Day s 2 to 4 Assessments ........................................................... 32
Table 3.e Part 2 for MRD Day  5 Through Day  9 Assessments, Follow -Up, and ET ........... 34
Table 3.f Part 3 for Dose Titration and Redosing Cohorts 18 to 20: Screening Through 
Day 15, Follow -Up, and ET ............................................................................... 37
Table 3.g Part 3 Screening Through Day 1 Assessments .................................................... 41
Table 3.h Part 3 Day s 2 to 6 Assessments .......................................................................... 44
Table 3.i Part 3 Day  7 and Day  8 Assessments .................................................................. 46
Table 3.j Part 3 Day  9 Through Day  15 Assessments, Follo w-Up, and ET ........................ 48
Table 6.a Overview of Treatment Cohorts ......................................................................... 58
Table 6.b Hum an Dose- Related Concentrations an d Exposures for Select Proposed Doses 
in Part 1 ............................................................................................................. 69
Table 9.a Primary Specimen Collections ........................................................................... 88
Table 10.a NCI CTCAE ...................................................................................................... 96
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 8of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALLIST OF IN -TEXT FIGURES
Figure 2.a Study  Schemat ic................................................................................................ 21
LIST OF APPENDICES
Appendix AResponsibilit ies o f the Invest igator ................................................................... 117
Appendix B Elements of the Subject Informed Consent ....................................................... 119
Appendix C Invest igator Consent to the Use of Personal Information .................................. 122
Appendix D Pregnancy and Contraception ........................................................................... 123
Appendix E Protocol  History............................................................................................... 126
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 9of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL1.0 STUDY SUMMARY
Name of Sponsor:
Takeda Development Center Americas, Inc, (TDC Americas)
95 Hayden Avenue
Lexingto n, Massachusetts USA 02421
Telepho ne: +1 (617) 679- 7000 Compound:
TAK -510
Study Identifier: TAK -510-1001 Phase: 1
Protocol Title: A Randomized, Double -Blind, Placebo -Controlled, Phase 1 Study to Evaluate the Safety, 
Tolerability, and Pharmacokinetics of TAK -510 in Healthy Subjects
Study Design:
This is a phase 1, randomized, double -blind, placebo -controlled study to evaluate the safety, tolerability, and 
pharmacokinetics (PK) of TAK -510 in healthy subjects. 
The study  will consist of 3 parts:
Part 1 is a first -in-human, randomized, double -blind, placebo -controlled, single rising dose (SRD) design to
assess the safety, immunogenicity, tolerability, and PK of TAK -510 in healthy subjects. Up to 17 cohorts may be
enrolled.
Part 2 is a randomized, double -blind, placebo -controlled, multiple rising dose (MRD) design to assess the safety,
immunogenicity, tolerability, and PK of TAK -510 in healthy subjects. Up to 8 cohorts may be tested in
independent subject cohorts.
Part 3 is a randomized, double -blind, placebo -controlled, multiple -dose, dose titration and redosing design to
assess the safety, immunogenicity, tolerability, and PK of TAK -510 in healthy subjects. Up to 3 cohorts may be
tested in independent subject cohorts using a dose titration design, followed by redosing with a single dose of
study drug after a 7-day washout (168 hours after the previous dose).
TAK -510 and matching placebo will be administered subcutaneously (SC). Safety will be assessed by monitoring for 
adverse events (AEs), vital signs, electrocardiogram (ECG)/telemetry, safety labora tory assessments after each dose, 
and immunogenicity. PK sampling times and scheme may vary based on emerging safety, tolerability and PK data, but 
the maximal number of samples or the maximum time point will not change. Subjects may not participate in more than 
1 part or dosing cohort of the study.
Study Primary Objective:
Part 1:
–To characterize the safety and tolerability of single SC doses of TAK -510 in healthy subjects.
Part 2:
–To characterize the safety and tolerability of multiple SC doses of TAK -510 in healthy subjects.
Part 3:
–To characterize the safety and tolerability of multiple SC dose regimens of TAK -510 that include titration
from lower doses in healthy subjects.
Secondary Objectives:
Part 1:
–To characterize the PK of TAK -510 in plasma follow ing single SC doses in healthy subjects.
–To assess the immunogenicity of TAK -510 following single SC doses in healthy subjects.
–To characterize the PK of TAK -510 in urine following single SC doses in healthy subjects.
Part 2:
–To characterize the PK of TAK -510 in plasma following multiple SC doses in healthy subjects.
–To assess the immunogenicity of TAK -510 following multiple SC doses in healthy subjects.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 10of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL–To characterize the PK of TAK -510 in urine following multiple SC doses in healthy subjects.
Part 3:
–To characterize the safety and tolerability of single SC rechallenge doses of TAK -510 after a washout from 
multiple SC dose regimens that include titration from lower doses in healthy subjects.
–To assess the immunogenicity of TAK -510 following multiple SC dose regimens that include titration from 
lower doses, washout, and redosing in healthy subjects. 
Study Subject Population: Healthy  male and female (nonchildbearing potential only) subjects aged 18 to 55 years, 
inclusive, at screening. Body mass index ≥18 and ≤30.0 (kg/m2) at the screening .
Planned Number of Subjects:
Part 1: Up to approximately 136 subjects.
Part 2: Up to approximately 64 subjects.
Part 3: Up to approximately 24 subjects.
Approximate values do not account for potential 
replacement of subjects who withdraw for nonsafety 
reasons.Planned Number of Sites:
Up to 2 sites.
Dose Levels:
Part 1: TAK -510 SRD: starting dose 5 μg
Part 2: TAK -510 MRD: doses to be determined based 
on Part 1.
Part 3: TAK -510 Dose Titration and Redosing: doses 
to be determined based on Parts 1 and 2. Route of Administration:
Subcutaneous (SC)
Duration of Treatment:
Part 1: 1 day.
Part 2: 5 days.
Part 3: 15 days (7 days plus 1 day after 7 days of 
washout.)Plan ned Study Duration :
Approximately 57 days from screening (Day -28) until last 
follow -up visit (Day 29).
Main Criteria for Inclusion:
In order to be eligible for study participation, the subject must: 
1.Understand the study procedures and agree to participate by providing written informed consent.
2.Be willing and able to comply with all study procedures and restrictions.
3.Be a healthy  man o r woman of nonchildbearing potential aged 18 to 55 years, inclusive, at the screening visit.
4.Continuous nonsmoker who has not used nicotine -and tobacco -containing products for at least 3 months prior to 
dosing and throughout the study.
5.Have a body mass index ≥18 and ≤30.0 (kg/m2) at the screening visit.
6.Be judged to be in good health (eg, no evidence of psychiatric, hepatic, renal, pulmonary, or cardiovascular 
disease) by the investigator, based on clinical evaluations including laboratory safety tests, medical history, 
physical examination, ECG, and vital sign measurements performed at the screening visit and before
administration of the initial dose of study drug or invasive procedure.
Main Criteria for Exclusion:
The subject must be excluded from participating in the study if:
The subject has participated in another investigational study within 4 weeks (or based on local regulations) or 
within 5 half -lives of the investigational product before the screening visit. The 4 -week or 5 half -lives window 
will be derived from the date of the last study dose and/or AE related to the study procedure in the previous study 
tothe screening visit of the current study.
The subject has a history  of significant multiple and/o r severe allergies (eg, food, drug, latex allergy ) or has had an 
anaphy lactic reaction or significant intolerance to prescription or nonprescription drugs or food.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 11of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALThe subject has a positive pregnancy test or is lactating or breastfeeding.
The subject is unable to refrain from or anticipates using all medications including herbal medicines beginning 
approximately 7 days before administration of the first dose o f study drug, throughout the study until 2 days after 
discharge.
The subject has a history or presence of: 
–3 or mo re incidences of vasovagal syncope within the last 5 years prior to screening; or
–A family history of unexplained sudden death or channelopathy; or
–Brugada syndrome (ie, RBBB pattern with ST -elevation in leads V1-V3); or
–Cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, sick 
sinus syndrome, pulmonary congestion, symptomatic or significant cardiac arrhythmia, second -degree 
atrioventricular (AV) block type 2, third degree AV block, prolonged QT interval with Fridericia correction 
method (QTcF) interval, hypokalemia, hypomagnesemia, or conduction abnormalities; or
–Risk factors for Torsade de Pointes (eg, heart failure, cardiomyopathy, or family history of Long QT 
Syndrome); or
–Any clinically  significant ECG findings or medical history including: long or short QTcF (over 450 msec or 
less than 360 msec), bifascicular block or QRS ≥120 msec or PR interval >210 msec at screening or Day -1 
pre-Hour 0; or
–The subject has a documented history of sinus bradycardia (<45 beats per minute [bpm]) based upon vital 
signs assessments, sinoatrial block as evidenced on ECG or sinus pause ≥3 seconds o n ECG or predose 
telemetry.
The subject has an average semirecumbent BP less than 90/60 mm Hg or greater than 140/90 mm Hg from 
screening to predose, inclusive. Any assessments on Day -1, where 2 consecutive time point values do not meet 
this criterion, must be discussed with the medical monitor for approval. 
The subject has an average HR <55 or >100 bpm from screening to predose, inclusive. Subjects with an average 
HR <55 bpm can be enrolled only with medical monitor approval. Any assessments after admiss ion with an 
average HR <55 bpm, from Day -2 to predose (inclusive), will be left to the judgment of the investigator, unless 
HR is <50 bpm, which must be discussed with the medical monitor for approval.
The subject has orthostatic hypotension defined as a decrease in systolic BP ≥20 mm Hg or a decrease in diastolic 
BP ≥10mm Hg atapproximately 3 minutes of standing when compared with BP from the semirecumbent position 
at screening to predose assessments, inclusive. In asymptomatic subjects, any assessments after screening that do 
not meet this criterion may be repeated after the subject has remained in the semirecumbent or supine position for 
15 minutes. If the repeat assessment is exclusionary based on the above criterion, the subject will not be eligible.
If the repeat assessment is not exclusionary, the subject will be eligible.
The subject has postural orthostatic tachycardia, defined as an increase of >30 bpm or HR >120 bpm at 
approximately 3 minutes of standing, at screening to predose assessments, inc lusive. Any assessments after 
screening that do not meet this criterion may be repeated with the subject remaining standing for up to a total of 5 
minutes, provided that the subject remains asymptomatic. If the repeat assessment occurring within 5 minutes is 
exclusionary based on the above criterion, the subject will not be eligible. A confirmed orthostatic increase of >30 
bpm, but <40 bpm, on 1 or more Day -1 assessments may not be considered exclusionary if not considered 
clinically significant by the inv estigator and the medical monitor. Such assessments must be discussed with the 
medical monitor prior to determination that the subject is eligible to proceed.
Main Criteria for Evaluation and Analyses:
The primary endpoint of the study is:
Safety and tole rability as assessed through vital signs, ECG, laboratory assessments, and AEs.
The secondary endpoints will be assessed through evaluation of the following parameters: 
Part 1: plasma PK parameters for TAK -510
–Maximum observed plasma concentration (C max).
–Area under the plasma concentration -time curve from time 0 to infinity (AUC ∞).
–Area under the plasma concentration -time curve from time 0 to time of the last quantifiable concentration 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 12of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL(AUC last).
–Time of first occurrence of C max(tmax).
–Terminal disposition phase half -life (t 1/2z).
–Apparent clearance after extravascular administration (CL/F).
–Apparent volume of distribution during the terminal disposition phase after extravascular administration 
(Vz/F).
Part 2: plasma PK parameters for TAK -510 on Day 1
– C max, tmax, and area under the plasma concentration -time curve during a dosing interval, where tau (τ) is the 
length of the dosing interval (AUC τ).
Part 2: plasma PK parameters for TAK -510 at steady state
–AUC τ, Cmax, tmax, t1/2z, CL/F, V z/F, observed plasma concentration at the end of a dosing interval (C trough), 
accumulation ratio based on AUC τ(Rac[AUC] ), calculated as AUC τat steady state/AUC τafter a single dose, 
and accumulation ratio based on C max(Rac[Cmax] ), calculated as C maxat steady  state/ Cmaxafter a single dose.
Parts 1 and 2: urine PK parameters for TAK -510
–Amount of drug excreted in urine from time 0 to time t (A et). 
–Amount of drug excreted in urine from time 1 to time 2 (A et1-t2). 
–Amount of drug excreted in urine during a dosing inte rval (τ) at steady state (Ae τ).
–Fraction of administered dose of drug excreted from urine from time 0 to time t (f e,t). 
–Renal clearance (CL R).
Part 3:
–Safety and tolerability of single SC rechallenge doses after a washout from multiple SC dose regimens of
TAK -510 as assessed through vital signs, ECG, laboratory assessments, and AEs.
All parts of the study:
–Status of subject’s antidrug antibody (ADA) assessment (ie, ADA -negative or ADA -positive, and low or 
high ADA titer). 
Statistical Considerations:
Safety analyses will be based on the safety analysis set (defined as all subjects who are randomized and receive at least 
1dose of study treatment). No formal statistical tests or inference will be performed for safety analyses. All summary 
analy ses will be performed by placebo, TAK -510 dose level (Parts 1 and 2 only)/dose regimen (Part 3 only), and 
TAK -510 overall within each part of the study separately. In particular, the number and percentage of subjects with at 
least 1 postdose value meeting the spons or’s markedly abnormal criteria for BP and HR will be provided. Placebo data 
will be pooled across cohorts within each part of the study. The same dose level (Parts 1 and 2 only)/dose regimen 
(Part 3 only) will be pooled across cohorts within each part of the study  where appropriate. For Part 3 only, similar 
safety summary analyses (excluding ADA assessments) will be performed for the single dose after washout from 
multiple dose regimens of TAK -510 by placebo, TAK -510 single dose level after washout, and TA K-510 single dose 
overall after washout.
The plasma (all parts of the study) and urine (Parts 1 and 2 only) concentrations of TAK -510 will be summarized by 
dose level (Parts 1 and 2 only)/dose regimen (Part 3 only) at each scheduled sampling day/time withi n each part of the 
study separately, using descriptive statistics based on the PK analysis set (defined as all subjects who receive at least 
1dose of TAK -510 and have at least 1 measurable postdose plasma or urine concentration for TAK -510). The PK 
parame ters of TAK -510 determined using a noncompartmental analysis approach will be summarized by dose level 
(Parts 1 and 2 only)/dose regimen (Part 3 only) of TAK -510, as appropriate, within each part of the study separately, 
using descriptive statistics based on the PK analysis set. Dose proportionality may be assessed graphically 
(log-transformed dose -normalized C maxand AUC versus dose) and by using a power model within each part of the 
study separately as data allow; no formal statistical comparisons will be conducted. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 13of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALSample Size Justification: 
The selected sample sizes in Parts 1, 2, and 3 of the study are considered sufficient for evaluation of safety and 
tolerability of TAK -510 in healthy subjects . No formal statistical hypothesis testing is planned in Parts 1, 2, or 3. 
Therefore, no formal power calculations were performed in the determination of sample size for the study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 14of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL1.1 Protocol Amendment 3 Summary of Changes
Protocol Amendment 3 Summary and Rationale:
This sect ion describes the changes in referen ce to the protocol incorporating Amendment 3. The 
primary  reasons for thi s amendment are to: 
1.Clarify  maximum  exposure of TAK -510.
2.Revise study  design to include addit ional single rising dose ( SRD) and multiple ri sing dose
(MRD )cohorts.
3.Add safet y measure s at follow -up visit s for coronavirus disease 2019 ( COVID -19) monitoring.
4.Remove buccal  epithelial cell  sampling from  the study .
5.Address inconsistencies in the schedule of study  procedures.
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affect ing the conduct of the study  are included for clarification and administrative purposes only.
Protocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Chan ge Description of Each Change and Rationale
Location Description Rationale 
1. Title Page For consistency
2. Section 1.0STUDY 
SUMMARYUpdated planned number of subjects. To include subjects from 
additional si ngle rising 
dose (SRD) and multiple 
rising dose (MRD) cohorts.
3. Section 1.0STUDY 
SUMMARY
Section 6.1.2 Part 1: SRD 
Cohorts 1 to 12 and 21 to 25
Section 6.1.3 Part 2: MRD 
Cohorts 13 to 17 and 26 to 28
Section 6.1.4 Part 3: Dose 
Titration and Redosing Cohorts 
18 to 20Clarified that approximate sample sizes 
do not account for potential 
replacement of subjects and updated 
total sample size due to the increase in 
number of cohorts.To clar ify the approximate 
sample sizes and to update 
total sample size to account 
for the increase in number
of cohorts.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 15of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Chan ge Description of Each Change and Rationale
Location Description Rationale 
4. Section 1.0STUDY 
SUMMARY
Section 2.0STUDY 
SCHEMATIC
Section 3.1Part 1 for SRD 
Cohorts 1 to 12 and 21 to 25
Section 3.2Part 2 for MRD 
Cohorts 13 to 17 and 26 to 28: 
Screening Through Day 9, 
Follow -Up, and Early 
Termination
Section 6.1.1 Overall Study 
Design
Section 6.1.2 Part 1: SRD 
Cohorts 1 to 12 and 21 to 25
Section 6.1.3 Part 2: MRD 
Cohorts 13 to 17 and 26 to 28
Section 6.3.1 Rationale of Study
Design
Section 6.3.2.2 FIH Proposed 
Dose Regimen for the SRD 
CohortsUpdated study design to add SRD and 
MRD cohorts. 
Figure 2.a, Table 3.a, Table 3.b, 
Table 3.f, Table 3.j, and Table 6.awere 
updated.To clarify the maximum 
exposure cap for TAK -510 
and study doses that will 
produce concentrations in 
efficacious range.
6.Section 3.1Part 1 for SRD 
Cohorts 1 to 12 and 21 to 25For Table 3.a, blood pressure (BP) and 
pulse assessments were added to the 
follow -up visits on Days 8, 14, and 29.Correction of study 
procedures.
Section 3.2.1 Overall Schedule 
of Study Procedu res for Part 2For Table 3.b, BP and pulse 
assessments were added to the 
follow -up visit on Day  14.
Section 3.2.4 Part 2 for MRD 
Day 5 Through Day  9 
Assessments, Follow -Up, and 
Early  TerminationFor Table 3.e, BP and pulse 
assessments were added to the 
follow -up visits on Days 14, and 29. 
Section 3.2.2 Part 2 for MRD 
Screening Through Day 1 
Assessments
Section 3.3.2 Part 3 Screening 
Through Day 1 AssessmentsTable 3.cand Table 3.gwas updated to 
remove footnote h “Only serum 
chemistry  to measure electrolytes 
(sodium, potassium, chloride, and 
carbon dioxide) should be performed at 
the 4 -hour assessment.”
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 16of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Chan ge Description of Each Change and Rationale
Location Description Rationale 
Section 3.3.5 Part 3 Day 9 
Through Day 15 Assessments, 
Follow -Up, and Early 
TerminationFor Table 3.j, BP and pulse assessments 
were added to the follow -up visit on 
Day 29and the “i nclusion/exclusion 
criteria ”row was removed .In addition, 
a footnote for BMI was added for 
clarificatio n.
7. Section 3.1Part 1 for SRD 
Cohorts 1 to 12 and 21 to 25
Section 3.2Part 2 for MRD 
Cohorts 13 to 17 and 26 to 28: 
Screening Through Day 9, 
Follow -Up, and Early 
Termination
Section 3.3Part 3 for Dose 
Titration and Redosing Cohorts 
18 to 20: Screening Through Day 
15, Follow -Up, and Early 
Termination
Section 9.2.4 Vital Signs
Section 11.1.4.3 Vital SignsTable 3.a, Table 3.b, Table 3.c, 
Table 3.d, Table 3.e, Table 3.f, 
Table 3.g, Table 3.h, Table 3.i, and 
Table 3.jwere updated.
Added language to define 
“inconsistent” BP measurements.Text added for 
clarificatio n.
8. Section 3.1Part 1 for SRD 
Cohorts 1 to 12 and 21 to 25
Section 3.2Part 2 for MRD 
Cohorts 13 to 17 and 26 to 28: 
Screening Through Day 9, 
Follow -Up, and Early 
Termination
Section 3.3Part 3 for Dose 
Titration and Redosing Cohorts 
18 to 20: Screening Through Day 
15, Follow -Up, and Early 
Termination
Section 9.2.10 PK, 
Immunogenicity, Biomarker, 
and DNA Samples
Section 9.2.10.4.1 Blood Sample 
for DNA
Section 9.2.10.4.2 Biological 
Sample Retention and 
Destructio nTable 3.a, Table 3.b, Table 3.e, 
Table 3.f, Table 3.i, Table 3.j, and 
Table 9.awere updated.
Rem oved collection of buccal epithelial 
cell sample from the study.Buccal sampling r emoved 
due to technical issues with 
the sample for the assay.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 17of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Chan ge Description of Each Change and Rationale
Location Description Rationale 
9. Section 3.1Part 1 for SRD 
Cohorts 1 to 12 and 21 to 25
Section 3.2Part 2 for MRD 
Cohorts 13 to 17 and 26 to 28: 
Screening Through Day 9, 
Follow -Up, and Early 
Termination
Section 3.3Part 3 for Dose 
Titration and Redosing Cohorts 
18 to 20: Screening Through Day 
15, Follow -Up, and Early 
TerminationTable 3.a, Table 3.b, Table 3.c, 
Table 3.f, and Table 3.gwere updated.
Modified language in footnote for 
predose time -matched telemetry.For clarification of time 
period for time -matched 
extractions.
10. Section 1.0STUDY 
SUMMARY
Section 6.1.1 Overall Study 
Design
Section 6.3.1 Rationale of Study
DesignUpdated wording “dose/dose regimen” 
to “cohort.”For consistency between 
Part 1 and Part 2/3.
11. Section 3.3.5 Part 3 Day 9 
Through Day 15 Assessments, 
Follow -Up, and Early 
TerminationTable 3.jwas updated to add adverse 
event (AE) monitoring on Days 9 to 13.To clarify A E monitoring .
12.Section 1.0STUDY 
SUMMARY
Section 7.1Inclusion Criteria
Section 7.2Exclusion CriteriaModified inclusion criterion #7 to 
clarify  the birth control criteria for male 
subjects.For clarification of birth 
control criteria #7 for male 
subjects .
Modified language in exclusion 
criterion #1 to “last dose.”For correction of exclusion 
criterion #1 that criterion is 
after last dose of study 
drug.
Modified language in exclusion criteria 
#14 and #15.For clarification of 
exclusion criteria #14 and 
#15. 
13.Section 4.3Benefit/Risk Profile Myalgia was added to potential risks of 
TAK -510.To include preliminary 
safety data from Study 
TAK -510-1001.
Updated with results from embryo -fetal 
development study.To include audited draft 
results from a definitive rat 
embryo -fetal development.
“TAK -510 is a modified peptide with a 
lipidated conjugation ” was removed.Repetitive text was deleted
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 18of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Chan ge Description of Each Change and Rationale
Location Description Rationale 
“excluding w omen of childbearing 
potential ” was added to the last 
paragraph.For clarification.
14. Section 6.1.2 Part 1: SRD 
Cohorts 1 to 12 and 21 to 25
Section 6.1.3 Part 2: MRD 
Cohorts 13 to 17 and 26 to 28
Section 6.1.4 Part 3: Dose 
Titration and Redosing Cohorts 
18 to 20
Section 6.3.2.2 FIH Maximum 
Dose Consideration
Section 6.3.2.2 FIH Proposed 
Dose Regimen for the SRD 
Cohorts
Section 6.3.2.4 Rationale for 
Dosing IntervalExposure levels, details of highest 
planned doses, and preliminary 
pharmacokinetic (PK) data were added.
The maximum exposure of TAK -510 
was updated to 705,000 h*ng/ mL. 
Table 6.bwas updated.To include observed 
preliminary  human data.
To clarify the maximum 
exposure cap for TAK -510 
and study doses that will 
produce concentrations in 
efficacious range. This 
range was predicted by 
emerging information and 
will allow optimal onset of 
response of 30 minutes and 
highest dose exposures of 
at least 2 -fold the 
anticipated efficacious 
exposure. The 
no-observed -adverse -effect 
level is unchanged.
15. Section 6.1.2 Part 1: SRD 
Cohorts 1 to 12 and 21 to 25
Section 6.1.3 Part 2: MRD 
Cohorts 13 to 17 and 26 to 28
Section 6.1.4 Part 3: Dose 
Titration and Redosing Cohorts 
18 to 20Language for injection volume added. Text edited for clarification 
and consistency.
16. Section 6.1.2 Part 1: SRD 
Cohorts 1 to 12 and 21 to 25
Section 6.1.3 Part 2: MRD 
Cohorts 13 to 17 and 26 to 28
Section 6.1.4 Part 3: Dose 
Titration and Redosing Cohorts 
18 to 20
Section 8.1.3 Clinical Study
Drug Blinding
Section 11.2 Interim AnalysisChanged terminology of “Dose 
Escalation Committee” to “dose 
escalatio n meeting.”Modified terminology to 
clarify  that this is not an 
official committee. This is 
a dose escalation meeting 
and does not require a 
charter as would a Dose 
Escalation Committee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 19 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALProtocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
17.Section 6.2.2 Criteria for 
Premature Termination or Suspension of the Studya. Added language clarifying that
criteria apply when related to studydrug administration.a. To clarify that criteria
apply when related to studydrug administration and forbetter consistency.
b. Removed “vasovagal” from“vasovagal syncope.”
Removed greater than or equal to sign 
in bullet for: “Two or more subjects experience a CTCAE v5.0 Grade ≥3 
event considered related to TAK-510 
administration”.
Added bullet for Grade ≥2 injection site 
reaction criterion.b. For correction.
18. Section 6.3.2.2 (previous 
numbering)Previous Section 6.3.2.2, "Other 
Supporting Estimated Pharmacologically Active Exposures" 
was removed.Removed because 
determination of doses  
efficacy
data and observed human 
PK data.
19. Section 6.3.2.3 (previous 
numbering)Previous Section 6.3.2.3 “Summary of 
FIH Starting Dose Consideration” was merged into Section 6.3.2.1.To remove repetitive 
information.
20. Section 6.4 Procedure 
Modifications Permitted Within Protocol ParametersRemoved details of Section 6.4 and 
provided general guidance.For correction following 
the guidance of other studies in the program to document changes in the study file.
21. Section 7.5 Criteria for 
Discontinuation or Withdrawal of a Subject“AE” was updated to “TEAE.” Text updated for 
clarification.
22. Section 9.2.4.1 Follow-Up 
Safety Monitoring (new section)Added to describe follo w-up safety
monitoring procedures.To continue safety 
monitoring of subjects who terminate early from the study.
23. Section 9.2.6.1 Screening and 
Safety ECGsAdded “in semirecumbent position.” For clarification.
24. Section 9.2.9.3 Urinalysis Changed “nitrate” to “nitrite.” Correct an error.
25. Section 9.2.10 PK, 
Immunogenicity, Biomarker, and DNA SamplesFootnotes added to Table 9.a.
Added language for sampling windows.Footnotes added for 
clarification to provide time sampling windows for protocol-specified assessments.ffffofooo
criteriacriteria
lated to sated to
istration strati
nsistenisten cm
n 
ts 
de e ≥3 ≥3 
AKK--51051
e e ≥2 inje≥2 injFor corrFor copli
he
n 6.3.2.26.3.2
EstimatedEstimat
ologicallyologicall
moved.oved.nd
PreviousPreviou
FIH SFIH
memUs
rci
d WithinWithierrr
CriteriaCriter
nuation nuatio
SubjectubjectNo
ectionction 9.9
Safety Safetya:
Ta
3..of
e242eerpeppp
TAK-510
Study ID TAK-510-1001 Page 20 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALProtocol Amendment 3
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
26. Section For clarification.
27. Section 10.2.8.3.1 SAE 
Follow-UpAdded “The site must use the eCRFs to 
report an SAE within 24 hours, and only if the eCRF is unavailable, should the site send a safety reporting form.”To clarify serious adverse 
event reporting.
28. Section 10.2.8.4.3 Injection Site 
ReactionLanguage for Grade 2 injection site 
reactions added.Text edited for 
clarification.
29. Section 11.2 Interim Analysis Language for interim analysis was 
revised.Add flexibility to conduct 
an interim analysis when a data-dependent internal decision is needed to inform the subsequent development of TAK-510 before database lock.
30. Section 12.2 Protocol Deviations Modified language to clarify protocol 
deviation.For clarification of 
protocol deviation language.
31. Section 15.1 Case Report Forms 
(Electronic and Paper)Remove sentence regarding case report 
forms being required for each subject who signs an informed consent.Correct an error. 
Property of Takeda: For Non-Commercial Use Only languagelanguag
on..ly and Subject to the Applicable Terms of Useffffofooo
m
fy seriouserio
t reportinreportble
eTexTe
ceeeAhe
was as to 
ly
Rememove ove
forms form
whwhUs
errcir
TAK -510
Study ID TAK -510-1001 Page 21of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL2.0 STUDY SCHEMATIC
Figure 2.a Study Schematic
D: day; MRD: multiple rising dose; QD: once daily. 
aThe D8 -
13 washout period for Cohorts 19 and 20 is subject to change based on emerging safety, tolerability, and available pharmacoki netic data.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 22of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.0 SCHEDULE OF STUDY PROCEDURES 
3.1 Part 1 for SRD Cohorts 1 to 12 and 21 to 25
Table 3.a Part 1 for SRD Cohorts 1 to 12 and 21 to 25
Day Scheduled Time Scheduled Time Follow -u
p Visit 
Day 8
-1 dayFollow -u
p Visit 
Day 14
±2 daysFollow -u
p Visit 
Day 29
±3 days ET-28 to -3 -2 aDay -1 (Hours) Day 1 (Hours)
Screening 00.5 1 2 3 4 5 7 10 12 16 24 bPre-
dose 00.5 1 2 3 4 5 7 10 12 16 24 30 48 7296 c
(discharge)
Administrative Procedures
Informed consent X
Inclusion/exclusion 
criteriaX X X
Medical 
history/demographicsX
Prior and concomitant 
medication reviewX X-------------------------------------------------------------------- Continuous Review----------------------------------------------------------------- X
Clinic Procedures/Assessments
Full physical 
examinationX X X dX dX
Height X
Weight and BMI X X
TAK -510/placebo 
administration e X
Temperature and 
respiratory rate X X X X X X
BP and pulse fX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
Standing BP and 
pulseg X X X X X X X X X X X X X X X X X
12-lead ECGs X X X X X X
ECG telemetry 
(12-lead)X------------ Continuous Monitoringh------------ X X ------------ Continuous Monitoring ------------ X
Telemetry extraction iX X X X X X X X X X X X X X X X X X X X X X X X
AE monitoring XjX--------------------------------------------------------Continuous Monitoring ------------------------------------------------- X X
Laboratory Procedures/Assessments
Safety laboratory 
collection (hematology 
and serum chemistry) X X X X kX X X X X X
Urinalysis X X X X
Serum sample for CK lX X X X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 23 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.a Part 1 for SRD Cohorts 1 to 12 and 21 to 25
Day Scheduled Time Scheduled Time Follow-u
p Visit 
Day 8
-1 dayFollow-u
p Visit 
Day 14
±2 daysFollow-u
p Visit 
Day 29
±3 days ET-28 to -3 -2 aDay -1 (Hours) Day 1 (Hours)
Screening 0 0.5 1 2 3 4 5 7 10 12 16 24 bPre-
d o s e 0 0 . 5 123457 1 0 1 2 1 6 2 4 3 0 4 8 7 296 c
(discharge)
Glucose finger stick X X X
Urine drug screen X X
Alcohol breath test X
Cotinine test X X
Hepatitis screen mX
HIV screen X
βhCG (pregnancy) 
testn XX XX
Serum FSH test oX
PK Evaluations
Plasma sample for 
TAK-510 PK X XXXXXXXXXXX X XX X X
Urine sample for 
TAK-510 PKp XX X X X
Immunogenicity and Biomarker Evaluations
Serum sample for immunogenicity 
q X XXX X
Blood sample for DNA 
(optional) r XX
Other
Confinement X-------------------------------------------------------------------------------------------------------X
ADA: antidrug antibodies; AE: adverse event; anti-HCV: antibodies to hepatitis C virus; AST: aspartate aminotransferase; βhCG: beta human chorionic gonadotropin; BMI: body 
mass index; BP: blood pressure; CK: creatine kinase; ECG: electrocardiogram; ET: early termination; FSH: follicle-stimulating hor mone; 
 HBsAg: hepatitis B surface antigen; PK: pharmacokinetic; SRD: single rising dose.
aSubjects will be admitted to the site on Day -2. 
bThe 24-hour sample on a given day is the same as the predose sample on the next day; only 1 assessment will be collected at thi s time point.
cSubjects will be confined for 96 hours after dosing (can be discharged after the 96-hour PK sample). 
dPhysical examination at the indicated visit will be symptom-driven.
eSubjects will be administered a single dose of TAK-510 or matching placebo. 
Property of Takeda: For ; antianti-HCH
ne kinasee kin
e antigen;antige
e on Day on Day
day is theday is thor NoXX------------Nercial Use Only and Subject to the Applicable Terms of UseTe
licpp
62 4 3 024 3AApApp
heAAp
hhheeethethththtothtototottoctctctecteeeccc
bjec
bbbjejeje
Subje
SSSububub
dSub
dddand
ya naaannn
XXXXXyyyaaa
Onlya
XOOnOnOn
sUsessse
XXUsUss
iUs
iiia
eci
r 96 hours96 hou
the indicaindi
nistered astereorComme
Non-Co
TAK-510
Study ID TAK-510-1001 Page 24 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.a Part 1 for SRD Cohorts 1 to 12 and 21 to 25
Day Scheduled Time Scheduled Time Follow-u
p Visit 
Day 8
-1 dayFollow-u
p Visit 
Day 14
±2 daysFollow-u
p Visit 
Day 29
±3 days ET-28 to -3 -2 aDay -1 (Hours) Day 1 (Hours)
Screening 0 0.5 1 2 3 4 5 7 10 12 16 24 bPre-
d o s e 0 0 . 5 123457 1 0 1 2 1 6 2 4 3 0 4 8 7 296 c
(discharge)
fAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the fi nal result. The investigator can take a third 
measurement if there is inconsistency (ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in systolic or diastolic BP) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout should be the average of the 2 more consistent assessments. O n Day -1, vital signs will be time-matched 
(±5 minutes) to the Day 1 clock time (ie, time-matched baseline). At predose, vital signs will be measured within approximately 1 hour before dosing.
gFor standing BP and pulse assessment, a BP and pulse assess ment will be performed after th e duplicate semirecumbent assessment has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP is <85 mm Hg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision). Day 1 time points will be time-matched (±5 minutes) to the 
Day -1 clock time (ie, time-matched baseline).
hAt least 24 hours of continuous telemetry monitoring will be conducted between check-in on Day -2 and predose on Day 1.
iPredose time-matched telemetry extractions may take place between Day -2 and Day -1 in conjuncti on with the 24-hour predose con tinuous telemetry.
jCollection of AEs will commence at the time the subject signs the informed consent form.
kOnly serum chemistry to measure electrolytes (sodium, potassium, chloride, and carbon dioxide) should be performed at the 4-hou r assessment. 
lIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s  discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
mHepatitis panel, including HBsAg and anti-HCV.
nSerum pregnancy test for female subjects only. 
oAn FSH level will be obtained to assess postmenopausal status.
pUrine PK samples will be collected at the following time intervals: predose, 0-4, 4-7, 7-12, and 12-24 hours.
qImmunogenicity serum samples for ADA testing will be taken at predose on Day 1, at ET (if applicable), and at follow-up visits o n Day 8, Day 14, and Day 29. If ADAs are present, 
subjects may be asked to return for additional sample collection. The sampling time points will be same for all subjects dosed with either placebo or study drug.
rIf subjects have provided consent for the optional DNA collection blood samples should be collected and can be collected at any  time on the day of discharge or at ET (if applicable).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
licpp
62 4 3 024 3AApApp
heAAp
alculate thculate
mmmmHgH
re consiste consi
ithin apprithin ap
mirecummirecum
mirecumbmirecum
ea, blurra, blur
n Day Day -2
in conjunn conju
form.rm.
carbon diarbon
es for CKes for C
g. 
ervals: prevals: p
aken at preen at p
llection. Tection
NA collecNA collhhheee
da: For No
TAK -510
Study ID TAK -510-1001 Page 25of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.2 Part 2 for MRD Cohorts 13 to 17 and 26 to 28: Screening Through Day 9, Follow- Up, and Early Termination
3.2.1 Overall Schedule of Study Procedu res for Part 2
Table 3.b Part 2 for MRD Cohorts 13 to 17 and 26 to 28: Screening Through Day 9, Follow -Up, and ET
Days
ETScreening -2 a-1 Dosing 6 7 89 
(Discharge)Follow -up 
Visit 
Day 14 
±2daysFollow -up 
Visit 
Day 29 
±3days
-28 to -3Pre
dose 1 2 3 4 5
Administrative Procedures
Informed consent X
Inclusion/exclusion 
criteriaX X X
Medical 
history/demographicsX
Prior and concomitant 
medicationsX----------------------------------------------------------------- Continuous review ----------------------------------------------------------------------- X
Clinic Procedures/Assessments
Full physical examination X X X bX bX
Height X
Weight and BMI X X
Vital signs cX X X X X X X X X X X X X
Standing BP and pulse dX X X X X X X X X
12-Lead ECGs X X X X
ECG telemetry (12 -lead) X eX-------------- Continuous ---------------- X
Telemetry extraction fX X X X X X X X
TAK-510/placebo 
administration g X X X X X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 26of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTable 3.b Part 2 for MRD Cohorts 13 to 17 and 26 to 28: Screening Through Day 9, Follow- Up, and ET
Days
ETScreening -2 a-1 Dosing 6 7 89 
(Discharge)Follow -up 
Visit 
Day 14 
±2daysFollow -up 
Visit 
Day 29 
±3days
-28 to -3Pre
dose 1 2 3 4 5
AE monitoring X X X----------------------------------------------------------- Continuous ------------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory 
collection h X X X X X X X X X X X
LFTs X
Serum sample for CK iX X X X
Glucose finger stick jX X X X X X
Urine drug screen X X
Alcohol breath test X
Cotinine test X X
Hepatitis screen kX
HIV test X
βhCG (pregnancy) test lX X X X
Serum FSH test mX
PKEvaluations
Plasma sample for 
TAK -510 PK X X X X X X X X X X X
Plasma sample for metID X X X X X X
Urine sample for 
TAK -510 PK X X X X
Immunogenicity and Biomarkers
Serum sample for 
immunogenicity n X X X X X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 27 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.b Part 2 for MRD Cohorts 13 to 17 and 26 to 28: Screening Through Day 9, Follow-Up, and ET
Days
ETScreening -2 a-1 Dosing 6 7 89 
(Discharge)Follow-up 
Visit 
Day 14 
±2 daysFollow-up 
Visit 
Day 29 
±3 days
-28 to -3Pre
dose 1 2 3 4 5
Blood sample for DNA (optional) 
o X X
Other
Confinement rX--------------------------------------------------------------------------------X
ADA: antidrug antibodies; AE: adverse event; ALT: alanine aminotransferase; ALP: alkaline phosphatase; anti-HCV: antibodies to hepatitis C virus; AST: aspartate 
aminotransferase; βhCG: beta human chorionic gonadotropin; BMI: body mass index; BP: blood pressure; CK: creatine kinase; ECG: electrocardiogram; E T: early termination; 
FSH: follicle-s timulating hormone; GGT: g amma-glutamy l transferase; ; HBsAg: hepatitis B surface antigen; LFT: liver function 
test; metID: metabolite identification; MRD: multiple rising dose; PK: pharmacokinetic; MRD: multiple rising dose.
aSubjects will be admitted to the site on Day -2. 
bPhysical examination at the indicated visit will be symptom-driven.
cVital signs will include body temperature, BP, respiratory rate, and pulse. On Day -1 and on dosing days, vital signs will be co llected as described in Table 3.c (Part 2 for MRD 
Screening Through Day 1 Assessments) ,Table 3.d (Part 2 for MRD Days 2 to 4 Assessments) , and Table 3.e (Part 2 for MRD Day 5 Through Day 9 Assessments, Follow-Up, and 
ET).
dAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the fi nal result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in sy stolic or diastolic BP) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout s hould be the average of the 2 more consistent assessments. On Day -1, vital signs will be time-matched 
(±5 minutes) to the Day 1 clock time (ie, time-matched baseline). At predose, vital signs will be measured within approximately 1 hour before the first dose. All BP and pulse 
assessments must be completed before PK blood sampling.
eAt least 24 hours of continuous telemetry monitoring will be c onducted between check-in on Day -2 and predose on Day 1.
fPredose time-matched telemetry extractions may take place between Day -2 and Day -1 in conjuncti on with the 24-hour predose con tinuous telemetry.
gDosing regimen for TAK-510/placebo will be  determined based on data from Part 1. 
hSafety laboratory will include hematology, serum chemistry, and urinalysis parameters. During Part 2 (MRD), if a LFT (includes ALP, ALT, AST, GGT, or total bilirubin) is 
Propertyyo fFoe;
mercK: pharm: phar
mm
Comdriven.riven.
-Cory rate, anate, 
on-Crt 2 for M2 for
Non
or Nin duplicaduplior ifferencefferenc
a: Fts are obtaare o
da: e,timetime--ma
kedare PK bloe PK bl
Taketelemetrytelemetr
fT aetry extratry extr
of ciaal Ue; ;ALPALP:almass indmass ineO neO
Use ---------------eSubject to the Applicable Terms of UseTe
ww--Up, Up
lic
77Apppp
teAp
tttoct t
SSbje
S
510/pla10/pl
rty ol include hncludUsOnly and S
ercia
TAK-510
Study ID TAK-510-1001 Page 28 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.b Part 2 for MRD Cohorts 13 to 17 and 26 to 28: Screening Through Day 9, Follow-Up, and ET
Days
ETScreening -2 a-1 Dosing 6 7 89 
(Discharge)Follow-up 
Visit 
Day 14 
±2 daysFollow-up 
Visit 
Day 29 
±3 days
-28 to -3Pre
dose 1 2 3 4 5
elevated, a repeat test should be performed before the next dose of study drug is administered. 
iIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s  discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
jGlucose finger stick will be performed at predose and ~1 hours postdose on each day.
kHepatitis panel, including HBsAg and anti-HCV.
lSerum pregnancy tests for female subjects only.
mAn FSH level will be obtained to assess postmenopausal status.
nImmunogenicity serum samples for ADA testing will be taken at predose on Day 1, on Day 8, at ET (if applicable), and at follow-u p visits on Day 14 and Day 29. If ADAs are 
present, subjects may be asked to return for additional sample collections. The sampling time points will be the same for all s ubjects dosed with either placebo or study drug. 
oIf subjects have provided consent for the optional DNA collection, blood samples should be collected and can be collected at an y time on the day of discharge or at ET (if applicable).
Property of Takeda: For Non-CommmmbjeubjeSubected at thcted at
nd Sandly a
OnlyeO n
Use y 1, on Dy 1, on
lU ssamplingamplinlU amples shamplesbject to the Applicable Terms of UseTe
ww--Up, Up
lic
77Apppp
teAp
tttoct t
bje
mmercia
TAK -510
Study ID TAK -510-1001 Page 29of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.2.2 Part 2 for MRD Screening Through Day 1 Assessments
Table 3.c Part 2 for MRD Screening Through Day 1 Assessments
Day
-
28 to -3Day
-2 aScheduled Time
Day -1 (Hours) Day 1 (Hours)
Screening0 0.5 1 2 3 4 5 7 10 12 16 24 bPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 b
Administrative Procedures
Informed consent X
Inclusion/exclusion 
criteriaX X X
Medical history/
demographicsX
Prior and 
concomitant 
medicationsX--------------------------------------------------------------- Continuous review --------------------------------------------------------- ------------------- X
Clinic Procedures/Assessments
Full physical 
examinationX X
Height X
Weight and BMI X X
Temperature and 
respiratory rateX X X X X X
BP and pulse cX X X X X X X X X X X X X X X X X X X X X X X X
Standing BP and 
pulse d X X X X X X X X X X X X X X
12-lead ECGs X X X X
ECG telemetry 
(12-lead)X ---------------------- Continuous monitoring e------------------------ X X ---------------------- Continuous monitoring ------------------------ X
Telemetry 
extractionf X X X X X X X X X X X X X X X X X X X X X X X X
TAK -510/placebo 
administrationX
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 30 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.c Part 2 for MRD Screening Through Day 1 Assessments
Day
-28 to -3Day
-2 aScheduled Time
AE monitoring X-------------------------------------------------------------- Continuous review---------------------------------- -------------------------------------------X
Day -1 (Hours) Day 1 (Hours)
Screening0 0.5 1 2 3 4 5 7 10 12 16 24 bPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 b
Laboratory Procedures/Assessments
Safety laboratory 
collection g XX X X
Serum sample for CK 
h XX
Glucose finger stick XX
Urine drug screen X X
Alcohol breath test X
Cotinine test X X
Hepatitis screen iX
HIV test X
βhCG (pregnancy) 
test j XX
Serum FSH test kX
PK Evaluations
Plasma sample for 
TAK-510 PKX X XXXX X X XXX X
Plasma sample for 
metID XX X X X X X
Urine sample for 
TAK-510 PKl XX X X X
Immunogenicity and Biomarkers
Serum sample for immunogenicityX
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
lic
------------Ap
he
oseos 0thhh
toh
ject ct
Xjjjebj
Su
ndndndndandaaalya
nlylyly
Oly
OOOOe
UsUsUsUslUslllUUU
rcial
ercrcrc
mrc
mmemmmem
CoCCC
NnC
NNNo
FN
FoFFFo
eda: Fda:FFFF
ededF
of Taked
TAK-510
Study ID TAK-510-1001 Page 31 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.c Part 2 for MRD Screening Through Day 1 Assessments
Day
-28 to -3Day
-2 aScheduled Time
Other
Confinement oX------------------------------------------------------------------------------------------------------------------------------ --------------------------------X
AE: adverse event; anti-HCV: antibodies to hepatitis C virus; βhCG: beta human chorionic gonadotropin; BMI: body mass index; BP: blood pressure; CK: creatine kinase; ECG: 
electrocardiogram; FSH: follicle-stimulating hormone; ; HBsAg: hepatitis B surface antigen; LFT: liver function test; 
metID: metabo lite identification; PK: pharmacokinetic.
aSubjects will be admitted to the site on Day -2. 
bThe 24-hour sample on a given day is the same as the predose sample on the next day; only 1 assessment will be collected at thi s time point.
cAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the fi nal result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in systolic or diastolic BP) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout s hould be the average of the 2 more consistent assessments. On Day -1, vital signs will be time-matched 
(±5 minutes) to the Day 1 clock time (ie, time-matched baseline). At predose, vital signs will be measured within approximately 1 hour before the first dose. All BP and pulse 
assessments must be completed before PK blood sampling.
dFor standing BP and pulse assessment, a BP and pulse assess ment will be performed after th e duplicate semirecumbent assessment has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP is <85 mm Hg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision). Day 1 time points will be time-matched (±5 minutes) to the 
Day -1 clock time (ie, time-matched baseline).
eAt least 24 hours of continuous telemetry monitoring will be conducted between check-in on Day -2 and predose on Day 1.
fPredose time-matched telemetry extractions may take place between Day -2 and Day -1 in conjuncti on with the 24-hour predose con tinuous telemetry.
gSafety laboratory will include hematology, serum chemistry, and urinalysis parameters. During Part 2 (MRD), if a LFT is elevated , a repeat test should be performed before the next 
dose of study drug is administered.
hIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s  discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
iHepatitis panel, including HBsAg and anti-HCV.
jSerum pregnancy tests for female subjects only.
kAn FSH level will be obtained for postmenopausal women.
lUrine PK samples will be collected at the following time intervals: predose, 0-4, 4-7, 7-12, and 12-24 hours.
oSubjects will be confined.
Property ofofty ofed.eda: For Non-Commercial Use Only and Subjecject MI: body MI: body
bjec; HBsAg; HBsA
SubjdS uand assessmensessm
ya nments shounts sho
Only ateeor a dor a
Onlye the averthe ave
eOsigns willgns wi
Use lU sformed formed af
ial Umust not bmust n
rciaeadednessdednes
mercmmenducted bducted
Combetween Dtween
Cotry, and ury, and 
on-CNoning, additng, add
or Nns for con for co
For CV.CV.
a: Fs only.only.thto ththhh
ct to------------to 
eda:stmenopamenop
edd at the foat the ctApplicable Terms of UseTe
lic
the Ap
of Take
TAK -510
Study ID TAK -510-1001 Page 32of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.2.3 Part 2 for MRD D ays 2 to 4 Assessments
Table 3.d Part 2 for MRD Days 2 to 4 Assessments
Scheduled Time
Days 2 -4 (Hours)
Predose 0 0.5 1 2 3 4 5 7 10 12 16 24 a
Administrative Procedures
Prior and concomitant medications X-------------------------------------------------------- Continuous review ---------------------------------------------------- X
Clinic Procedures/Assessments
Temperature and respiratory rate X X X X
BP and pulse bX X X X X X X X X X X X
Standing BP and pulse cX X X X X X X
TAK -510/placebo administration d X
ECG telemetry (12 -lead) X------------------------------------------------------------ Continuous monitoring ------------------------------------------- X
Telemetry extraction X
AE monitoring X----------------------------------------------------- Continuous review -------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory collection eX f
LFTs X g
Glucose finger stick X X
PK Evaluations
Plasma sample for TAK -510 PK Xh
Other
Confinement iX----------------------------------------------------------------------------------------------------------------------------- -----X
AE: adverse event; BP: blood pressure; ECG: electrocardiogram; LFT: liver function test; PK: pharmacokinetic.
aThe 24 -hour sample on a given day is the same as the predose sample on the next day; only 1 assessment will be collected at this tim e point.
bAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the final result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in systolic or diastolic BP) between assessments 
(see Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout should be the average of the 2 more consistent assessments. At predose, vital signs will 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 33of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTable 3.d Part 2 for MRD Days 2 to 4 Assessments
Scheduled Time
Days 2 -4 (Hours)
Predose 0 0.5 1 2 3 4 5 7 10 12 16 24 a
bemeasured within approximately 1 hour before the first dose. All BP and pulse assessments must be completed before PK blood sa mpling.
cFor standing BP and pulse assessment, a BP and pulse assessment will be performed after the duplicate semirecumbent assessment has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP i s <85 mmHg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision, etc.). 
dFollow- up doses should be given at the same time as on Day 1.
eSafety laboratory will include hematology, serum chemistry, and urinalysis parameters . During Part 2 (MRD), if a LFT is elevated, a repeat test should be performed before the next 
dose of study drug is administered.
fSafety laboratory assessments (including hematology, serum chemistry, and urinalysis parameters) will be performed on Day 2and Day 4.
gSampling for LFTs will be performed on Day 3.
hBlood samples for PK may be drawn 10 minutes before dosing. 
iSubjects will be confined.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 34of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.2.4 Part 2 for MRD Day 5 Through Day 9 Assessments, Follow -Up, and Early Termination 
Table 3.e Part 2 for MRD Day 5 Through Day 9 Assessments, Follow -Up, and ET
Scheduled Time
ETDay 5 (Hours) Day 6 Day 7 Day 8Day 9
(Discharge)Follow -
up Visit 
Day 14
±2daysFollow -
up Visit 
Day 29
±3 daysPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 48 72 96
Prior and concomitant 
medicationsX---------------------------------------------------------------- Continuous review ------------------------------------------------------------------------ X
Clinic Procedures/Assessments
Full physical examination X aX aX
Temperature and 
respiratory rate X X X X X X
BP and pulsebX X X X X X X X X X X X X X X X
Standing BP and pulse cX X X X X X X X
TAK -510/placebo 
administration d X
12-lead ECGs X
ECG telemetry (12 -lead) X-------------------------------- Continuous --------------------------------------- X
Telemetry extraction X X X X X X X X X X X X
AE monitoring X--------------------------------------------------------------------- Continuous ------------------------------------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory 
collection e X X X X X
Serum sample for CK fX X
Glucose finger stick X X
βhCG (pregnancy) test gX X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 35 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.e Part 2 for MRD Day 5 Through Day 9 Assessments, Follow-Up, and ET
Scheduled Time
ETDay 5 (Hours) Day 6 Day 7 Day 8Day 9
(Discharge)Follow-
up Visit 
Day 14
±2 daysFollow-
up Visit 
Day 29
±3 daysPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 48 72 96
PK Evaluations
Plasma sample for TAK-510 PKX 
hXXXXXXXXXX X X X X X
Plasma sample for metID X hX X XXX X X
Urine sample for 
TAK-510 PK i XX X X
Immunogenicity and Biomarkers
Serum sample for immunogenicity 
j X X X X
Blood sample for DNA (optional) 
k X X
Other
Confinement mX------------------------------------------------------------------------------------------------------------------------------ X
ADA: antidrug antibodies; AE: adverse event; βhCG: beta human chorionic gonadotropin; BP: blood pressure; CK : creatine kinase; ECG: electrocardiogram; ET: early termination; 
metID: metabolite identification; PK: pharmacokinetic.
aPhysical examination at the indicated visit will be symptom-driven.
bAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the fi nal result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per min ute in heart rate or a difference >10 mm Hg in systolic or diastolic BP ) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout should be the average of the 2 more consistent assessments. A t predose, vital signs will be measured 
within approximately 1 hour before the first dose. All BP and pulse assessments must be completed before PK blood sampling.
cFor standing BP and pulse assessment, a BP and pulse assessment will be performed after the duplicate semirecumbent assessment has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP is <85 mm Hg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision, etc.). 
dFollow-up doses should be given at the same time as those given on Day 1.
Propertyon-Cbeta humaeta hu
Nonetic.tic.
For Nbe symptbe sym
Forade in dupde in du
a: Fa differa diffe
eda:ments arents ar
akedthe first dthe first
Takssment, a ssment, mm
Commn-Co--------------Coy and Subject to the Applicable Terms of UseTe
lic
7 Day 8DayApppppp
hepp
4848hehehe
the
ect totttt o
XXeccc
Sc
XSSSuS
Xd
Only y
sese OneOnOnnn
sen
ialalal UseUsseUsesese
alse
fT abefore thisefore t
yo f  ostural hyural 
rty old be gived be gn-Cmmercia
TAK-510
Study ID TAK-510-1001 Page 36 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.e Part 2 for MRD Day 5 Through Day 9 Assessments, Follow-Up, and ET
Scheduled Time
ETDay 5 (Hours) Day 6 Day 7 Day 8Day 9
(Discharge)Follow-
up Visit 
Day 14
±2 daysFollow-
up Visit 
Day 29
±3 daysPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 48 72 96
eSafety laboratory will include hematology, serum chemistry, and urinalysis parameters. Additional assessments may be collected at the investigator’s discretion.
fIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s  discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
gSerum pregnancy tests for female subjects only.
hBlood samples for PK and metID may be drawn 10 minutes before dosing.
iUrine PK samples will be collected at the following time intervals: predose, 0-4, 4-7, 7-12, and 12-24 hours.
jImmunogenicity serum samples for ADA testing will be taken at predose on Day 1, on Day 8, at ET (if applicable), and at follow-u p visits on Day 14 and Day 29. If ADAs are 
present, subjects may be asked to return for additional sample collection. All subjects receiving either study drug or placebo will have the same collection time points.
kIf subjects have provided consent for the optional DNA collection, blood samples should be collected and can be collected at an y time on the day of discharge  or at ET (if applicable).
mSubjects will be confined.
Property of Takeda: For Non-Commercial UsUsal Ut to the Applicable Terms of UseTe
lic
7 Day 8DayApppppp
hepp
4848hehehe
the
ect tonts may bs may 
bjecat the invt the in
SubjedS und Sandnd 1212--24 24
nly aayy8, at E8, a
Onlyeceiving eceiving e
eOhould be could betttt o
Use 
TAK -510
Study ID TAK -510-1001 Page 37of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.3 Part 3 for Dose Titration and Redosing Cohorts 18 to 20: Screening Through Day 15, Follow -Up, and Early 
Termination
3.3.1 Overall Schedule of Study Procedures for Part 3
Table 3.f Part 3 for Dose Titration and Redosing Cohorts 18 to 20: Screening Throug h Day 15, Follow -Up, and ET
Days
ETScreen
-2 a-1Dosing
8
(Dis-
charge)9 to 13 
Wash
out bDay 13 
±1day
(Confine 
again)Day 14
±1 day
(Single 
Dose)Day 15 
±1day
(Dis-
charge)Follow -
up Visit 
Day 29 
±3days-28 to
-3Pre
dose 1 2 3 4 5 6 7
Administrative Procedures
Informed consent X
Inclusion/exclusion 
criteriaX X X
Medical 
history/demographicsX
Prior and concomitant 
medicationsX----------------------------------------------------------------- Continuous review ----------------------------------------------------------------------- X
Clinic Procedures/Assessments
Full physical 
examinationX X X cX X cX X
Height X
Weight and BMI X X X
Vital signs dX X X X X X X X X X X X X X X X
Standing BP and pulse 
e X X X X X X X X X X X X X
12-Lead ECGs X X X X X X
ECG telemetry 
(12-lead)X fX --------------- Continuous ----------------- X X
Telemetry extractiongX X X X X X X X X X X X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 38of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTable 3.f Part 3 for Dose Titration and Redosing Cohorts 18 to 20: Screening Throug h Day 15, Follow -Up, and ET
Days
ETScreen
-2 a-1Dosing
8
(Dis-
charge)9 to 13 
Wash
out bDay 13 
±1day
(Confine 
again)Day 14
±1 day
(Single 
Dose)Day 15 
±1day
(Dis-
charge)Follow -
up Visit 
Day 29 
±3days-28 to
-3Pre
dose 1 2 3 4 5 6 7
TAK -510/placebo 
administration h X X X X X X X X
AE monitoring X X X----------------------------------------------------------- Continuous ------------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory 
collection i X X X X X X X X X X X X X X
LFTs X X
Serum sample for 
CKj X X X X
Glucose finger stick kX X X X X X X X X
Urine drug screen X X X
Alcohol breath test X X
Cotinine test X X X
Hepatitis screen lX
HIV test X
βhCG (pregnancy) 
test m X X X X X
Serum FSH test nX
PK Evaluations
Plasma sample for 
TAK -510 PK X X X X X X X X X X X X
Immunogenicity and Biomarkers
Serum sample for 
immunogenicity o X X X X X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 39 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.f Part 3 for Dose Titration and Redosing Cohorts 18 to 20: Screening Through Day 15, Follow-Up, and ET
Days
ETScreen
-2 a-1Dosing
8
(Dis-
charge)9 to 13 
Wash
out bDay 13 
±1 day
(Confine 
again)Day 14
±1 day
(Single 
Dose)Day 15 
±1 day
(Dis-
charge)Follow-
up Visit 
Day 29 
±3 days-28 to
-3Pre
d o s e1234567
Blood sample for DNA (optional) 
p X X
Other
Confinement sX--------------------------------------------------------------------------------X X--------------------------X
ADA: antidrug antibodies; AE: adverse event; anti-HCV: antibodies to hepatitis C virus; βhCG: beta human chorionic gonadotropin; BMI: body mass index; BP: blood pressure; CK: 
creatine kinase; ECG: electrocardiogram; ET: early terminati on; FSH: fo llicle-s timulating hormone; ; HBsAg: hepatitis B s urface 
antigen; LFT: liver function test; PK: pharmacokinetic.
aSubjects will be admitted to the site on Day -2. 
bBased on emerging safety, tolerability, and available PK data, subjects may be confined during washout at the discretion of the  investigator in consultation with the sponsor and 
medical monitor. Duration of washout period may be shortened or lengthened in Cohorts 19 and 20 based on emerging data, refer to  Section 6.1.4 for confinement and discharge 
during redosing interval.
cPhysical examination at the indicated visit will be symptom-driven.
dVital signs will include body temperature, BP, respiratory rate, and pulse. On Day -1 and on dosing days, vital signs will be co llected as described in Table 3.g (Part 3 Screening 
Through Day 1 Assessments) ,Table 3.h (Part 3 Days 2 to 6 Assessments) ,Table 3.i (Part 3 Day 7 and Day 8 Assessments) , and Table 3.j (Part 3 Day 9 Through Day 15 Assessments, 
Follow-Up, and ET) .
eAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the fi nal result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in systolic or diastolic BP ) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout s hould be the average of the 2 more consistent assessments. On Day -1, vital signs will be time-matched 
(±5 minutes) to the Day 1 clock time (ie, time-matched baseline). At predose, vital signs will be measured within approximately 1 hour before the first dose. All BP and pulse 
assessments must be completed before PK blood sampling.
fAt least 24 hours of continuous telemetry monitoring will be conducted between check-in on Day -2 and predose on Day 1.
gPredose time-matched telemetry extractions may take place between Day -2 and Day -1 in conjuncti on with the 24-hour predose con tinuous telemetry.
Property of Takeda: For Non-Commercial UlU sis C viruss C vir
ial Uclecle--stimustim
rcia
mercmmeubjects mbjects m
Commd or lengtor len
Com
on-Cptomtom-drivd
Nonpiratory rairatory 
rN oays 2 to 6ys 2 to 
For :F omade in duade in
da: e, a diffe, a dif
kedaements arments 
akeme (ie,e (ie, timtOn yOnOneO nOnOnOn
Use ---------------eO
fT a kbefore Pbefore 
of Tuous telemous t
ty otelemetryelemetrUsanaaaanabject to the Applicable Terms of UseTe
Day 15, FDay 15,
lic
13 3 
WashWash
out out bbDayDay
±1AppAA
teA
bject tectt tottttoct t
bjebje
and Subje
Only an
TAK-510
Study ID TAK-510-1001 Page 40 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.f Part 3 for Dose Titration and Redosing Cohorts 18 to 20: Screening Through Day 15, Follow-Up, and ET
Days
ETScreen
-2 a-1Dosing
8
(Dis-
charge)9 to 13 
Wash
out bDay 13 
±1 day
(Confine 
again)Day 14
±1 day
(Single 
Dose)Day 15 
±1 day
(Dis-
charge)Follow-
up Visit 
Day 29 
±3 days-28 to
-3Pre
d o s e1234567
hDosing regimen for TA K-510/placebo will be determined based on data from Part 1. 
iSafety laboratory will include hematology, serum chemistry, and urinalysis parameters. During Part 3, if an LFT is elevated, a repeat test should be performed before the next dose 
of study drug is administered.
jIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
kGlucose finger stick will be performed at predose and ~1 hours postdose on each day.
lHepatitis panel, including HBsAg and anti-HCV.
mSerum pregnancy tests for female subjects only.
nAn FSH level will be obtained to assess postmenopausal status.
oImmunogenicity serum samples for ADA testing will be taken at predose on Day 1, on Day 8, at ET (if applicable), predose on Day 14, and at the follow-up visit on Day 29. If ADAs 
are present, subjects may be asked to return for additional sample collections. All subjects receiving either study drug or pla cebo will have the same collection time points. 
pIf subjects have provided consent for the optional DNA collection, blood samples should be collected and can be collected at an y time on the day of discharge or at ET (if applicable). 
Property of Takeda: For Non-Commmme Only and Subject to the Applicable Terms of UseTe
Day 15, FDay 15,
lic
13 3 
WashWash
out out bbDayDay
±1AppAA
teA
ct tojectn LFT is eLFT is
ubjeSubected at thcted at 
d Sandly an
OnlyeO n
Use O1, on Dayon D
UseAll subjecll subj
lU amples shamplesttto
mercial
TAK -510
Study ID TAK -510-1001 Page 41of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.3.2 Part 3 Screening Through Day 1 Assessments
Table 3.g Part 3 Screening Through Day 1 Assessments
Day
-28 to -3Day
-2 aScheduled Time
Day -1 (Hours) Day 1 (Hours)
Screening 0 0.5 1 2 3 4 5 7 10 12 16 24bPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24b
Administrative Procedures
Informed consent X
Inclusion/exclusion criteria X X X
Medical history/demographics X
Previous and concomitant 
medicationsX--------------------------------------------------------------- Continuous review ------------------------------------------------------------------------- ---X
Clinic Procedures/Assessments
Full physical examination X X
Height X
Weight and BMI X X
Temperature and respiratory rate X X X X X X
BP and pulse cX X X X X X X X X X X X X X X X X X X X X X X X
Standing BP and pulse dX X X X X X X X X X X X X X
12-lead ECGs X X X X
ECG telemetry (12 -lead) X ----------------------- Continuous monitoring e-------------------- X X --------------------------- Continuous monitoring ------------------------ X
Telemetry extraction fX X X X X X X X
TAK -510/placebo administration X
AE monitoring X--------------------------------------------------------------Continuous review ----------------------------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory collection gX X X X
Serum sample for CK hX X
Glucose finger stick X X
Urine drug screen X X
Alcohol breath test X
Cotinine test X X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 42 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.g Part 3 Screening Through Day 1 Assessments
Day
-28 to -3Day
-2 aScheduled Time
Day -1 (Hours) Day 1 (Hours)
Screening 0 0.5 1 2 3 4 5 7 10 12 16 24bPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24b
Hepatitis screen iX
HIV test X
βhCG (pregnancy) test jXX
Serum FSH test kX
PK Evaluations
Plasma sample for TAK-510 PK X X X X
Immunogenicity and Biomarkers
Serum sample for immunogenicity X
Other
Confinement nX------------------------------------------------------------------------------------------------------------------------------ --------------------------------X
AE: adverse event; anti-HCV: antibodies to hepatitis C virus; βhCG: beta human chorionic gonadotropin; BMI: body mass index; BP: blood pressure; CK: creatine kinase; ECG: 
electrocardiogram; FSH: follicle-stimulating hormone; ; HBsAg: hepatitis B surface antigen; LFT: liver function test.
aSubjects will be admitted to the site on Day -2. 
b The 24-hour sample on a given day is the same as the predose sample on the next day; only 1 assessment will be collected at thi s time point.
cAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the fi nal result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in systolic or diastolic BP) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout s hould be the average of the 2 more consistent assessments. On Day -1, vital signs will be time-matched 
(±5 minutes) to the Day 1 clock time (ie, time-matched baseline). At predose, vital signs will be measured within approximately 1 h our before the first dose. All BP and pulse 
assessments must be completed before blood sampling.
dFor standing BP and pulse assessment, a BP and pulse assess ment will be performed after th e duplicate semirecumbent assessment has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP is <85 mm Hg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision). Day 1 time points will be time-matched (±5 minutes) to the 
Day -1 clock time (ie, time-matched baseline).
eAt least 24 hours of continuous telemetry monitoring will be conducted between check-in on Day -2 and predose on Day 1.
fPredose time-matched telemetry extractions may take place between Day -2 and Day -1 in conjuncti on with the 24-hour predose con tinuous telemetry.
Propertyonmm
CommComdose samose sam-C icate, andate, a
Nonnce >10 nce >10 b
rNbtainedtained ,th
For matched matche
a: Fod samplinsam
da: a BP and BP an
kedahis assessmasses
akehypotensioypotens
fT a kched baseched ba
of Tuous telemous t
ty oelemetry elemetrmeercbeta humta huialUUUUUUal UUUU
rcia----------------iase sseesenlnlnlnlly and Subject to the Applicable Terms of UseTe
licpp
00 0.50AAA
theA
ttthhhoth
toooo
ct
bjbjbjbjeubj
dS uSuu
nd Snd SdSd SdSdSdSdS
ya nnaa
nly aaayaaa
nla
rce Only
Use
mme
TAK-510
Study ID TAK-510-1001 Page 43 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.g Part 3 Screening Through Day 1 Assessments
Day
-28 to -3Day
-2 aScheduled Time
Day -1 (Hours) Day 1 (Hours)
Screening 0 0.5 1 2 3 4 5 7 10 12 16 24bPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24b
gSafety laboratory will include hematology, serum chemistry, and urinalysis parameters. During Part 3, if a LFT is elevated, a r epeat test should be performed before the next dose o f 
study drug is administered.
hIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s  discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
iHepatitis panel, including HBsAg and anti-HCV.
jSerum pregnancy tests for female subjects only.
kAn FSH level will be obtained for postmenopausal women.
Subjects will be confined.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
licpp
00 0.50AAA
theA
to thelevated, levated
ct toject t the int the in ve
ubjeSubjd Sand
Use ttthhh
e Only an
TAK -510
Study ID TAK -510-1001 Page 44of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.3.3 Part 3 Days 2 to 6 Assessments
Table 3.h Part 3 Days 2 to 6 Assessments
Scheduled Time
Days 2 -6 (Hours)
Pre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 a
Administrative Procedures
Previous and concomitant medications X-------------------------------------------------------- Continuous review ---------------------------------------------------- X
Clinic Procedures/Assessments
Temperature and respiratory rate X X X X
BP and pulse bX X X X X X X X X X X X
Standing BP and pulse cX X X X X X X
TAK -510/placebo administration dX
ECG telemetry (12 -lead) X------------------------------------------------------------ Continuous monitoring ------------------------------------------- X
Telemetry extraction X X eX eX e
AE monitoring X----------------------------------------------------- Continuous review -------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory collection fXg
LFTs Xh
Glucose finger stick X X
PK Evaluations
Plasma sample for TAK -510 PK X iX jX jX j
Other
Confinement kX----------------------------------------------------------------------------------------------------------------------------- -----X
AE: adverse event; BP: blood pressure; ECG: electrocardiogram; LFT: liver function test; PK: pharmacokinetic.
aThe 24 -hour sample on a given day is the same as the predose sample on the next day; only 1 assessment will be collected at this time p oint.
bAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate t he final result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in systolic or diastolic BP) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout should be the average of the 2 more consistent assessments . At predose, vital signs will be measured 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 45of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTable 3.h Part 3 Days 2 to 6 Assessments
Scheduled Time
Days 2 -6 (Hours)
Pre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 a
within approximately 1 hour before the first dose. All BP and pulse assessments must be completed before PK blood sampling.
cFor standing BP and pulse assessment, a BP and pulse assessment will be performed after the duplicate semirecumbent assessmen t has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP i s <85 mmHg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision, etc.). 
dFollow- up doses should be given at the same time as on Day 1.
eTelemetry extractions will be performed only on day(s) when the dose has changed from the previous day, and only if PK sample s are collected at the given time point. 
fSafety laboratory will include hematology, serum chemistry, and urinalysis parameters. During Part 3, if a LFT is elevated, a repeat test should be performed before the next dose of 
study  drug is administered.
gSafety laboratory assessments (including hematology, serum chemistry, and urinalysis parameters) will be performed on Day 2, Day 4, and Day 6.
hSamples for LFTs will be performed on Day 3 and Day 5.
iBlood samples for PK may be drawn 10 minutes before dosing. 
jSamples will be collected only on day(s) when the dose has changed from the previous day. Sampling times may change based on emerging data from Part 1.
kSubjects will be confined.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 46of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.3.4 Part 3 Day 7 and Day 8 Assessments
Table 3.i Part 3 Day 7 and Day 8 Assessments
Scheduled Time
Day 7 (Hours)Day 8
(Discharge)
Pre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 30
Previous and concomitant medications X----------------------------------------------------------- Continuous review ----------------------------------------------------------- X
Clinic Procedures/Assessments
Full physical examination X a
Temperature and respiratory rate X X X X X
BP and pulsebX X X X X X X X X X X X X
Standing BP and pulse cX X X X X X X
TAK -510/placebo administration dX
12-lead ECG X
ECG telemetry (12 -lead) X-------------------------------- Continuous --------------------------------------- X
Telemetry extraction X X X X X X
AE monitoring X------------------------------------------------------- Continuous ------------------------------------------------------- X
Laboratory Procedures/Assessments
Safety laboratory collection eX X
Serum sample for CK fX
Glucose finger stick X X
βhCG (pregnancy) test gX
PK Evaluations
Plasma sample for TAK -510 PK X hX X X X X
Immunogenicity and Biomarkers
Serum sample for immunogenicity iX
Blood sample for DNA (optional) jX
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 47 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.i Part 3 Day 7 and Day 8 Assessments
Scheduled Time
Day 7 (Hours)Day 8
(Discharge)
Pre
dose 0 0.5 1 2 3 4 5 7 10 12 16 24 30
Other
Confinement lX------------------------------------------------------------------------------------------------------------------X
AE: adverse event; βhCG: beta human chorionic gonadotropin; BP: blood pressure; CK: creatine kinase; ECG: electrocardiogram; ET: early termination; P K: pharmacokinetic.
aPhysical examination at the indicated visit will be symptom-driven.
bAll BP and pulse assessments should be made in duplicate, and the average of both assessments should be used to calculate the fi nal result. The investigator can take a third 
measurement if there is inconsistency ( ie, a difference >10 beats per minute in heart rate or a difference >10 mm Hg in systolic or diastolic BP ) between assessments (see 
Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout should be the average of the 2 more consistent assessments. At predose, vital signs will be measured 
within approximately 1 hour before the first dose. All BP and pulse assessments must be completed before PK blood sampling.
cFor standing BP and pulse assessment, a BP and pulse assessment will be performed after the duplicate semirecumbent assessment has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP is <85 mm Hg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision, etc.). 
dFollow-up doses should be given at the same time as those given on Day 1.
eSafety laboratory will include hematology, serum chemistry, and urinalysis parameters. Additional assessments may be collected at the investigator’s discretion.
fIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s  discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
gSerum pregnancy tests for female subjects only.
hPlasma sample for TAK-510 PK may be drawn 10 minutes before dosing.
iImmunogenicity serum samples for ADA testing will be taken at predose on Day 1, on Day 8, at ET (if applicable), predose on Day 14, and at the follow-up visit on Day 29. If ADAs 
are present, subjects may be asked to return for additional sample collections. All subjects receiving either study drug or pla cebo will have the same collection time points. 
jIf subjects have provided consent for the optional DNA collection, blood samples should be collected and can be collected at an y time on Day 8 (discharge) or at ET (if applicable; 
seeTable 3.j ).
lSubjects will be confined.
Property of TafT adaand e kinase; kinase
ly an
Only essments ssment
Onart ratet rate o
se Ould be thed be th
Usemust be cmust be
al Urformed aformed
cial must notmust n
erciaeadednesdedne
meron Day 1.n Day 1
mmnd urinalyd urina
Comtional serutional s
n-Continued mnued
Non-rN o0 minutesminut
For Nng will be ng will b
Fofor additior addi
da: Fe optionale optio
kedabjebje
Subjbj
dS u--------- -Suto the Applicable Terms of UseTe
lic
App
77hehehehe
dbject to
Taked
TAK -510
Study ID TAK -510-1001 Page 48of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL3.3.5 Part 3 Day 9 Through Day 15 Assessments, Follow -Up, and Early Termination
Table 3.j Part 3 Day 9 Through Day 15 Assessments, Follow -Up, and ET
Days
9 to 13Day
13Scheduled Time
ETDay 14 (Hours)Follow -up 
Visit 
Day 29 
±3days Washout aPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 2430 
(Discharge)
(Day 15)
Administrative Procedures
Previous and concomitant 
medicationsX X---------------------------------------------------------- Continuous review----------------------------------------------------------------------- X
Clinic Procedures/Assessments
Full physical examination X X bX X
Weight and BMIcX
Temperature and respiratory rate X X X X X
BP and pulse cX X X X X X X X X X X X X X X X
Standing BP and pulse dX X X X X X X X X
12-lead ECGs X X X
ECG telemetry (12 -lead) X----------------------------------------- Continuous monitoring ----------------------------------------- X
Telemetry extraction X X X X X X X X
TAK -510/placebo administration X
AE monitoring X X---------------------------------------------------- Continuous review ------------------------------------------------------------------- X X
Laboratory Procedures/Assessments
Safety laboratory collection eX X X X X X
Serum sample for CK fX
Glucose finger stick X X
Urine drug screen X
Alcohol breath test X
Cotinine test X
βhCG (pregnancy) test gX X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 49 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.j Part 3 Day 9 Through Day 15 Assessments, Follow-Up, and ET
Days
9 to 13Day
13Scheduled Time
ETDay 14 (Hours)Follow-up 
Visit 
Day 29 
±3 days Washout aPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 2430 
(Discharge)
(Day 15)
PK Evaluations
Plasma sample for TA K-510 PK X X X X X X X X X
Immunogenicity and Biomarkers
Serum sample for 
immunogenicity h X X X
Other
Confinement kX--------------------------------------------------------------------------------------------------------X
ADA: antidrug antibodies; AE: adverse event; anti-HCV: antibodies to hepatitis C virus; βhCG: beta human chorionic gonadotropin; BMI: body mass index; BP: blood pressure; CK: 
creatine kinase; ECG: electrocardiogram; ET: early termination; ; HBsAg: hepatitis B surface antigen; PK: pharmacokinetic.
aBased on emerging safety, tolerability, and available PK data, subjects may be confined during washout at the discretion of the  investigator in consultation with the sponsor and 
medical monitor. Duration of washout period may be shortened or lengthened in Cohorts 19 and 20 based on emerging data.
bPhysical examination at the indicated visit will be symptom-driven.
cFor BMI, any assessment on Days 13 through 15 will be acceptable as noted also in Table 3.f . All BP and pulse assessments should be made in duplicate, and the average of both 
assessments should be used to calculate the final result. The investigator can take a third measurement if there is inconsisten cy (ie, a difference >10 beats per minute in heart rate
or a difference >10 mm Hg in systolic or diastolic BP) between assessments (see Section 9.2.4 for details). If 3 measurements are obtained, the final BP readout should be the 
average of the 2 more consistent assessments. At predose, vital signs will be measured within approximately 1 hour before the fi rst dose. All BP and pulse assessments must be 
completed before PK blood sampling.
dFor standing BP and pulse assessment, a BP and pulse assess ment will be performed after th e duplicate semirecumbent assessment has been completed. The subject should stand still 
for approximately 3 minutes before this assessment. Standing assessments must not be performed if semirecumbent systolic BP is <85 mm Hg or if the subject presents with signs or 
symptoms suggestive of postural hypotension after standing (eg, lightheadedness or dizziness, nausea, blurry vision). Day 1 time points will be time-matched (±5 minutes) to the 
Day -1 clock time (ie, time-matched baseline).
eSafety laboratory will include hematology, serum chemistry, and urinalysis parameters.
fIf CK is elevated in an individual subject after dosing, additional serum samples for CK may be collected at the investigator’s  discretion. The medical monitor will be updated 
regularly on any findings of elevated CK and plans for continued monitoring. 
gSerum pregnancy tests for female subjects only.
Propertyerccts may bs may 
mmelengtheneengthe
ommiven.ven.
Comcceptable ceptabl
n-Cohe investie inves
NonccBPBP) ) betb
Noredose, vedose, 
For NFoand pulseand pul
a: Fssessmentessme
eda:tension afnsion a
kedd baseline)baselin
Takeematologematolo
fT aidual subjdual su
yo f  Tf elevatedleva
rty os for femafor feial Use OOOO
sese OOOO
Use---------------UselU titis C virtis C vlUy and Subject to the Applicable Terms of UseTe
licpp
10 1AAA
thA
ct toto ctctctct
ubjebje
dddS u bdS uubububub
dub
y and 
Only 
rcia
TAK-510
Study ID TAK-510-1001 Page 50 of 137
Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 3.j Part 3 Day 9 Through Day 15 Assessments, Follow-Up, and ET
Days
9 to 13Day
13Scheduled Time
ETDay 14 (Hours)Follow-up 
Visit 
Day 29 
±3 days Washout aPre
dose 0 0.5 1 2 3 4 5 7 10 12 16 2430 
(Discharge)
(Day 15)
hImmunogenicity serum samples for ADA testing will be taken at pre dose on Day 1, on Day 8, at ET (i f applicable), predose on Day 1 4, and at the follow-up visit on Day 29. If ADAs 
are present, subjects may be asked to return for additional sample collections. All subjects receiving either study drug or pla cebo will have the same collection time points. 
iIf subjects have provided consent for the optional DNA collection, blood samples should be collected and can be collected on Da y 8 (discharge; see Table 3.i ) or at ET (if 
applicable).
kSubjects will be confined.
Property of Takeda: For Non-Commercial Use Only andnd
ya nbject to the Applicable Terms of UseTe
licpp
10 1AAA
thA
tt oe), predos), predo
ect udy drug ody drug
bjecd can be cd can be
Subjto 
nd Su
TAK-510
Study ID TAK-510-1001 Page 51 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
Nausea and vomiting are among the most common and debilitating symptoms encountered in 
medicine as either symptoms of disease or side effects of treatments. Because of the complex 
multifactorial nature of nausea and vomiting, targeted therapies against the serotonin 3 (5-HT3) 
and neurokinin-1 receptors do not work effectively as monotherapies, making it a significant 
unmet medical need. 
4.2 Rationale for the Proposed Study
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, and 
pharmacokinetics (PK) of TAK-510 in healthy subjects to support further development of 
TAK-510. The study will be conducted in 3 parts: SRD via SC administration will be assessed in 
Part 1, and repeat-dose SC administration will be assessed in Part 2 (MRD) and Part 3 (dose 
titration and redosing after washout).
4.3 Benefit/Risk Profile
This study represents the first study in humans with TAK-510.
The main objective of this study is to assess th e safety and tolerability of TAK-510 in healthy 
subjects; as such, no clinical benefit is expected for study participants. Property of Takeda: For Nonfor theor th
of this fift h i s  f
inetneticics(
0. The 0. The
1, and re1, and r
atition anon 
4.34.3
TSubject to the Applicable Terms of Usein in 
mplex mplex 
3 (5-3 (5- HTH
significignifi
licab
ApplicApp
the Ato thect to 
bject 
Subjed Suandly a
Only
se OUse
ial Urcia
mercmme
Com
on-Co
TAK-510
Study ID TAK-510-1001 Page 52 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALThe potential risks of TAK-510 include HR increase, decreased BP, body weight loss, renal effects 
(proximal tubule vacuolation), elevated liver enzymes, injection site reaction, hypersensitivity,
immunogenicity, postural hypotension, and myalgia. These potential risks are based on safety 
observations from the Good Laboratory Practi ce (GLP)-compliant nonclinical safety 
pharmacology and repeat-dose toxicity studies  conducted with TAK-510, and clinical experience 
with TAK-510 (refer to the TAK-510 
Investigator’s Brochure for additional details). 
In nonclinical safety studies, the magnitude and dur ation of HR and BP changes in dogs were 
equivalent  at predicted therap eutic doses (sponsor data on file). 
Safety results from the FIH study demonstr ated a transient increase in HR within the 
first hour of dosing as well as decreases in sy stolic BP and diastolic BP that were more 
prominent with postural changes (orthostatic) in some individuals within the first 2 hours 
postdosing ( ; refer to the TAK-510 Investigator’s Brochure for additional 
details). Postural hypotension is an identified risk 
 Given the findings 
of decreased BP and increased HR
, it is hypothesized that TAK-510 causes vasodilation which leads to decreased BP 
and increased HR. 
Audited draft results from a definitive rat embryo-fetal development study indicate fetal 
malformations were observed in a single fetus at each of the mid and high dose 
; the no-observed-adverse-effect level (NOAEL) for embryo-fetal
development  (refer to investigat or’s broc hure, Section 4.3.6 for additional
details).
All of these factors could contribute to 
the risk of immunogenicity and thus an assessmen t of antidrug antibodies (ADA) in all parts of the 
study will be included as part of the risk mitigation strategy.Property of Takeda: For Non-Commercial Use O510 cau10 c
ve rat eme rat e
a singlesingl
he e nono-o
 (ref (re
Com
keda: For Non-C
fT a kof T
rty oertyeubjeSubj
nd Sand
nly at to the Applicable Terms of Useerience rience
TAKTAK -5
in dogsin dog
ponsor donsor
ase in Hse in H
astolic Btolic
thin thein th
ator’sator’s B
ject t
Only
TAK -510
Study ID TAK -510-1001 Page 53of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALSubjects with a history  of serious hypersensi tivity to any  medicati on or any  com ponent of 
TAK -510 formulat ion or with a history of significant multip leand/or severe allergies are excluded 
from this study . Subjects will be evaluated for the development of ADA as part of the study . The 
potenti al risks rel ated to HR increase, decreased BP, body weight loss, renal effects (proximal 
tubul e vacuo lation), elevated liver enzymes, and inject ion site reactions will be m onitored 
clinically and/or with laboratory  tests and have bee n considered when determining the stopping 
rules for this clinical study .
In addit ion to the potential risks associated with study  drug administration, there is minimal risk 
associ ated wi th study  procedures, including scheduled periodic phlebotomy (limited to <575 mL).  
Total  blood sampling vo lumes will not exceed approximately 319 mL (over 7 days o f confinement) 
in Part 1, approximately 505 mL (over 11 day s of confinement) in Part 2, and approximately  573 
mL (over 10 days of confinement fo llowed by  3 days o f confinement after washout) in Part 3. The 
maximum vo lume of blood sampling on any  single day  is approximately  117 mL in Part 1, 
approximately  147 mL in Part 2, and approximately 82 mL in Part 3.
To minimize the risks to the subjects in this study, the s ponsor considers the fo llowing measures to 
be appropriate: selecting TAK -510 doses with appropriate safet y margins based on nonclinical 
study  data; managing study  eligibilit y criteria; excluding women of childbearing potential; 
prespecifying safet y monitoring procedures, such as frequent BP assessments that include 
orthostati c BP m easurements, tel emetry , and 12 -lead el ectrocardi ogram  (ECG); devel oping 
guidance for invest igators; and using a clinical study  facility where cl ose m onitoring can be 
perform ed and urgent medical care can be init iated rapidly as appropriate. Overall, the proposed 
risk mit igation plan i s adequate to monitor subjects enrolled in the study . 
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Study Objectives
5.1.1 Study Primary Objective
The primary  object ive o f the study  is:
Part 1:
–To characterize the safet y and tol erabili ty of single SC doses of TAK -510 in healthy 
subjects.
Part 2:
–To characterize the safet y and tol erabili ty of multiple SC doses of TAK -510 in healthy 
subjects.
Part 3:
–To characterize the safe ty and tol erabili ty of multiple SC dose regimens of TAK -510 that 
include titration fro m lower doses in healt hy subje cts.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 54 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL5.1.2 Study Secondary Objectives
The secondary objectives of the study are:
!Part 1:
– To characterize the PK of TAK-510 in plasma following single SC doses in healthy 
subjects.
– To assess the immunogenicity of TAK-510 following si ngle SC doses in healthy subjects.
– To characterize the PK of TAK-510 in urine following single SC doses in healthy subjects.
!Part 2:
– To characterize the PK of TAK-510 in plasma fo llowing multiple SC doses in healthy 
subjects.
– To assess the immunogenicity of TAK-510 following mult iple SC doses in healthy 
subjects. 
– To characterize the PK of TAK-510 in urine following multiple SC doses in healthy 
subjects.
!Part 3:
– To characterize the safety and tolerability of single SC rechallenge doses of TAK-510 after 
a washout from multiple SC dose regimens that include titration from lower doses in 
healthy subjects.
– To assess the immunogenicity of TAK-510 following multiple SC dose regimens that 
include titration from lower doses, washout, and redosing in healthy subjects.
5.1.3 Study Explor atory Objectives
Exploratory endpoints of this study include: 
– To characterize the PK of TAK-510 in plasma following multiple SC doses and dosing 
schedules in healthy subjects.
Property of T–Non-Commercial Use Only and Subject to the Applicable Terms of Usehy hy 
ealtalthy shy 
in healtn hea
iple SC ple SC
mululmtitilllplepl
oowing mwing
ilitytyiiooyyf
regimenregim
citty y ofofTff
wer doswer do
tory Obtory O
s of this s of th
f Takeda: For No
TAK -510
Study ID TAK -510-1001 Page 55of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL5.2 Endpoints
5.2.1 Primary Endpoint
All parts of the study :
–The primary safet y endpoint of the study is safet y and tolerabilit y as assessed through vital 
signs, ECG, l aboratory  assessments, and adverse events (AEs). 
5.2.2 Secondary Endpoints 
Secondary  endpoints include: 
Part 1: pl asma PK parameters for TAK -510 
–Maximum observed plasma concentration (C max).
–Area under the plasma concentration -time curve from time 0 to infinit y (AUC ∞).
–Area under the plasma concentration -time curve from time 0 to time of the last quantifiable 
concent ration (AUC last).
–Time o f first occurrence of C max(tmax).
–Terminal disposit ion phase half -life (t 1/2z).
–Apparent cl earance after extravascular administration (CL/F).
–Apparent volume o f distribut ion during the terminal disposit ion phase after extravascular
administration (V z/F).
Part 2: plasma PK parameters for TAK -510 on Day 1 
– C max, tmax, and area under the plasma concentration- time curve during a dosing interval, 
where tau (τ) is the length of the dosing interval (AUC τ).
Part 2: plasma PK parameters for TAK -510 at steady  state 
–AUC τ, Cmax, tmax, t1/2z, CL/F, V z/F, observed plasma concentration at the end of a dosing 
interval  (Ctrough), accumulat ion rati o based on AUC τ(Rac[AUC] ), cal culated as AUC τat 
steady  state/AUC τafter a single dose, and accumulation ratio based on C max(Rac[Cmax] ), 
calculated as C maxat steady  state/C maxafter a single dose.
Parts 1 and 2: urine PK parameters for TAK -510
–Amount of drug excreted in urine from time 0 to time t (Aet). 
–Amount of drug ex creted in urine from time 1 to time 2 (Aet1-t2). 
–Amount of drug excreted in urine during a dosing interval (τ) at steady state (Ae τ).
–Fract ion of administered dose of drug excreted from urine fro m time 0 to tim et (fe,t). 
–Renal clearance (CL R).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 56 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL!Part 3:
– Safety and tolerability of single SC rechallenge doses after a washout from multiple SC 
dose regimens of TAK-510 as assessed through vi tal signs, ECG, laboratory assessments, 
and AEs.
!All parts of the study:
– Status of subject’s ADA assessment (ie, ADA-negative or ADA-positive, and low or high 
ADA titer).
5.2.3 Exploratory Endpoints
Exploratory endpoints will be assessed through the following parameters: 
!Part 3 includes the following plasma PK parameters:
– AUC τ, AUC last, Cmax.
6.0 STUDY DESIGN AND DESCRIPTION6.1 Study Design 
6.1.1 Overall Study Design
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety,
tolerability, and PK of TAK-510 in healthy subjects. 
The study will consist of 3 parts: 
!Part 1 is a FIH, randomized, double-blind, placebo- controlled, SRD design to assess the safety,
immunogenicity, tolerability, and PK of TAK-510 in healthy subjects. Up  to 17 cohorts may 
be enrolled. 
!Part 2 is a randomized, double-blind, placebo-c ontrolled, MRD design to assess the safety,
immunogenicity, tolerability, and PK of TAK-510 in  healthy subjects. Up to 8 cohorts may be 
tested in independent subject cohorts. 
!Part 3 is a randomized, double-blind, placebo-controlled, multiple-dose, dose titration and 
redosing design to assess the safety, immunogenicity, tolerability, and PK of TAK-510 in 
healthy sub jects. Up to 3 cohorts may be tested in independent subject cohorts using a dose 
titration design, followed by redosing with a single dose of study drug after a 7-day washout 
(168 hours after the previous dose).
TAK-510 and matching placebo will be administered SC. Safety will be assessed by monitoring 
for AEs, vital signs, ECG/telemetry, safety laboratory assessments after each dose, and Property of Takeda: For Non-Commercial Use Only and Srs:s:
TIONON
d, doubledoub
KK-510 in510 
of 3 parof 3 pa
, randomrando
niciticity,y, to
ed. d. 
2 i2 is a ras a r
mmunogmmuno
tested teste
!!the Applicable Terms of Usents, 
nd low ond low
rs: rs: 
Pad Subject to th
TAK -510
Study ID TAK -510-1001 Page 57of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALimmunogenicit y. PK sampling t imes and scheme may vary based on emerging safet y, tolerabil ity 
and PK data, but the maximal number of samples or the maximum t ime point will not change. 
Subjects m ay not parti cipate in more than 1 part or dosing cohort of the study .
An overview of treatment cohorts is outlined in Table 6.a. A schemat ic of the study design is 
presented in Section 2.0. The schedule o f study  procedures is presented in Section 3.0.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 58of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTable 6.a Overview of Treatment Cohort s
Cohort Regimen Treatment
Part 1
TAK -510 Placebo
1
SRD a6 2
2 6 2
3 6 2
4 6 2
5 6 2
6 6 2
7 6 2
8 6 2
9 6 2
10 6 2
11 6 2
12 6 2
21 6 2
22 6 2
23 6 2
24 6 2
25 6 2
Part 2 
TAK -510 Placebo
13
MRD6 2
14 6 2
15 6 2
16 6 2
17 6 2
26 6 2
27 6 2
28 6 2
Part 3 
TAK -510 Placebo
18
Dose Titration, Washout, 
Redosing6 2
19 6 2
20 6 2
MRD: multiple rising dose; SRD: single rising dose.
aUp to 17 doses may be explored with a maximum escalation factor between cohorts of 5 -fold at lower exposures and 
2-fold at high exposures.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 59 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL6.1.2 Part 1: SRD Cohort s 1 to 12 and 21 to 25
Part 1 will consist of up to 17 sequential cohorts with 8 healthy subjects per cohort. Subjects in 
each cohort will be randomly assigned to r eceive a single dose of TAK-510 or matching placebo 
via SC administration in a 3:1 ratio in a double-blind manner. Up to approximately 136 healthy
subjects will be randomized in Part 1 (approximate value do not account for potential replacement 
of subjects who withdraw for nonsafety reasons).
Subjects from each cohort will be admitted into the study unit on Day -2. Baseline HR and BP 
assessments, including postural measurements, will be taken on Day -1, and Day -1 HR and BP 
assessments will be time-matched to the Day 1 assessments. Subjects will be dosed with TAK- 510 
or matching placebo on Day 1 after a minimum of 8 hours of fasting. Subjects will be confined for 
96 hours after dosing (ie, they can be discharged after the 96-hour PK sample). Assessments of 
postural hypotension will be measured predose and at 0.5, 2, 4, 7, 10, 24, 48, 72, and 96 hours after 
the dose on Day 1, as well as at time-matched  time points on Day -1. Blood samples for 
assessment of TAK-510 plasma concentrations w ill be collected up to 96 hours postdose. Urine 
will be collected up to 24 hours postdose. 
Optional DNA 
samples will also be collected from subjects that provide consent for collection through a separate 
procedure. DNA samples can be co llected at any time on the day of discharge or at early 
termination (if applicable). Samples for immunoge nicity will be collected at discharge and at 
follow-up visits on Days 14 and 29.
Cohort 1 will use a staggered dosing scheme. After dosing the first 2 subjects (1 receiving 
TAK-510 and 1 receiving placebo), the investigator will review all available safety and tolerability 
data up to 24 hours postdose before dosing the remaining subjects in the cohort. A staggered 
dosing approach may be used for subsequent cohor ts in Part 1 (if decided in the dose escalation 
meeting). Except the starting dose, doses may be modified based on emerging safety and available 
PK data during the study, but will have a corresponding dose that does not exceed the maximal 
defined exposure. 
The exposure levels (AUC ∞) of TAK-510 range
 with a planned maximum dose escalation factor of 5-fold between lower 
exposures and 2-fold at high exposures.
 Doses may change based on emerging safety,
tolerability, and available PK data. The sponsor may decide to administer lower doses, repeat 
doses, and cancel cohort(s) if deemed appropriate. Subjects who drop out of the study may be 
replaced at the discretion of the sponsor af ter discussion with the investigator.
After completion of each dosing cohort, and before selecting the next dose, a blinded assessment 
of the safety and tolerability, laboratory results of at least 24 hours, and available PK data will be Properttakedres and es andFor Non-Commercial Use Only anrovide crovide 
nyytitiyme ome
munogenunoge
scheme.scheme
,ththe inve in
fore dosore do
d for subfor su
ing doseng dos
dyy, but w, but 
vels (AUvels (bject to the Applicable Terms of Useo 
thyhy
lacemenlaceme
HR anHR an
ayy--1 HR1 H
dosed wdosed 
ects wilts w
sample)samp
, 24, 48 24, 4
y--1. Bl1. B
ted up toed up 
SubjedS uand S
fT a kof Ta: Foeda: 
rty oerty
TAK-510
Study ID TAK-510-1001 Page 60 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALanalyzed in the dose escalatio n meeting (composed of representatives from the sponsor and site 
study teams).
The blind may be broken for select sponsor representatives before each blinded cohort review 
and/or dose escalatio n meeting, if n ecessary, due to safety considerations based on the 
prospectively prepared unblinding plan. Following each blinded dose cohort review and after dose 
escalation decisions have been made, the spons or may be unblinded using the prospectively 
prepared unblinding plan, to enable further data review to inform later parts of the study.
Study Drug Administration
 The single SC 
dose of TAK-510 should be administered in the abdomen (at least 2 cm away from the umbilicus) 
followed by upper arms, then thigh, as alternative si tes. In all cases, care should be taken to avoid 
areas of scars, moles, tattoos, or other irritated skin (eg, vitiligo, eczema, etc). TAK-510 must not 
be administered into an area where the skin appears to be tender to touch, signs of 
bruising/bleeding are noted, or the area seems indurated or erythematous. When locating injection 
sites on the abdomen, avoid giving the injection in the umbilicus, ribs, or hip bone. Subjects will be 
semirecumbent during dosing until requested to stand for orthostatic BP and pulse measurements. 
For additional information on study drug adminis tration, please refer to the study pharmacy 
manual.
6.1.3 Part 2: MRD Cohorts 13 to 17 and 26 to 28
Part 2 may start before the completion of Part 1. If Part 2 is started before the completion of Part 1, 
the starting dose in Part 2 will be based on predicted exposure to be below that observed at the 
highest completed cohort in Part 1. The daily ma ximum exposure anticipated at steady state will
not exceed an exposure established as tolerated in Part 1. Similar to Part 1, a staggered dosing 
approach may be used for cohorts in Part 2. Pa rt 2 consists of sequential dosing in up to 
8 ascending cohorts of healthy subjects. In each cohort, 8 healthy subjects will be randomly 
assigned to receive TA K-510 or matching placebo in a 3:1 ratio  in a double-blind manner. Up to 
approximately 64 h ealthy subjects may be randomized in Part 2 (approximate value do not account 
for potential replacement of subjects who withdraw for nonsafety reasons). 
Subjects will be admitted to the study unit on Day -2. Baseline HR and BP assessments will be 
taken on Day -1, and Day -1 HR and BP assessm ents will be time-matched to the Day 1 
assessments. Subjects will be dosed on Day 1 in each cohort/period after a minimum of 8 hours of 
fasting. Subjects will be confined until Day 9, 96 hours after the Day 5 dose, to assess safety,
tolerability, immunogenicity, and PK. Assessments of postural hypotension will be measured 
predose and at 0.5, 2, 4, 7, 10, and 24 hours after each  dose, as well as at time-matched time points 
on Day -1. Blood samples for assessment of TAK- 510 plasma concentrations will be collected up 
to 96 hours after the last dose. 
 Optional DNA samples will also be collected from subjects that provide consent for Property of Takeda: For Non-Commercial Use Only and Subject to thcmm awaawm
es, cares, car
o, eczemo, ecze
ender to nder t
or erythor eryt
umbilicmbi
and for ond for
istrationistratio
17 and17 an
on on of Paf P
e based based
Part 1.art 1. TT
ablishedablish
or cohocoh
of healtf heal h
e TAKTAK
64 healt64 hea
replacereplac
s will bewill b
on Dayon Da
sessmenessme
faststingin
toltolere
pApplicable Terms of Usefter dosfter do
tively vely 
studytudy.
App
the A
TAK-510
Study ID TAK-510-1001 Page 61 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALcollection through a separate procedure. DNA samples  can be collected at any time on the day of 
discharge or at early termination (if applicable). Subjects will return after discharge for additional 
immunogenicity and other assessments at follow-up visits on Days 14 and 29.
In Part 2, up to 8 tolerated doses from Part 1 up to the current planned maximum exposure (AUC ∞) 
of 705,000 h*ng/mL will be studied in an ascending manner. The daily maximum exposure in 
Part 2 will not exceed exposures determined to be tole rated in Part 1. Doses in Part 2 are planned to 
be administered SC once daily. Based on safety , tolerability, and emerging PK data from Part 1 
and any available PK data from Part 2, reductions in dose and in repeat dosing duration may be 
implemented. 
After completion of each dosing cohort, and before selecting the next dose, a blinded assessment 
of the safety and tolerability, laboratory results of at least 24 hours after the last dose in the cohort, 
and available PK data will be analyzed in the dose escalation meeting (composed of 
representatives from the sponsor and site study teams). At the dose escalat ion meeting, th e starting 
dose in Part 2 will be d ecided based on emerging safety, tolerability, and available PK data from 
Part 1.
The blind may be broken for select sponsor representatives before each blinded cohort review 
and/or dose escalation meeting, if n ecessary, due to safety concerns based on the prospectively 
prepared unblinding plan. Following each blinded dose cohort review and after dose escalation 
decisions have been made, the sponsor may be unblinded using the prospectively prepared 
unblinding plan, to enable further data review to inform later parts of the study. 
Subjects who drop out may be replaced at the discretion of the sponsor after discussion with the 
investigator.
Study Drug Administration
In Part 2, when administering TAK-510, injection sites must be rotated. 
The single SC dose of TAK-510 
should be administered in the abdomen first ( at least 2 cm away from the umbilicus), followed by 
upper arms, then thigh as alternative sites, avoiding areas of scars, moles, tattoos, or other irritated 
skin (eg, vitiligo, eczema, etc). If repeat injections of TAK-510 are given in the same spot, this 
may cause scarring and hardening of fatty tissue, wh ich may interfere with the absorption of the 
drug, and therefore injections should not be give n at the same location repeatedly. Each TA K-510 
injection must be administered approximately 2 inches (5 centimeters) apart and must not be 
administered into an area where the skin appears to be tender to touch, signs of bruising/bleeding 
are noted, or the area seems indurated or erythematous. If locating injection sites on the abdomen,
avoid giving the injection in the umbilicus, ribs, or hip bone. If injecting in the thighs, use the outer 
areas, below th e groin a nd above the knee. Subjects will be semirecumbent during dosing until 
requested to stand for orthostatic BP and pulse measurements. For additional information on study 
drug administration, please refer to the study pharmacy manual.Property of Takeda: For Noned in thd in th
high as igh a
o, eczemo, ecze
carring carring
therefoheref
on n mumust
ministereinister
are notede not
avoavoid
arearCommercial Use Only and Subject to the Applicable Terms of UseAUCUC∞∞) )
ure in ure in 
e planneplann
a fromfrom Pm
uration uration
se, a blina bl
r the lasr the l
ng (cong (co m
e escalaesca
abilitbility, y
tives befves be
safetafety y
d dose cdose 
e unblinunblin
w to inw to i
d at the dat the
ing TAKing TA
n-Co
TAK-510
Study ID TAK-510-1001 Page 62 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL6.1.4 Part 3: Dose Titration a nd Redosing Cohorts 18 to 20
The overall purpose of Part 3 is to characterize the safety and tolerability of multiple SC dose 
regimens of TAK-510 involving dose titration over 7 days of treatment. The intent of this study 
part is to enable a descriptive comparison (ie, without hypothesis testing) of tolerability findings 
between Part 3 cohorts and cohorts in Parts 1 and 2 with comparable exposures, to determine 
whether dose titration results in different toler ability. The redosing component of Part 3 is 
intended to provide an evaluation to assess the effects of a single rechallenge dose (after 7 days 
[168 hours] of wa shout following the 7-day treatment period) on the safety and tolerability profile 
(vital signs, adverse events, and other safety parameters). 
Part 3 may start before the completion of Parts 1 and 2. If Part 3 is started before the completion of 
Part 2, the maximum daily exposure in Part 3 will be at a total daily exposure level below or at the 
highest completed cohort in Part 2 that has been determined to be well tolerated. Similar to Part 1 
and Part 2, a staggered dosing approach may be used for cohorts in Part 3. Part 3 consists of up to 
3 sequential cohorts of healthy subjects. In each cohort, 8 healthy subjects will be randomly 
assigned to receive TAK-510 or matching placebo in  a 3:1 ratio in a double-blind manner. Up to 
approximately 24 h ealthy subjects may be randomized in Part 3 (approximate value do not account 
for potential replacement of subjects who withdraw for nonsafety reasons). 
Subjects will be admitted to the study unit on Day -2. Baseline HR and BP assessments will be 
taken on Day -1, and Day -1 HR and BP assessm ents will be time-matched to the Day 1 
assessments. Subjects will be dosed on Day 1 in each cohort/period after a minimum of 8 hours of 
fasting. Subjects will be confined until Day 8, 30 hours after the Day 7 dose, to assess safety,
tolerability, immunogenicity, and PK. Assessments of postural hypotension will be measured 
predose and at 0.5, 2, 4, 7, 10, and 24 hours after each  dose, as well as at time-matched time points 
on Day -1. Blood samples for assessment of TAK- 510 plasma concentrations will be collected on 
Days 1 to 7 and on Day 14, at predose and at select postdose time points to capture the predicted 
Cmax, as well as at 30 hours after the Day 7 and Day 14 doses. 
 Optional DNA samples will also be collected 
from subjects that provide consent for collection through a separate procedure. DNA samples can 
be collected at any time on the day of discharge  (Day 8) or at early termination (if applicable). 
Subjects will be discharged on Day 8 and will be readmitted the evening prior to redosing. After a 
7-day washout (168 hours after the last dose of the 7-day treatment period), subjects will be dosed 
with a single dose of study drug (ie, at the same  dose and double-blind treatment assignment as 
their highest daily dose during the 7-day treatment period). The duration of washout may be 
subject to change based on emerging safety, tolerability, and available PK data. Subjects will be 
confined the evening prior to redosing and for at least 30 hours after their redosing, while not being 
confined for the entire washout period. Subjects will return after discharge for additional 
immunogenicity and other assessments at follow-up visits on Day 29. Based on emerging safety,
tolerability, and available PK data, subjects may be confined during washout at the discretion of 
the investigator in consultation with the sponsor and medical monitor.Property of Takeda: Fothat provhat pr
d at any at an
will be will b
washouwasho
hh a singa sihh
heieir higrhiiii
subjesubj
coCommercial Use Only and Subject to the Applicable Terms of Usey 
dings ngs 
mine mine 
3 is is
(after 7 after 
olerabiliolerabi
before tfore 
posure lposur
ell tolerll tol
in Part n Part
lthy subthy su
ratio inatio in
Part 3Part 3
or nonsar non
y--y2. Ba2. B
sments ments 
y 1 in ea1 in e
Dayay8, 38, 
. AssessAsses
244houhouruu
ssessmesessm
at predospredo
rs after ts after
on-CNon
For N
TAK-510
Study ID TAK-510-1001 Page 63 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALIn Part 3, up to 3 cohorts may be dosed sequentially for 7 days using a dose titration design of 1 to 
5 days at lower doses followed by 2 to 6 days at the highest dose for that cohort, which will not 
exceed the dose studied in the highest completed dose cohort in Part 2. Cohorts 18 and 19 may be 
started in parallel. The proposed dose titration designs for the 3 cohorts are as follows:
Cohort 18: Single doses that escalate on a daily basi s will be given on the first 2 to 5 days of 
the 7-day dosing period, followed by a max imum daily dose on the remaining days of the 
7-day dosing period. 
Cohort 19: A lower starting dose will be given on the first 2 to 3 days of the 7-day dosing 
period, followed by a maximu m daily dose for the remaining days of the 7-day dosing 
period. The lower starting dose is to be determined based on Cohort 18. 
Cohort 20: The initial daily dose(s) are to be determined by Cohorts 18 and 19 and will be 
given on the first 1 to 3 days, followed by the maximum daily dose for the remaining days 
of the 7-day dosing period. The maximum daily dose will be the same as that Cohorts 18 
and 19, or higher as supported by safety, tolera bility, and PK data from at least the same 
daily dose (or higher) in Part 2 MRD cohorts.
Dose regimens up to the current planned maximum exposure level (AUC ∞) of 705,000 h*ng/mL 
will be studied as determined by the prior dosing regimen in Part 2. The daily exposure will not 
exceed an exposure established as well tolerated in Part 2. Doses in Part 3 are planned to be 
administered SC once daily. Based on emerging PK data from Parts 1 and 2, and PK data from
prior cohorts in Part 3, adjustments to dose and to repeat dosing duration may be implemented. 
The dose escalatio n meeting will determin e the doses and dose schedule of Cohort 18 and 19 based 
on safety, tolerability and available PK data from Pa rts 1 and 2. After completion of Cohort 18 and 
19, and before selecting the next dose schedule, a blinded assessment of the safety and tolerability,
laboratory results of at least 24 hours after the last dose in the cohort, and available PK data will be 
analyzed in the dose es calation meeting (composed of representatives from the sponsor and site 
study teams).
The blind may be broken for select sponsor representatives before each blinded cohort review 
and/or dose escalation meeting, if n ecessary, due to safety concerns based on the prospectively 
prepared unblinding plan. Following each blinded dose cohort review and after dose escalation 
decisions have been made, the sponsor may be unblinded using the prospectively prepared 
unblinding plan. 
Subjects who drop out may be replaced at the discretion of the sponsor after discussion with the 
investigator.
Study Drug Administration
In Part 3, when administering TAK-510, injection sites must be rotated.
. The single SC dose of TAK-510 
should be administered in the abdomen first ( at least 2 cm away from the umbilicus), followed by 
upper arms, then thigh as alternative sites, avoiding ar eas of scars, moles, tattoos, or other irritated 
skin (eg, vitiligo, eczema, etc). If repeat injections of TAK-510 are given in the same spot, this Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usebe 
5 days o5 days 
days of ays o
f the 7f the 7 d
f the 7the 7 -d
ort 18. 18. 
ohorts 1horts 
ailyilydosedoy
ll be thbe l
and PKand P
xposureposu
egimen gimen
d in Partd in Pa
ing PK g PK
eeand toand 
rmine thmine t
PK dataPK da
dose scdose 
4 hours hour
attioion n mm
roken fooken 
latatioion nm
linding pnding
have beeave be
ing planng pla
jects whjects w
nvestigavesti
StuS
TAK -510
Study ID TAK -510-1001 Page 64of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALmay cause scarring and hardening of fatty  tissue, which may  interfere wi th the absorpti on of  the 
drug, and therefore, injections should not be given at the same location repeatedly. Each TAK -510 
inject ion must be administered approximately 2 inches (5 centimeters) apart and must not be 
administered into an area where the skin appears to be tender to touch, signs of bruising/bleeding 
are noted, or the area seems i ndurated or ery thematous. If locating inject ion sites on the abdo men, 
avoid giving the injection in the umbilicus, ribs, or hip bone. If injecting in the thighs, use the outer 
areas, below the groin and above the knee. Subjects will be semirecumbent during dosing until 
requested to stand for orthostatic BP and pulse measurements. For addit ional informat ion on study 
drug administration, please refer to the study  pharmacy manual.
6.2 Stopping Rules
6.2.1 Stopping Criteria for Individual Subjects
Subjects will permanent ly discont inue study  drug for any  study  drug -related adverse events that 
are rated Grade ≥3 in severit y on the Nati onal Cancer Insti tute (NCI) Commo n Termino logy 
Criteria for Adverse Events (CTCAE) scale (v5.0).
6.2.2 Criteria for Premature Termination or Suspension of the Study
The study  will be com pleted as pl anned unless one or more of the fo llowing cri teria are satisfied 
that require temporary  suspensi on or early  terminati on of  the study :
Any subject experiences a Hy’s Law react ion (defined as alanin e aminotransferase [ALT] or
aspartate aminotransferase [AST] >3 ×the upper limit of normal [ ULN] in conj uncti on wi th
elevated total  bilirubin >2 ×ULN wi thout findings of cho lestasis or other alternate etio logy).
New informat ion or other evaluat ion regard ing the safet y or efficacy  of the study  drug that
indicates a change in the known risk profile for TAK -510, such that the risk is no longer
acceptable for subjects participating in the study .
Significant vio lation of Good Clinical Practice (GCP) that compr omises the abilit y to achieve
the primary  study  objectives or compromises subject safet y.
The sponsor elects to terminate or suspend the study for administrative reasons including plans
to modify , suspend, or di scontinue development of the study  drug.
In addition, the study  may  be interrupted for review of the safety data during Parts 1, 2, or 3 if one 
of the below criteria is met:
Two or more subjects experience a sinus tachycardia with HR >120 bpm at rest while
semirecumbent with symptoms of palpitation or lightheadedness requiring medical
intervent ion and considered related to TAK -510, or
Two or more subjects experience a CTCAE v5.0 Grade ≥3 hy potensi on (ie, requi ring medical
intervent ion) and considered related to TAK -510, or
One subject experiences a C TCAE v5.0 Grade ≥3 syncope (faint ing or orthostatic co llapse)
and considered related to TAK -510, or
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 65of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTwo or more subjects experience a CTCAE v5.0 Grade 3 event considered related to TAK -510 
administration, or 
One subject experience a CTCAE v5.0 Grade 4 eve nt consi dered related to TAK -510 
administration, or
One subject with ALT or AST >5 × ULN after TAK -510 administration, or
One subject with ALT or AST >3 × ULN wi th appearance of fat igue, nausea, vo miting, right 
upper quadrant pain or tenderness, fever, ras h, and/or eosinophilia (>5%), or
One subject with increases in creatinine >1.5 × ULN after TAK -510 administration, or 
One subject with a serious adverse event (SAE) considered related to TAK -510 administration ,
or
Two or more subjects experience a CTCAE v 5.0 Grade ≥2 injection site react ion (defined as 
pain co mbined with lipodystrophy and/or edema).
If a safet y concern i s ident ified after review of the data, the invest igator and/or the sponsor may 
consider potential changes in the next planned dose level. Possible changes in dose administration 
include, but are not limited to:
Administrati on of  an interm ediate dose between the current and next planned dose.
Repeated administration of the current dose.
Administrati on of  a lower dose than the exist ing dose le vels.
Study  terminat ion. 
Study  drug dosing m ay resume if the event is considered unlikely to be related to treatment with 
study  drug by  the investi gator and sponsor.
During Study Drug Dosing in Part 2 (MRD)
If the cr iteria for pausing occurs in SRD Part 1 at a hig her level than is being dosed in MRD Part 2, 
dosing in Part 2 may  cont inue provided it is at a lower daily dose than in Part 1 than that at which 
the event was observed, and the sponsor and investigator agree after careful review of the totalit y 
of the available blinded data.
During Study Drug Dosing in Part 3 (Titration and Redosing After Washout)
If the criteria for pausing occurs in MRD Part 2 or SRD Part 1 at a higher level than is being dosed 
in Part 3 (i e, higher l evel than the m axima l dose during ti tration or Day  14), dosing in Part 3 may 
continue provided it is at a lower daily  dose than in Parts 1 or 2 than that at which the event was 
observed, and the sponsor and invest igator agree after careful review of the totalit y of the available 
blinded data.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 66 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL6.3 Rationale for Study Design, Dose, and Endpoints
6.3.1 Rationale of Study Design 
A randomized, double-blind, placebo-controlled design for Part 1 is considered adequate to 
characterize the safety, tolerability, and PK of single doses of TAK-510.
Part 2 of the study is a randomized, double-blind, placebo-controlled, sequential panel MRD study 
where up to 8 cohorts may be studied under repeat-dose conditions.
The intention with the dose titration part of Part 3 is to provide an exploratory evaluation to assess 
the safety and tolerability profile of dose titrati on at the start of the 7-day treatment period. This 
comparison will be descriptive (ie, without hypothesis testing) versus tolerability findings in Parts 
1 and 2 with comparable exposures to determine whether dose titration results in different 
tolerability. The redosing part of Part 3 is intended to provide an exploratory evaluation to assess 
the effects of a single dose (after 7 days [168 hours] of washout following the 7-day treatment 
period) on vital signs, adverse even ts, and other safety parameters.
6.3.2 Rationale for Dose 
The starting dose for this FIH study is 5 μg. The 4 considerations for the selection of the starting 
dose for the FIH study are summarized here and described in more detail below:
1. Nonclinical safety data and Food and Drug Administration (FDA) maximum safe starting dose 
guidance [10].
2. Nonclinical cardiovascular safety pharmacology data for TAK-510.
3. Benchmarking to  cardiovascular findings.
4. Lowest projected antiemetic effect and insulin secretion effect as demonstrated in nonclinical 
species.
6.3.2.1 FIH Starting Dose Consideration Based on Nonclinical Safety Study Results, 
Published  Results,  Experience
The principle of the FDA Guidance “Estimating the Maximum Safe Starting Dose in Init ial 
Clinical Trials for Therapeutics in Adult Healthy Volunteers” [10] is to use a 10-fold safety factor 
on the no-observed-adverse-e ffect level (NOAEL) from nonclinical data to identify a starting 
clinical dose.
For TAK-510, NOAELs were identified in the 2- week GLP-compliant, repeat-dose toxicity 
studies, and no-observed-effect levels (NOELs) we re identified in the respiratory and central
nervous system safety pharmacology studies. 
The NOAEL in the rat was 60 mg/kg (highest dos e investigated); minimal body weight loss and 
dose-dependent minimal to moderate vacuolation of the proximal convoluted tubule of the kidney 
(without degeneration/necrosis or changes in clinical pathology) were considered nonadverse. The 
NOAEL in the dog was 15 mg/kg; body weight loss and associated clinical observations were 
considered adverse at 50 mg/kg. Property of Takeda: For Non-Commeetic effeic eff
rting Doing D
hed ed 
of the Fof the 
ials for als fo
oo-obserobse
al doseal dos
or TAKr TA
studistudcial Use Only and Subject to the Applicable Terms of Usel MRD s MRD
evaluatvaluat i
eatmenteatme
erabilitrabilit
n resultn resu
xploratoplorat
foollollowi
eters.eters.
considernside
describescr
ug Admg Ad
phapharmr
e
nernNomerci
TAK-510
Study ID TAK-510-1001 Page 67 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALHowever, cardiovascular effects in dogs were th e principal finding in the safety pharmacology
studies. In this study, the lowest dose of  TAK-510 produced a transient increase in 
HR and a transient decrease in BP, and a NOEL was not identified.
Given the reversible nature of the cardiovascular changes, and the lack of other significant safety 
findings at this dose level, the  TAK-510 dos e is not anticipated to result in any 
clinically significant effects or significant safety risk.
 Incretin effects 
were as expected with transient, glucose-dependent increases in both insulin and glucagon 
reported. Cardiovascular effects were consistent across studies with an increase in HR and 
decrease in BP reported during the 2 to 4 hours of infusion. 
Additionally, the lowest dose tested  in the first-in-human 
clinical study of  resulted in changes in BP 
(diastolic BP changes at 30 minutes) that were not considered clinically significant.  
 Refer to the current edition of the 
TAK-510 Investigator’s Brochure for additional details of FIH study findings .
The selected FIH dose  and derived from a combination of 
nonclinical and clinical cardiovascular profiles in which submaximal or minimal cardiovascular 
changes, respectively, were reported. 
Property of Takeda: For igator’sigato
FIH doFIH d
al and cl and 
es, respees, resp
of Ta
perty ofCommercial Use Only and Subject to the Applicable Terms of Useolologyogy
ncrease crease
sisignificgnif
d to resuto res
ases in bses in 
s studiestudie
fusiousionn
ed d 
minuminu testo
eA p pthe A
ect t
ubjec
nly aOnly
se OUse
ial U
erci
mme
-Co
Non-CrN o
TAK-510
Study ID TAK-510-1001 Page 68 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALIn summary, given the totality of these findings from nonclinical safety, published literature, and 
nonclinical pharmacology, the proposed starting dose is 5 μg.
6.3.2.2 FIH Maximum Dose Consideration
No adverse toxicological findings were observed in 2-week repeat dose GLP-compliant 
toxicology study in rats at doses up to 60 mg/kg; however; body weight loss and associated clinical 
observations were considered adverse in dogs at 50 mg/kg. The NOAEL was determined to be the 
mid-dose of 15 mg/kg/day in dogs, which produced an AUC (705,000 h*ng/mL) that was less than 
half the rat NOAEL AUC (2,470,000 h*ng/mL); the dog was considered to be the most sensitive 
species. As per the International Council for Harmonisation of Technical Requirements for 
Pharmaceut icals for Human Use (ICH) “Guidance on Nonclinical Safety Studies for the Conduct 
of Human Clinical Trials and Marketing Authorization for Pharmaceut icals M3(R2)” [13], for 
situations where only one species demonstrates adverse toxicities, the maximum clinical dose will 
be limited to AUC exposure at the NOAEL in the species showing toxicity or half the AUC at the 
NOAEL in the species without toxicity. Thus, the AUC of TAK-510 in the clinic will not exceed 
705,000 h*ng/mL, which is the dog NOAEL AUC.
Preliminary data from other studies recently analyzed have helped refine  
 The doses that are 
predicted to maintain concentration in the efficacious range and allow for optimal onset of 
response within 30 minutes are planned to be evaluated.
Given the available formulation  and f easibility limitation of maximum administered 
volume of 1 mL per SC injection,  is the highest planned dose predicted to be evaluated in 
Part 1. The predicted exposure  will be
below the dog NOAEL (most sensitive species; AUC ∞= 705,000 h*ng/mL).
6.3.2.3 FIH Proposed Dose Regimen for the SRD Cohorts
The proposed dose regimen with target PK and safety margins for select proposed doses is 
presented in Table 6.b.
Property of Takeda: For Non-Commercial Uthe effihe ef
nned to ned t
n 
ctioion, n, 
osure sure 
NOAELOAE
ProposePropo
d dose rdose
inTablTabmmermse Only and Subject to the Applicable Terms of Use, and and 
mpmplianlia
nd assond ass
was as detedete
h*ng/mL*ng/m
dered to ered t
chnicalchnic
ical Safcal Sa
Pharmaharm
oxicitxicitiei
cies shoies s
AUC ofUC o
UC.UC.
y analyzanalyof U
omUse
TAK-510
Study ID TAK-510-1001 Page 69 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALTable 6.b Human Dose-Related Concentrations and Exposures for Select Proposed 
Doses in Part 1
Dose a(μg) C max(ng/mL) AUC ∞(h*ng/mL)Safety Margin NOAEL 
Exposure
5
AUC: area under the plasma concentration-time curve; AUC ∞: area under the plasma concentration-time curve from 
time 0 to infinity; C max: maximum observed plasma concentration; NOAEL: no-observed-adverse-effect level; PK: 
pharmacokinetic.Exposure at NOAEL in dog 705,000 h*ng/mL (AUC). 
Values represent geometric mean.
aSingle dose administered. 
bPreliminary observed PK parameters.
cPredicted assuming linear PK from observed  preliminary human PK data from this ongoing study. 
It is planned that up to 17 doses may be explored with a maximum escalation factor between 
cohorts  at lower exposures and  at high exposures. 
Dose levels may be adjusted based on emerging safety and available PK data from previous 
cohorts, and after discussion between the sponsor and investigator. Doses may be repeated if 
safety and tolerability are acceptable, or lower doses may be studied to increase data within the 
dose range. Any decision to resume dosing at the current dose level or to escalate the dose will be 
made jointly by the investigator and the sponsor after careful evaluation of all available blinded 
data.
6.3.2.4 Rationale for Dosing Interval
Multiple dose cohorts (Part 2) will be administered TAK-510 once daily.
The dosing regimens selected for Parts 2 and 3 will have a projected AUC ∞that will not exceed an 
AUC∞of 705,000 h*ng/mL or the highest AUC ∞determined to be tolerated in Part 1.
6.3.2.5 Rationale for Dose Titration and Redosing After Washout
Part 3 of the study is intended to evaluate whether dose titration can result in a different tolerability, 
particularly with regard to cardiovascular effects, and whether redosing after a 7-day washout 
results in cardiovascular effects (ie, loss of potential attenuation of cardiovascular effects with 
dose titration and multiple dosing). GLP-compliant a nd non–GLP-compliant cardiovascular safety 
studies in telemetered dogs with TAK-510 have demonstrated: (1) a dose-response of 
cardiovascular effects, where the lowest dose tested  results in an ~ED 50(median 
effective dose) of maximal heart rate and blood pressure effects observed in dogs; (2) 
repeat-dosing at therapeutic doses results in a significant attenuation of cardiovascular effects 
following administration of the second daily dose. These data demonstrate that sub-therapeutic Property of Takeda: For Noimens semens 
5,000 h5,000 
RaR
t 3 3ofoftfCommercial Use Only and Subject to the Applicableon--time ctime
rsese--effeceffe
ata from ta fromble
aximumaximum
exposurxposu
ety y and and
r and invand in
r doses mdoses m
at the cat the 
sponsorpons
g IntervInter
2) will b) will
h
partiparticulcu
resulresu
dodCom
Non-Ce Terms of UseAEL EL o
erTe
ble T
TAK -510
Study ID TAK -510-1001 Page 70of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALdoses can elicit minimal cardio vascular effects and that repeat dosing may elicit tachyphylaxis. 
Thus, Part 3 of this study  is designed to test th ese concepts clinically to ident ify the appropriate 
tolerizing doses, escalat ion, and length of time of exposure that can potentially minimize 
cardi ovascular effects at therapeutic doses. 
6.3.3 Rationale for Endpoints
The PK and safet y endpo ints are standard fo r this type of study  and are used wi dely and are 
recogni zed as reliable, accurate, and relevant. Additional PK parameters may  be calculated if 
deem ed necessary  for the interpretati on of  the data.
6.3.4 Critical Procedures Based on Study Objectives: Timing of Pro cedures 
For thi s study , the fo llowing procedures are critical: 
Parts 1, 2, and 3:
Timing of PK, BP, and telemetry  assessments.
All other procedures should be performed as close as possible (either before or after) the 
scheduled times.
The order of priori ty can be changed during the study  with joint agreem ent of  the invest igator 
and the sponsor.
Any nonscheduled procedures required for urgent evaluat ion of safet y concerns take precedence 
over all routine scheduled procedures. 
6.4 Procedure Modifications Permitted Within Protocol Parameters
This is a phase 1 study of TAK -510 in humans, and the PK and safet y profiles of the compound are 
still being elucidated. This protocol is written to accommodate the dependence on evo lving data 
and the inherent dynamic nature of phase 1 clinical studies. Minor changes in procedures, for 
example , changes to the specific dose regimen in any cohort or the specific timing of assessments, 
will be documented and may not require a protocol amendment or informed consent form update if
the changes do not impact the burden of subjects or safet y monitoring.
6.5 Study Beginning and End/Completion
6.5.1 Definition of Beginning of the Study
The overall study  begins when the first subject signs the study  informed consent form.
6.5.2 Definition of End of the Study
The overall study  ends when the l ast subject com pletes the l ast pl anned or follow -up 
visit/interact ion associated with a planned visit (this can be a phone contact), discont inues fro m the 
study , or is l ost to foll ow-up (ie, the invest igator is unable to contact the subject).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 71of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL6.5.3 Definition of Study Discontinuation
Study  discontinuation because of nonsafet y reasons, such as the fo llowing: 
A finding (eg, PK, efficacy) fro m another nonclinical or clinical study  using the study  
treatm ent resul ts in the study being stopped for a nonsafet y-related reason. 
Data from co mparator(s), drug(s) of the same class, or methodology(ies) used in this study 
beco me available and results in the study  being stopped for a nonsafety- related reason. 
The study  is stopped because of nonscient ific and nonsafet y reasons, such as slow enrollment. 
Study  discontinuation because of safet y reasons: 
Early study  terminat ion because of concerns of safety  to the study  subjects ari sing fro m 
clinical or nonclinical studies wit h the study  treatment(s), comparator(s), drug(s) of the same 
class, or m ethodol ogy(ies) used in this study .
6.5.4 Criteria for Premature Termination or Suspension of the Study
6.5.4.1 Criteria for Premature Termination or Suspension of Study 
See Secti on6.2for study -specific stopping rules and addit ional criteria for premature termination 
or suspensio n of the study .
6.5.4.2 Procedures for Premature Termination or Suspension of the Study
In the event tha t the sponsor, an Inst itutional Review Board (IRB) and/or Independent Ethics 
Committee (IEC), or regulatory  authori ty elects to terminate or suspend the study  or the 
participat ion of an invest igational site, a study -specific procedure for early terminat ionor 
suspension will be provided by the sponsor; the procedure will be fo llowed by  applicable 
investigat ional sites during the course of termination or study  suspensi on.
6.5.5 Criteria for Premature Termination or Suspension of a Site
6.5.5.1 Criteria for Premature Termi nation or Suspension of a Site 
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of Good Clinical Practices (GCP), protocol, or contractual 
agreem ent, is unable to ensure ade quate performance of the study, or as otherwi se permitted by the 
contractual agreement.
6.5.5.2 Procedures for Premature Termination or Suspension of a Site
In the event that the sponsor, an IRB and/or IEC, or regulatory  authori ty elects to terminate or 
suspend th e study  or the parti cipati on of  an invest igational site, a study- specific procedure for 
early terminat ion or suspensio n will be provided by the sponsor; the procedure will be fo llowed by 
applicable invest igational sites during the course of terminat ion or study  suspensi on.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 72of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.1 Inclusion Criteria 
To be eligible for participat ion in this study , the subject m ust:
1.Understand the study  procedures and agree to participate by  providing wri tten informed 
consent.
2.Be willing and able to comply with all study  procedures and restrict ions.
3.Be a healthy man or woman of nonchildbearing potential aged 18 to 55 years, inclusive, at the 
screening visit.
4.Continuous nonsmoker who has not used nicotine -and tobacco -containing pro ducts for at least 
3months pri or to dosing and throughout the study .
5.Have a body  mass index (BMI) ≥18 and ≤30.0 (kg/m2) at the screening visit.
6.Be judged to be in good health (eg, no evidence of psychiatric, hepatic, renal, pulmo nary, or 
cardi ovascular di sease) by the invest igator, based on clinical evaluations including laboratory 
safet y tests, m edical history , physical  examinat ion, ECG, and vital sign measurements 
perform ed at the screening visit and before administration of the init ial dose of study  drug or 
invasive procedure.
7.Meet the fo llowing bi rth control  requi rements (see Appendix D): 
–Is a m ale subject who i s sterile or agrees to use an appropriate method of contraception, 
including a condom wit h spermicidal cream or jelly, from the first dose of study drug unt il 5 
half-lives after the last dose of study  drug. No restrict ions are required for a vasectomized 
male subject provided the subje ct is at l east 1 y ear after bilateral vasectomy procedure 
before the first dose of study  drug. A m ale subject whose vasectomy procedure was 
perform ed less than 1 y ear before the first dose of study  drug m ust fo llow the same 
restri ctions as a nonvasectomize d man. Appropriate documentation of surgical procedure 
shoul d be provi ded. Male subjects should agree to use condom wit h spermicide fro m 
screening time point if they  cannot bring docum entati on for bilateral  vasectomy.
–Is a m ale subject who agrees not to do nate sperm from the first dose of study drug unt il 
5half-lives after the last dose of study  drug.
–Is a female subject of nonchildbearing potential, defined by at least 1 of the fo llowing 
criteria:
a)Postmenopausal  (defined as 12 months of spontaneous amenor rhea in females 
aged >45 years or 6 months o f spontaneous amenorrhea in females aged >45 y ears wi th 
serum  follicle-stimulat ing hormone (FSH) levels >40 mIU/mL). Appropriate 
docum entati on of  FSH levels is required.
b)Surgically sterile by hysterectomy, bilate ral salpingectomy, and/or bilateral oophorectomy 
with appropri ate docum entati on of  surgi cal procedure.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 73of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALc)Had a bilateral tubal ligat ion with appropri ate documentati on of  surgical  procedure.
d)Has a congenital condit ion result ing in no uterus.
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study :
1.The subject has part icipated in another investigational study wit hin 4 weeks (or based on local 
regul ations) or within 5 half -lives of the invest igational product before the screening visit. The 
4-week or 5 half -lives window will be derived from the date of the last dose and/or AE related 
to the study  procedure in the previous study  to the screening visit of the current study .
2.The subject is an emplo yee o f the sponsor or study site or immediate family  member 
(eg,spouse, parent, child, sibling) of the sponsor or study site.
3.The subject has a history  of significant m ultiple and/or severe allergies (eg, food, drug, latex 
allergy ) or has had an anaphylact ic reaction or si gnificant intol erance to prescript ion or 
nonprescript ion drugs or food.
4.The subject has a known hypersensit ivity or contraindicat ion to any  com ponent of TAK -
510.
5.The subject has a posit ive pregnancy test or is lactating or breastfeeding.
6.The s ubject has a positive test result for hepatit is B surface ant igen, hepat itis C virus ant ibody , 
or hum an immunodeficiency  antibody /antigen, at the screening visit. 
7.The subject had major surgery  or donated or l ost 1 unit of blood (approximately 500 mL) 
within 4 weeks before the screening visit.
8.The subject is unable to refrain fro m or anti cipates using all medications including herbal 
medicines beginning approximately 7 days before administration of the first dose of study drug, 
throughout the study  until 2 days after di scharge. 
9.The subject is unable to refrain fro m or anti cipates using marijuana or cannabis -containing 
products beginning approximately 7 days before administration of the first dose of study drug, 
throughout the study  until after the l ast PK d ose. 
10.The subject has a history or presence of alcoho lism or drug abuse within the past 2 years prior 
to dosing, or frequent or heavy use (ie, near -daily) of m edical or recreati onal cannabis in the 
past 3 months before screening.
11.The subject drinks alcoho lin excess of 7 drinks/week for women or 14 drinks/week for men 
(where 1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces 
[45mL] of hard liquor [45% alcoho l]) within 3 m onths before screening. 
12.The subject has a posit ive alcoh ol breath test or urine drug screen result s at screening or 
check -in.
13.The subject has had a previous major psy choti c disorder.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 74of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL14.The subject has a history  or presence of: 
–3 or m ore incidences of vasovagal syncope within the last 5 y ears pri or to screening; or
–A family history  of unexplained sudden death or channelopathy; or
–Brugada syndro me (ie, RBBB pattern with ST -elevation in leads V1- V3); or
–Cardi ovascular or cerebrovascular disease, such as cardiac valvulopathy, my ocardi al 
infarction, stroke, sick sinus syndrom e, pulm onary congest ion, symptomat ic or significant  
cardi ac arrhy thmia, second- degree atri oventri cular (AV) block ty pe 2, thi rd-degree AV 
block, prol onged QT interval with Fridericia correction method ( QTcF) interval, 
hypokal emia, hypo magnesemia, o r conduction abnormalit ies; or
–Risk factors for Torsade de Pointes (eg, heart failure, cardio myopathy, or family history of 
Long QT Syndrome); or
–Any clinically  significant ECG findings or medical history  including: l ong or short QTcF 
(over 450 msec or les s than 360 msec), bifascicular block or QRS ≥120 msec or PR 
interval  >210 msec at screening or Day -1 pre -Hour0; or
–The subject has a documented history  of sinus brady cardia (<45 bpm) based upon vital 
signs assessments, sinoatrial block as evidenced on EC G or sinus pause ≥3 seconds on 
ECG or predose telemetry .
15.The subject has an average semirecumbent BP less than 90/60 mm Hg or greater than 
140/90 mmHg from screening to predose, inclusive. Any assessments on Day  -1, where 
2consecutive t imepoint values d o not m eet thi s criterion, must be discussed with the medical 
monitor for approval. 
16.The subject has an average HR <55 or >100 bpm from screening to predose, inclusive. 
Subjects with an average HR <55 bpm can be enrolled only wit h medical monitor approval .
Any assessments after admissio n with an average HR <55 bpm, from Day  -2 to predose 
(inclusive), will be left to the judgment of the investigator, unless HR is <50 bpm, which must 
be discussed wit h the m edical mo nitor for approval.
17.The subject has orthosta tic hypotensi on defined as a decrease in systolic BP ≥20 mm Hg or a 
decrease in diastolic BP ≥10 mm Hg atapproximately 3 minutes of standing when co mpared 
with BP f rom the semi recumbent posi tion at screening to predose assessments, inclusive. In 
asymptoma tic subjects, any  assessments after screening that do not meet this criterion may be 
repeated after the subject has remained in the semirecumbent or supine posit ion for 15minutes. 
If the repeat assessment is exclusio nary based on the above criterion, the subject will not be 
eligible. If the repeat assessment is not exclusio nary, the subject will be eligible. 
18.The subject has postural orthostatic tachycardia, defined as an increase of >30 bpm or 
HR > 120 bpm at approximately 3 minutes of standing, at screening to predose assessments, 
inclusive. Any assessments after screening that do not meet this criterion may be repeated with 
the subject remaining standing for up to a total o f 5 minutes, provided tha t the subject remains 
asymptomat ic. If the repeat assessment occurring within 5 minutes is exclusio nary based on 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 75of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALthe above criterion, the subject will not be eligible. A confirmed orthostatic increase of >30 
bpm, but <40 bpm, on 1 or more Day -1 assessment s may not be considered exclusio nary if not 
considered clinically significant by  the investi gator and the m edical mo nitor. Such 
assessments must be discussed with the medical monitor prior to determinat ion that the subject 
is eligible to proceed.
19.The subje ct has a known or suspected current COVID- 19 infect ion or is at risk of COVID -19 
infect ion as assessed by the invest igator.
7.3 Excluded and Allowed Concomitant Medications, Supplements, and Dietary 
Products
7.3.1 Concomitant Medications
The use of conco mitant m edications approximately  7 days before administration of the first dose 
of study  drug, throughout the study unt il 2 days after discharge is not permitted. Subjects must be 
instructed not to take any  medicat ions wit hout first consult ing with the invest igator. Any 
concomitant medicat ion use must first be discussed with the sponsor, unless the investigator or 
designee considers immediate administration is necessitated.
The occasional use of acetaminophen (approximately <1 g/day) is allowed.
7.3.2 Fruit Juice
Subjects will refrain fro m consuming grapefruit juice, grapefruits, and products containing 
grapefruit beginning approximately 2 weeks before administration of the first dose of study  drug, 
throughout the study , and unt il the last PK sample has been collected.
7.3.3 Alco hol
Subjects will refrain fro m co nsuming alcoho l, 24 hours before admissio n until the final PK sample 
has been collected. Subjects may undergo an alcohol breath test at the discret ion of the 
investigator. 
7.3.4 Caffeine
In Part 1, subjects will refrain fro m consuming caffeinated beverages fro m the evening of Day -2 
until the PK blood sample at 30 hours after dosing in each cohort. At all other times in Part 1 and in 
Parts 2 and 3, caffeinated beverages or xanthine -containing products will be limited to amounts o f 
no m ore than 6 uni ts per day  (1unit= 120 mg of caffeine).
7.3.5 Smoking
Subjects will abstain fro m the use o f tobacco -or nicotine -containing products fro m screening until 
discharge after the l ast scheduled dose.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 76of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL7.4 Diet, Fluid, Activity 
7.4.1 Diet and Fluid
7.4.1.1 Part 1
On Day -1 of each cohort, subjects will fast overnight (at least 8 hours) and will continue to fast for 
4hours after Hour 0 for the collection of baseline time -matched HR and BP assessments. On 
Day 1 of each cohort, subjects will fast overnight (at least 8 hours) before study  drug dosing and 
will cont inue to fast for an additional 4 hours (after Hour 0) postdose. 
On Day 1 of each cohort, meals and snacks must be completed at least 1 hour before any telemetry 
recording extractions and/or safety  ECG.
Norm alfluid intake of water is permitted and encouraged, and decaffeinated coffee or tea with 
nothing added are also permitted. Standard meals will be administered at approximately 4 (lunch), 
7 (snack), 10 (dinner), and 13 (snack) hours postdose on Day 1. Stand ardized meals will be served 
on all other confinement day s.
7.4.1.2 Part 2 and 3
On Day -1 of each cohort, subjects will fast overnight (at least 8 hours) and will continue to fast for 
4hours after Hour 0 for the collect ion of baseline t ime-matched HR and BP asse ssments. On Days 
1 and 5 in Part 2, and Day s 1, 7, and 14 in Part 3, subjects will fast overnight (at least 8 hours) 
before the dose and will cont inue to fast for an addit ional 4 hours (after Hour 0) postdose. 
Norm al fluid intake of water is permitted and encouraged, and decaffeinated coffee or tea with 
nothing added are also permitted. Standard meals will be administered at approximately 4 (lunch), 
7 (snack), 10 (dinner), and 13 (snack) hours postdose on dosing days. All meals should be served 
at approxim ately the same time each day .
7.4.2 Activity
Subjects will avo id strenuous physical act ivity (eg, wei ght lift ing, running, bicycling) from 
72hours before admissio n to t he study site, throughout the study (including the washout interval in 
Part 3), and until aft er discharge after the last scheduled dose.
7.5 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the electronic case report form (eCRF ) using the fo llowing categori es.
Pretreatment event or TEAE. The subject has experienced a pretreatment event or AE that 
requi res early  terminat ion because continued part icipation imposes an unacceptable risk to the 
subject’s health or the subject is unwilling to continue because of the pretreatment event or 
AE.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 77of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALLiver function test (LFT) abnormalit ies.
–ALT or AST >3 × ULN in conjunct ion with elevated total  bilirubin >2 ×ULN wi thout 
findings of cho lestasis or other alternate etiology.
Significant protocol  deviat ion. The discovery that the subject failed to meet protocol entry  
criteria or di d not adhere to protocol requirements, and cont inued participat ion poses an 
unacceptable risk to the subject’s healt h.
Lost to follow -up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
docum ents.
Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from the study . The reason for withdrawal, if provided, should be recorded in the 
eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an AE 
shoul d not be recorded in the “vo luntary withdrawal ” category ). Similarly , lack of efficacy should 
not be recorded in the “voluntary  withdrawal” category .
Study  terminat ion. The sponsor, IRB and/or IEC, or regulatory  agency  termina tes the study .
Pregnancy. The subject is found to be pregnant. Note: If the subject is found to be pregnant, the 
subject must be withdrawn immediately .
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
If a subject chooses to wi thdraw from  study  parti cipati on due to personal  concerns rel ated to the 
COVID -19 pandemic, this should be specified as the reason for subject withdrawal in the eCRF. 
The reason for discontinuat ion shoul d be entered on the eCRF including unavoidable 
circumstances such as the COVID- 19 pandemic.
7.6 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any t ime during the study when 
the subject meets the study terminat ion criteria descri bed in Sect ion7.5. In addit ion, a subject ma y 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s parti cipat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the invest igator. In addit ion, efforts should be made to perform all procedures scheduled for the 
early  terminat ion visit.
7.7 Subject Replacement
If a subject di scont inues from the study , a repl acement subject may  be enrolled, if deemed 
appropriate by  the investi gator and sponsor. The study  site shoul d contact the sponsor for the 
replacement subject’s treatment assignment and allocation number.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 78 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL8.0 CLINICAL STUDY MATERIAL MANAGEMENT
8.1 Clinical Study Drug 
TAK-510 will be supplied to the study site by the sponsor 
for injection. The matching placebo is normal saline.
TAK-510 and placebo will be prepared for inj ection by licensed pharmacy staff at the clinical 
research unit according to the procedures outlined in the pharmacy manual.
Details regarding the dosage form description and strengths, or composition for the 
extemporaneous preparation, can be found in the pharmacy manual. Study drug will be packaged 
to support enrollment and replacement of subjects as required.
8.1.1 Clinical Study Drug Labeling
A clinical label will be affixed to study drug containers in accordance with local regulatory
requirements.
TAK-510 will be provided in a labeled glass vial and packaged in an appropriately labeled carton 
with a single-panel label that will contain, but w ill not be limited to, the following: sponsor’s name 
and address, protocol number, packaging job/lot number, name and strength of the product, 
caution statement, and storage conditions.
8.1.2 Clinical Study Drug Inventory and Storage
The same lot number will be used throughout the study. The lot numbers and expiration dates 
(where available) of the study drugs supplied will be recorded in the final report. 
Records will be made of the receipt, preparation, dispensing, and final disposition of the study
drugs supplied.
Study drug must be stored in a secure, limited -access location under the storage conditions 
specified on the label and must remain in the original container until dispensed. A daily 
temperature log of the drug st orage area must be maintained.
TAK-510 must be stored at -25°C to -15° C (-13°F to 5°F) with protection from light.
The temperature excursion information can be found in the pharmacy manual. Receipt and 
dispensing of study drug must be recorded by authorized personnel at the study site.
8.1.3 Clinical Study Drug Blinding
This is a double-blind study; the investigator and subjects are blinded to treatment assignment. An 
unblinded study drug supply will be provided to  an unblinded pharmacist or other qualified 
personnel at the study site who will blind the st udy supplies. Treatment identity (name and strength 
or potency) will be included on th e study drug container label. Rando mization code/disclosure 
envelopes or lists will be provided per the standard operating procedures of the study site. Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usee clinicae clini
r the the 
drug widrug w
rdance rdance
ackaged ckaged
t be limibe lim
umber, umber
and Stand S
oughoutoughou
gs supplisupp
ceipt, preipt, p
ed in a d in a
l and muand m
 the druthe drf
t be stobe st
erature erature
sing of ssing of
1.3.3
This Thi
unu
TAK -510
Study ID TAK -510-1001 Page 79of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALAfter complet ion of each dosing cohort, and before selecting the next dose, a blinded assessment 
of the safet y and tolerabilit y, laboratory  results of at least 24 hours after the last dose in the cohort , 
and available PK data will be perform ed in the dose escalat ion meet ing(com posed of 
representatives from the sponsor and site study  teams).
The blind may  be broken for select sponsor representatives before each blinded cohort review 
and/or dose escalat ion meet ing, if necessary, due to safet y concerns based on the prospectively 
prepared unblinding plan. Following each blinded dose cohort review and after dose escalat ion 
decisio ns have been made, the sponsor may be unblinded using the prospectively prepared 
unblinding plan, to enable f urther data review to inform later parts of the study .
8.1.4 Randomization Code Creation and Storage 
Randomization personnel o f the sponsor or designee will generate the randomization schedule. All 
rando mizat ion informat ion will  be stored in a secured area, ac cessible only by authorized 
personnel.
8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
The study  drug blind will be maintained through a randomizat ion schedule held by the unblinded 
pharmacist at the study  site or by  the sponsor. The study  drug blind shall not be broken by  the 
investigator unless informat ion concerning the study drug is necessary for the medical treatment of 
the subject. If possible, the medical mo nitor shoul d be contacted before the blind is broken. 
Unblinding will be performed per t he standard operating procedures of the study  site.
8.1.6 Accountability and Destruction of Sponsor- Supplied Drugs
The invest igator and invest igator’s designated site pharmacy must ensure that the sponsor -or 
contract research organization (CRO) -supplied drug is used in accordance with the protocol and 
pharmacy manual and is dispensed only to subjects enro lled in the study. To document appropriate 
use of the sponsor -supplied drug, the investigator pharmacy/site must maintain records of drug 
delivery  to the si te, si te inventory , dispensat ion and use by each subject, and return to the sponsor 
or desi gnee.
Upon receipt of sponsor -supplied drug, the designated blinded pharmacist must verify the contents 
of the shipments against the packing list. The verifier should en sure that the quantit y is correct, and 
the medicat ion is in good condit ion. If quantit y and condi tions are acceptable, designated site 
pharmacist should acknowledge the receipt of the shipment by signing bottom half o f the packing 
list. If there are any  discrepancies between the packing list versus the actual product received, 
Takeda must be contacted to resolve the issue. The packing list should be filed in the invest igator’s 
essent ial docum ent file.
The invest igator’s designated blinded pharmacist must ma intain 100% accountabilit y for all 
sponsor -supplied drugs received and dispensed during his or her ent ire parti cipat ion in the study. 
Proper drug accountabilit y includes, but is not limited to:
Moni toring expirat ion dates.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 80of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALFrequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the drug accoun tabilit y log is completed for each prepared dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accurately and leg ibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
8.2 Ancillary Supplies
All ancillary supplies will be provided by eit her the study  site or the sponsor or desi gnee, 
depending upon availabilit y. The list of ancillary  supplies and source information can be found in 
the pharmacy  manual or in the referenced compounding manual when applicable. If provided by 
the sponsor, unused ancillary supplies will be accounted for and disposed of as directed by the 
sponsor or desi gnee.
9.0 STUDY PROCEDURES
The fo llowing sect ions describe the study  procedures to be performed and data to be collected as 
indicated in the Schedule of Study Procedures (Section 3.0). For each procedure, subjects are to be 
assessed by  the same investi gator or si te personnel whenever possible. Please note that it may  
beco me necessary  to perform  the f ollowing procedures at unscheduled t ime periods, per the 
discreti on of  the invest igator.
9.1 Administrative Procedures
9.1.1 Informed Consent Procedure
Inform ed consent m ust be obtained before the subject enters into the study  and before any 
protocol -directed procedures are performed. The requi rements of inform ed consent are described 
in Appendix B.
9.1.1.1 Assignment of Screening and Randomization Numbers 
All consented subjects will be given a uni que screening number that will be used to identify the 
subject for all procedures that occur before randomizat ion or allocat ion. Each subject will be 
assigned only one screening number. Screening numbers must not be reused for different subjects. 
Any subject who is screened mult iple times will be assigned a new screening number for each 
screening event. Rescreening o f subjects will be considered on a case -by-case basis by the 
sponsor.
All eligible subjects will be rando mly allocated and will receive a rando mizat ion number. The 
rando mizat ion number identifies the subject for all procedures occurring after randomizat ion. 
Once a rando mizat ion number is assigned to a subject, it can never be reassigned to another subject. 
A single subject cannot be assigned more than one rando mizat ion number.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 81of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL9.1.1.2 Study Drug Assignment
On Day 1, subjects will be assigned a randomizat ion number in ascending numerical order at the 
clinical site. The rando mizat ion number encodes the subject assignment to either TAK -510 or 
placebo, a ccording to the randomizat ion schedule generated before the study. Each subject will be 
dispensed blinded study  drug, labeled wi th his/her unique rando mization number, throughout the 
study .
9.1.2 Inclusion and Exclusion 
Each subject will be assessed through ran domization, according to the eligibilit y criteria provi ded 
in Section 7.0.
9.1.3 Medical History/ Demography
Qualified site personnel will collect subject si gnificant m edical history  (past and concurrent 
medical condit ions), per the clinical site’s standard of care and appropriate clinical judgment, and 
subject demographics.
9.1.4 Concomitant Medications
Qualified site personnel will review subject prior and conco mitant m edicat ion use. Medicat ions 
are defined as prescription and over -the-counter drugs, vaccines, supplements, nutraceuticals, and 
oral herbal preparations.
9.2 Clinical Procedures and Assessments
9.2.1 Full Physical Examination
Qualified site personnel will conduct full or symptom -driven physical examinat ions as indicated in 
the Schedule of Study  Procedures (Secti on3.0).
9.2.2 Height and Weight
Body  weight an d height will be obtained with the subject’s shoes off, and jacket or coat removed.
9.2.3 BMI
BMI equals a subject’s weight in kilograms divided by height in meters squared (BMI = kg/m2). 
BMI will be rounded to the nearest whole number according to the standard convent ion of 
0.1 to 0.4, round down, and 0.5 to 0.9, round up.
9.2.4 Vital Signs
Body  temperature will be measured with eit her an oral (temperature taken at floor of the mouth) or 
tympanic thermo meter. The same method (ie, oral or tympanic) must be used for all measurements 
for each individual subject and should be the same for all subjects. The same size cuff must be used 
for all BP m easurements for each individual subject.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 82of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALAt screening, and from admissio n to t he clinical research unit through predose (inclusiv e of Day -1 
and predose on Day  1) vi tal signs including orthostatic BP and HR will be used to assess for 
eligibilit y for randomization and dosing (see exclusion criteria #15 to #18 in Sect ion7.2). 
After rando mizat ion, results of BP, HR, orthostatic BP, and orthostatic HR assessments 
immediately  prior to dosing (the single dose in Part 1, first dose in Part 2, and first dose in Part 3) 
shoul d be consis tent with the vital sign criteria as defined in Section 7.2(exclusio n criteria). If vit al 
sign cri teria are outsi de of the specified range defined in Section 7.2for any  dose after the first 
dose in Parts 2 and 3, the invest igator may exercise discret ion related to appropri ateness of the 
subject’s ongoing study  parti cipat ion on the basis of assessment of clinical significance of vital 
signs and any  ongoing AEs. The invest igator will regularly update the Takeda medical mo nitor of 
vital sign findings outsi de of the ranges described in Section 7.2and ongoing AEs. No protocol 
deviat ion will be issued for dosing that may be delay ed for up to 1 hour due to an ongoing AE 
(Part 2 and Part 3) or vital sign criteria defined in Section 7.2. Should dosing be delayed in Parts 2 
or 3 of the study, adjust ment should be made on subsequent days to administer the dose as close as 
possible to the originally  planned TAK -510 dosing time based on Day 1 dosing. 
Subjects should rest in a semirecumbent position for at least 3 minutes before vital signs are 
measured. Vital signs will include pulse rate (bpm), respiratory rate, and systolic and diastolic BP 
in all parts of the study. BP and pulse assessments should be made in duplicate with an interval o f 
approximately  2 minutes between the 2 assessments. The invest igator can take a third BP and 
pulse assessment if results are inconsistent (ie, a difference >10 bpm in HR or a difference >10 mm
Hg in SBP or DBP between assessments). If 3 measurements are obtained, the final BP and pulse 
readout should be the average of the 2 more consistent assessments. All original values (all 3) 
shoul d be entered into the database and the average will be derived in the datasets.
Subjec ts in each study part will have baseline HR and BP assessments performed on Day -1 which 
are time -matched (±5 minutes) to the Day  1 assessments (ie, time-matched baseline).
At the predose or prior to Hour 0 time points, BP and HR will be measured within 1 hour pri or to 
dosing or Hour 0. When scheduled after the dose, vital signs will be performed within 
approximately  15minutes of the scheduled time point. 
Orthostatic BP and pulse assessment will be performed with the subject standing after the 
semirecumbent assessment has been co mpleted. The subject should stand still for approximately 3 
minutes before this assessment. 
If the HR increases by more than 30 bpm on standing and the subject i s asymptom atic, the 
subject may remain standing for up to a total of 5 minutes and the investigator may repeat 
standing measurements within 5 minutes as appropriate. Individual HR values and the average 
shoul d be reported.
If there is a decre ase in systolic BP ≥20 mm Hg or a decrease in diastolic BP ≥10 mm Hg after 
approximately  3minutes of standing when compared with BP fro m the semirecumbent 
position and the subject is asymptomat ic, semirecumbent and standing measurements may be 
repeated af ter the subject has remained in the semirecumbent or supine posit ion for 15minutes. 
Individual BP values and the average should be reported. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 83of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALStanding assessments must not be performed if semirecumbent systolic BP is <85 mm Hg or if 
the subject presents w ith signs or symptoms suggestive o f postural  hypotensio n after standing 
(eg, lightheadedness or dizziness, nausea, blurry  vision, etc). See Secti on 10.2.8.4.2 for 
management of symptomat ic hypotension. 
Subjects will remain semirecumbent for the first 4 hours with vital signs obtained at 0.5, 1, 2, 3, 
and 4 hours after dosing, except at the time that orthostatic vital signs are obtained or for other 
study-related procedures, if needed. Subjects will then be permitted to ambulate provided that their 
vital signs remain stable and there are no significant orthostatic changes observed.
When vital signs are scheduled at the same t ime as blood draws, they wil
l be obtained before the 
scheduled blood draw.
9.2.4.1 Follow -Up Safety Monitoring 
All subjects who early terminate the study  will be provi ded wi th the tel emetry  patch and BP cuff 
for safet y monitoring for the duration of the protocol -specified observat ion period . Any addit ional 
AE data will be collected in the database. Follow-up telemetry  and BP cuff data will not be entered 
into the database, but the telemetry  patch and BP report will be stored in the site source documents. 
If the subject does not agree to allo w the use of m onitoring and woul d like to wi thdraw from  the 
study , an Against Medical Advice form will be provided to the subject prior to discharge fro m the 
study  site.
Any subject who early terminates the study  for any reason, eg, if a subject tests posi tive for 
COVID -19 (Point of Care or Polymerase Chain) and is required to discharge fro m the study  site
per policy ,or if a subject should leave the study  site due to unforeseen circumstances, the sponsor 
will be consulted immediately to discuss the fo llowing:
If the subject is asymptomat ic in relation to cardiovascular symptoms but without telemetry  
observat ions during the postdose period, the subject could be discharged ho me after discussio n 
with the sponsor, but with adequate real -time monitori ng (eg, Hol ter m onitor, rem ote 
continuous telemetry  monitoring and ambulatory  blood pressure) fo r the protocol -specified 
telemetry  observat ion peri od.
If the subject is asymptomat ic in relation to cardiovascular symptoms but with telemetry  
observat ions during the postdose period, the subject could be discharged to home after 
discussio n with the spons or. Adequate real -time monitoring (eg, Holter monitor, remote 
continuous telemetry  monitoring and ambulatory  blood pressure) for the protocol -specified 
telemetry  observat ion peri od will be implemented and potential transfer to emergency  
departm ent will be considered in consultat ion with the sponsor. 
If the subject has cardiovascular symptoms with or without telemetry  observations during the 
postdose period, the recommendat ion is to discuss disposit ion wit h the sponsor and potentially 
discharge to the emerg ency depart ment.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 84of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALBased on assessment, a decisio n will be made to either remove the monitor because of sufficient 
data/safet y assessment, continue remote monitoring under the supervisio n of an external physician, 
or refer the subject to the emergency depart ment or outpati ent cardi ology.
9.2.5 Glucose
Blood glucose will be monitored using finger -stick blood samples in Parts 1, 2, and 3 and will also  
be monitored using safet y laboratory  testing.
9.2.6 ECG Procedure
9.2.6.1 Screening and Safety ECGs
A 12 -lead ECG will be co llected at the time po ints specified in the Schedule of Study  Procedures 
(see Section 3.0). Ad hoc 12 -lead ECGs will also be required if a subject complains of palpitat ions, 
dizziness, breathlessness, chest tightness, or any  other symptom s suggest ive o f arrhy thmia, 
develops tachycardia with HR >120 bpm (in semirecumbent posit ion), or experiences hypotensio n 
with systolic BP <85 mmHg between Day 1 (postdose) and discharge. If the subject experiences 
symptoms suggest ive of hypotension, the subject should be instructed to lie flat, BP and HR 
shoul d be re -assessed, and a 12 -lead ECG shoul d be perform ed to assess arrhy thmia. The BP, 
pulse, and ECG, m easurements wi ll be reviewed by the investigator, who will use clinical 
judgment regarding further monitoring and management. See Section 10.2.8.4 for management o f 
symptom atic tachycardia or hy potensi on.
The invest igator will interpret the safet y ECG using 1 of the fo llowing categori es: wi thin normal  
limits, abnormal but not clinically significant, or abnormal and clinically significant. The time that 
the ECG was performed will be recorded. If the 12- lead ECG tracing is inco mplete, or has motio n 
or other artefact, the ECG will be repeated.
The fo llowing param eters will  be recorded on the eCRF from the subject’s ECG trace: HR, RR 
interval , QRS interval, PR interval, QT interval, and QTcF (using the formula QTcF =QT/RR1/3). 
The invest igator will be responsible for providing the interpretation of all safety ECGs 
(norm al/abnorm al). These results will be reviewed by  the investi gator f or subject safet y and will 
be provi ded in an appropriate format with the clinical study  report (CSR).
ECGs will be performed with subjects in a semirecumbent posit ion. All ECG tracings will be 
reviewed by  the invest igator or designee.
9.2.6.2 Telemetry
In Parts 1, 2, and 3, cardiac monitoring (pulse and ECG) will be assessed via telemetry and will be 
perform ed for at l east 24 hours before dosing and at least 24 hours postdose. 
All subjects who terminate early  from the study  will have rem ote blood pressu re monitoring and 
real-time cont inuous single lead telemetry (monitoring) for the duration of the protocol -specified 
observat ion peri od included in the protocol (see Section 9.2.4.1 for details).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 85of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALTelemetry  data (12 -lead) will be used for real -time safet y monitoring to alert site staff and will not 
be recorded in the eCRF. Data will be stored for review. If an AE occurs, a 12 -lead ECG should be 
collected and interpreted by the invest igator as specified in Sect ion 9.2.6.1 .
Extractions of the 12- lead telemetry  will be captured in Parts 1, 2, and 3 with a minimum of 
48hours of cardiac monitoring (24 hours predose and 24 hours postdose) (see Section 3.0)
. The 
purpose of the telemetry  extracti on data i s to support future detailed thorough QT (TQT ) analysis 
as described below. For all postdose ECG collect ions, three 10-second ECGs will be extracted at 
each extraction window time point. 
ECG extraction t ime points will occur before PK blood draws. Accordingly, subjects will be 
supervised and quiet ly resting semirecumbent beginning a minimum o f 5 minutes before each 
actual ECG extraction window of 5 minutes if possible. The rest period prio r to the early PK draws 
(<1 hour postdose) may  need to be shortened to accommodate the events schedule. At all other 
time points, subjects will be supervised while remaining at rest, quiet, and awake and in a 
semirecumbent posit ion fro m at least 5 minutes before the beginning o f each ECG extraction time 
point and will remain quiet, awake, motionless, and semirecumbent for at least 5 minutes after the 
beginning of each ECG extraction time po int.
ECG extraction data fro m 12-lead telemetry will be archived. Th e continuous telemetry  data are 
not intended to be analyzed as a predefined safet y endpo int for all subjects for this study. However, 
these data will be available for real -time safet y monitoring and to further evaluate individual 
subjects who present with symptoms or signs that could be suggestive of an arrhythmia. Data will 
be archived for potential concentration -QT analysis unless a safety  signal  is detected and 
additional information is requi red for proper i nterpretati on of  the findings. eCRF data for 
telemetry  extracti ons will  only include date and start and stop time and whether assessment was 
perform ed.
Collected ECG data from 12 -lead telemetry  may also be used to explore the relat ionship wit h 
TAK -510 exposure. If conducted, the results from these anal yses will not be included in the CSR 
but will be reported in a standalo ne report. 
9.2.7 Study Drug Administration
Study  drug (TAK -510 or m atching placebo) will be administered as shown in the Schedule of 
Study  Procedures in Section 3.0.
9.2.8 AE Monitoring
AE monitoring begins after signing of the informed consent form. Changes in subject health status 
from the baseline assessment until study  drug administration shoul d be captured in the subject’s 
medical history . A com plete descri ption of AE collections and procedures is provided in 
Secti on10.0.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 86of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL9.2.9 Laboratory Procedures and Assessments
Laboratory  samples will be collected in accordance with acceptable laboratory  procedures. 
Samples will be co llected fo llowing a minimum 8 -hour overnight fast at the time po ints stipulated 
in the Schedule of Study  Procedures (Sect ion 3.0).
9.2.9.1 Hematology
Hem atology will consist of the following tests:
Erythrocy tes (red blood cells [RBCs]) Hemoglobin
Hematocrit Platelets
Leukocytes (white blood cells [WBCs ] with absolute 
differential)
9.2.9.2 Chemistry 
Chemistry  evaluat ions will consist of the fo llowing standard chemistry  panel:
Albumin Alkaline phosphatase
ALT AST
Blood urea nitrogen Calcium
Carbon dioxide Chloride and lipase
Creatinine Glucose 
Gamma -glutamyl transferase Sodium
Potassium Bilirubin (total); if above the upper limit of normal, total 
bilirubin will be fractionated
Protein (total) Creatine kinase
ALT: alanine aminotransferase; AST: aspartate aminotransferase.
If subjects experience ALT or AST >3 ×ULN, fo llow-up laboratory tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, gamma -glutamyl  transferase, and internat ional 
norm alized rati o) shoul d be perform ed 24 hours af ter the abnorm ality was noted, and the medical 
monitor shoul d be contacted. In Parts 2 and 3, if subjects experience ALT or AST >3 ×ULN or 
total bilirubin >2 ×ULN, l aboratory  tests for ALT and AST should be repeated before the next 
scheduled dose. 
If AL T or AST remains elevated >3 ×ULN, the investigator must contact the medical mo nitor for 
consideration of addit ional test ing, close monitoring, possible discont inuat ion of study  drug, and 
discussio n of the relevant subject details and possible alternative etiologies. The abnormalit y 
shoul d be recorded as an AE.
Please see Sect ion7.5for subject discont inuat ion criteria regarding abnormal liver test resul ts and 
Secti on10.2.8.5 for guidance on reporting abnormal liver test results.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 87of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL9.2.9.3 Urinalysis
Urinalysis will consist of the fo llowing tests:
Prote in Glucose
Blood Nitrite
Specific gravity
Urine microscopy  will be perform ed if urinalysis is abnormal. Microscopy  consists of 
RBC/high -power field, WBC/high -power field, and casts.
9.2.9.4 Diagnostic Screening
Other 
Hepatitis B surface antigen Hepatitis C virus antibody
HIV FSH (f or females only)
Serum pregnancy test (βhCG) (for females only) Urine cotinine
βhCG: beta human chorionic gonadotropin; FSH: follicle -stimulating ho rmone.
Alcohol Screen
Subjects will undergo an alcoho l breath test. A urine alcoho l test m ay be perform ed at the 
discreti on of  the invest igator.
Urine
The urine drug screening assessment will include the fo llowing tests:
Amphetamines 3,4-methy lenedioxy -methamphetamine
Barbiturates Methadone/metabolite
Benzodiazepines Opiates
Bupreno rphine/metabolite Oxycodone/oxy morphone
Cannabinoids Phency clidine
Cocaine/metabolites
9.2.10 PK, Immunogenicity, Biomarker, and DNA Samples
Samples for PK, ADA, and other bio marker analysis will be co llected as specified in the Schedule 
of Study  Procedures (Secti on 3.0). Pl ease refer to the laboratory  manual  for inf ormation on the 
collect ion, processing, and shipment of samples to the central laboratory .
The decision as to which plasma and/or serum samples collected will be assayed for evaluation of 
PK will be determined by the sponsor (eg, samples at lower doses may not be assayed if samples at 
higher doses reveal undetectable drug concentrations). If indicated, these samples may also be 
assayed and/or pooled for assay in an exploratory  manner for metabo lites and/or addit ional 
biomarkers.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 88 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALPrimary specimen collection par ameters are provided in Table 9.a.
Table 9.a Primary Specimen Collections
Specimen NamePrimary 
SpecimenPrimary Specimen 
DerivativeDescription of 
Intended UseSample 
Collection
Plasma sample for TAK-510 PK Blood Plasma PK analysis Mandatory
Plasma sample for metID Blood Plasma metID analysis Mandatory
Urine sample for TAK-510 PK Urine N/A PK analysis Mandatory
Serum sample for immunogenicity Blood Serum ADA analysis Mandatory
Blood sample for DNA Blood DNA DNA analysis Optional
ADA: antidrug antibody; metID: metabolite identification; N/A: 
not applicable; PK: pharmacokinetic.
During the confinement period, the sponsor’s expectation is that the investigators will ensure that every effort is made 
to collect all blood samples at the precise protocol-scheduled time (as shown in the schedule of study procedures, Section 3.0). PK blood collection must not deviate from the nominal collection time set forth in the protocol by more 
than ±5 minutes. In case of repeat vital sign measurements, PK samples may be collected within ±10 minutes of nominal time. During the confinement period, the collection time of samples collected for the assessment of 
 hematology, and chemistry, must not deviate from the nominal collection time set in the protocol 
(Section 3.0) by more than ±10 minutes.
Follow up laboratory assessments can be taken at any time during the follow-up visit.Samples drawn outside these parameters will be considered a protocol deviation but may be considered on case by case basis. 
9.2.10.1 PK Measurements 
The PK parameters of TAK-510 will be determined from the concentration-time profiles for all 
evaluable subjects. Actual sampling times, rather than scheduled sampling times, will be involved 
in all computations involving sampling times.
Exploratory metabolite profiling may be conducted on blood samples to determine the metabolites 
of TAK-510. If conducted, these data will be reported separately and not be reported in the CSR.
PK parameters that will be determined after single dose and at steady state include, but are not 
limited to, the following:
Property of Takeda: For Non-Commercial Use Only and Subject metI me
investigainvestig
e (as sho(as s
ominal cominal 
PK sampPK sam
samplesampl
t not devnot d
en at anyen at a
will be coll be cctctct
nts ts 
TAKAK-515
Actual saActual 
ns invos inv l
metaboetab li
10. If co0. If c
rameterramete
ited to, ted toApplicable Terms of Usemple ple 
ollectionlectioso
MandaMandTe
MaMe
ababab
ysissislic
analysisalysisApp
ct to the A
bje
TAK -510
Study ID TAK -510-1001 Page 89of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALSymbol/Term Definition
Plasma/Blood/Serum
AUC 24 Area under the plasma concentration -time curve from the time 0 to time 24 hours. 
AUC τ Area under the plasma concentration -time curve during a dosing interval, where tau (τ) is the 
length of the dosing interval.
AUC last Area under the plasma concentratio n-time curve from time 0 to time of the last quantifiable 
concentration.
AUC ∞ Area under the plasma concentration -time curve from time 0 to infinity, calculated as 
AUC ∞=AUC t+ C last/λz
Rac(AUC) Accumulation ratio (based on AUC), calculated as AUC τat steady  state/AUC τafter a single 
dose.
Rac(Cmax) Accumulation ratio (based on C max), calculated as C maxat steady state/C maxafter a single dose.
Cmax Maximum observed plasma/blood/serum concentration.
Cmax,ss Maximum observed steady -state plasma/blood/serum concentration during a dosing interval.
CL/F Apparent clearance after extravascular administration, calculated as = Dose/AUC ∞after a 
single dose and as Dose/AUC τafter multiple dosing (at steady state).
Ctrough Observed plasma concentration at the end of a dosing interval.
λz Terminal elimination rate constant calculated as the negative of the slope of the log -linear 
regression of the natural logarithm concentration -time curve during the terminal phase.
t1/2z Terminal disposit ion phase half -life calculated as ln(2)/λ z.
tlag Lag time to first quantifiable concentration.
tmax Time of first occurrence of C max.
Vz/F Apparent volume of distribution during the terminal disposition phase after extravascular 
administration, calculated as (CL/F)/λ z.
The fo llowing urine PK parameters of TAK -510 will  be determined after SC administration in 
Parts 1 and 2:
Urine
Aet1-t2 Amount of drug excreted in urine from time 1 to time 2, calculated as C ur×Vur, where C uris the 
concentrat ion of drug excreted in urine and V uris the volume of urine excreted.
Aet Total amount of drug excreted in urine from time 0 to time t.
Aeτ Amount of drug excreted in urine during a dosing interval (τ) at steady state.
fe Fraction of drug excreted in urine, calculated as (Ae t/dose). 
CL R Renal clearance, calculated as Ae 0-24/AUC 24.
Addit ional PK parameters may be calculated as appropriate. Addit ional details will be provided in 
the clinical pharmaco logy analysis plan.
9.2.10.1.1 Plasma for PK Measurements and Metabolite Identification
Plasma sam ples f or PK analysis o f TAK -510 will be collected into chilled blood collect ion tubes 
(vacutainer) containing the ant icoagulant K2EDTA. The collected blood or resultant plasma 
samples may  be archived for exploratory  char acterizat ion of potenti al circulat ing metabolites. If 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 90 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALconducted, these data will be  reported separately and not be reported in the CSR. A full description 
of PK sample collection, handli ng, storage, and shipping can be found in the laboratory manual.
The actual time of sample collection will be recorded on the source document and eCRF. Sampling 
time points may be adjusted based on the preliminary emerging concentration data collected from 
prior subject(s), but the total number of samples collected per subject should not exceed the 
planned number.
 An evaluation of the coverage and relative abundance of human catabolites 
will be conducted for cross-comparison to nonclinical species. Therefore, subject plasma samples 
will be collected for catabolite profiling analysis to provide an assessment of catabolite coverage 
in nonclinical safety testing [14]. Samples will be collected as specified in the Schedule of Study
Procedures (Section 3.0). These data will be reported separately and will not be reported in the 
CSR.
9.2.10.1.2 Urine for PK Measurements
Urine concentrations of TAK-510 will be meas ured by a validated high-performance liquid 
chromatography with tandem mass spectrometry assay. A full description of urine sample
collection, handling, storage, and shipping can be  found in the laboratory manual. The collected 
urine samples may be archived following bioanalysis of TAK-510 levels for exploratory
characterization of potential urinary metabolites.
9.2.10.2 Immunogenicity (ADA) Measurements
Protein products have the potential to induce antidrug immune response that may affect the safety 
and efficacy of the compound under study. Detection and analysis of ADA formation is a helpful 
tool in understanding drug immunogenicity, efficacy, and safety. To understand drug 
immunogenicity, bl ood samples will be co llected in all study parts according to the Schedule of 
Study Procedures (Section 3.0), on Day 1, predose, at Day 8, a nd at the follow-up visits. Other 
have reported the formation of ADAs; however, an ADA assay may be 
influenced by several factors including assay methodology, sample handling, timing of sample 
collection, conco mitant medications, and underlying disease. Therefore, the incidences of ADA 
formation cannot be directly compared with the other products. ADA samples will be taken in all 
parts of the study across all cohorts.
A 3-tiered ADA testing strategy will be applied to  this study. A sample will initially be screened 
for ADA by the ADA screening assay. Any positive sample in the screening assay is considered a 
potential positive, which will be confirmed for true positivity by the confirmatory assay. If a 
sample is confirmed as an ADA true positive, ADA titer will be assessed. 
The extra immunogenicity samples will be stored for future potential further ADA 
characterization which will be dependent on the initial assessment of the effect of ADA status on 
the observed PK, pharmacodynamic, safety, and efficacy profile of TAK-510 in this study as well 
as the regulatory request if it is applied.Property of Takeda: For Non-Commercial Use Only and Subject to the Applicahuman chuman
ubject plbject p
t of cataof ca
d in thed in th
d will nod will n
a validavalid
ay. A fuy. A 
e found ifound
nalysis nalysis 
littes.es.
easuremasure
l to induto ind
under stunder s
mmunogmmun
mmples wplesmmm
tionon3.03
have rehave r
veral facveral f
ncomitaomit
annot bannot
the studthe stu
titiered Aered 
or ADAAD
potentpote
samsable Terms of Useing g 
d frofrom m
he e 
able
TAK-510
Study ID TAK-510-1001 Page 91 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL9.2.10.4 DNA Measurements 
9.2.10.4.1 Blood Sample for DNA 
Sampling of blood for DNA analysis is optional in this study and both will be obtained for all 
subjects who consent to providing a sample for DNA. Collection of DNA will be performed for 
each consented subject as indicated in the Schedule of Study Procedures (Section 3.0). 
As DNA research is an evolving science, further assessments may be performed based on newly 
available data. DNA sequencing analysis will not be reported in the CSR.
Detailed instructions for collection, storing, handling, and shipping samples will be provided in the 
laboratory manual. 
9.2.10.4.2 Biological Sample Retention and Destruction
In this study, sample of blood for DNA analysis will be collected as described in Section 9.2.10.4.1.
Any leftover samples, if not used, will be preserved and retained at the sponsor-selected long -term 
storage facility for up to 5 years from the end of  the study. Genetic material will be init ially stored 
at a vendor or comparable laboratory, under contract to the sponsor, with validated procedures in Property of TakedaA researA resea
able datable d
Detailedtaile
laborlaboCommercial Use Only and Subject to the Applicable Terms of Useysis is osis is 
ding a sang a s
ndicateddicateOnly and Subject to the Applicable Terms of Use
da: For Non-Co
TAK -510
Study ID TAK -510-1001 Page 92of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALplace, and then preserved and retained at a long- term storage vendor, or a comparable laboratory , 
with validated procedures in place, for up to but not longer than 15  years fro m the end of the study 
when the CSR is signed, or if less, the maximum period permitted under applicable law or until 
consent is withdrawn. 
The sponsor and vendors working wit h the sponsor will have access to the samples collected and 
any test results. All samples co llected during the s tudy will be stored securely wit h limited access, 
and the sponsor will require anyo ne who works with the samples to agree to hold the research 
inform ation and any results in confidence.
The sample will be labeled with a unique sample ident ifier as in the m ain study  but using a code 
that is different from the code attached to the healt h informat ion and other clinical test results 
collected in the study . The sample and data are linked to personal healt h informat ion with code 
numbers; the samples are stripped of all personal  ident ifying informat ion but a key  linking the 
samples to clinical analysis data exists. This link means that the subject may be ident ified but only 
indirect ly. The sample ident ifier will be kept secure by or on behalf o f the sponsor. 
Subje cts who consented and provided a sample for DNA analysis can wit hdraw their consent at 
any time and request disposal o f a stored sample. Any remaining sample that can be ident ified as 
coming fro m the subject will be destroy ed. The investigator and sponsor may cont inue to use and 
distribute any  information and test results gathered before the request to withdraw. 
9.3 Confinement
9.3.1 Part 1 (SRD)
Subjects will report to the clinical site on Day  -2. Subjects will remain in the clinic for 96 hours 
postdose (Day 5). At the discretion of the invest igator, subjects may be requested to remain in the 
clinical site longer.
9.3.2 Part 2 (MRD)
Subjects will report to the clinical site on Day -2. Subjects will remain in the clinic unt il discharge 
on Day 9 (96 hours after last dose of study drug). At the discretion of the invest igator, subjects may 
be requested to remain in the study  site longer.
9.3.3 Part 3 (Dose Titration and Redosing)
Subjects will report to the clinical site on Day -2. Subjects will remain in the clinic unt il discharge
on Day  8, 30 hours after last dose of study  drug. Based on emerging safety, tolerabilit y, and 
available PK data, subjects may be confined during washout at the discret ion of the invest igator in 
consultation wit h the sponsor and medical mo nitor. Subjects w ill report to the clinical site for 
readmissio n on the evening before the scheduled day  of study  drug redosing (Day  13). Subj ects 
will remain in the clinic until discharge on Day 15, 30 hours after the single dose of study drug on 
Day 14. At the discretion of the invest igator, subjects may be requested to remain in the study site 
longer.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 93of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL9.4 Childbearing Status and Methods of Contraception
9.4.1 Women of Childbearing Potential
Women of childbearing potential will be excluded fro m this study .
9.4.1.1 Definition of Women of Childbearing Potential
A wo man is considered of childbearing potential (ie, fertile) fo llowing menarche and unt il 
beco ming postmenopausal, unless permanent ly sterile.
9.4.2 Women of Nonchildbearing Potential
A female subject of nonchildbearing potential is defin ed as sat isfying at l east 1 of the fo llowing 
criteria: 
Postmenopausal: At l east 12 m onths of spontaneous amenorrhea and an FSH 
concentration >40  mIU/mL.
Surgically sterile by  hysterectomy , bilateral  salpingectomy, and/or bilateral oophorectomy  
with approp riate docum entati on of  surgi cal procedure. 
Has no uterus as a result of a congenital condit ion.
Has had a bilateral tubal ligat ion with appropri ate docum entati on of  surgical  procedure. 
9.4.2.1 Contraception for Women of Nonchildbearing Potential
No contraception is required for women of nonchildbearing potential.
10.0 ADVERSE EVENTS
10.1 Definitions and Elements of AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study; it does n ot necessarily  have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, w hether or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be conside red AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discontinuation or a change in dose of study medicat ion or a concomitant medicat ion.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 94of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALBe considered unfavorable by the invest igator for any reason.
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) should be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG parameters may be considered AEs if they are judged to 
be clinically  significant (i e, if som e act ion or intervent ion is requi red or if the investigator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  
retest and/or continued monitoring of an abnormal value are not considered an intervent ion. In 
addition, repeated or addit ional noninv asive testing for verificat ion, evaluat ion or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in ren al failure), the di agnosis only  should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorde d as an AE. A baseline 
evaluat ion (eg, laboratory  test, ECG, X -ray, etc) shoul d NOT be recorded as an AE unless 
related to a study  procedure. However, if the subject experiences a worsening or complicat ion 
of such a concurrent medical history  condi tion, th e worsening or complication should be 
recorded appropriately as an AE (worsening or complicat ion occurs after informed consent is 
signed). Invest igators should ensure that the event term recorded captures the change in the 
condi tion (eg, “worsening of…”).
If a subject has a pre -exist ing episodic condit ion (eg, asthma, epilepsy), any occurrence of an 
episode should only be captured as an AE if the episodes beco me more frequent, serious, or 
severe in nature, that is, invest igators should ensure that the AE te rm recorded captures the 
change from Baseline in the condit ion (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion should only be captured as an AE if occurring to a g reater extent to 
that which would be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
study  medicat ion or after any  change in study  medicat ion, the worsening or complicat ion 
shoul d be recorded as a new AE. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening o f…”).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 95of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALChanges in severit y of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in study  medicati on, the event shoul d be captured once with the maximum severit y recorded.
Prepl anned surgeries or procedure s:
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion,the worsening o f 
the condi tion shoul d be captured appropriately  as an AE. Com plicati ons resul ting fro m any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental ad ministrati on of  investigational 
drug, to or by  a study  subject, at a dose above that which is assigned to that individual subject 
according to the study protocol. It is up to the investigator or the reporting physician to decide 
whether a dose is to be con sidered an overdose, in consultation wit h the sponsor.
All cases of overdose (with or without associated AEs) will be documented in the Dosing 
section of the eCRF, in order to capture this important safet y information consistent ly in the 
database. AEs asso ciated wi th an overdose will be documented on AE eCRF(s) according to 
Secti on 10.0.
SAEs of overdose should be reported according to the procedure ou tlined in Sect ion 10.2.8 .
In the event of drug overdose, the subject should be treated symptomat ically.
10.1.1 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENIN G.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPITALIZATION or pr olongati on of  exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 96 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:
!May require intervention to prevent items 1 through 5 above.
!May expose the subject to danger, even though the event is not immediately 
life-threatening or fatal or does not result in hospitalization.
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner (see Sections 10.1 and10.1.1) .
10.1.2 AEs of Sp ecial Interest
AEs of special interest (AESIs) for TAK-510 include injection site reactions, hypotension, and 
tachycardia. In addition, orthostatic hypotension is considered as a potential risk based on clinical 
experience 
10.2 AE Procedures
10.2.1 Assigning Severi ty/Intensity of AEs
All AEs, including clinically significant treatment- emergent laboratory abnormalities, will be 
graded according to NCI CTCAE v5.0. AEs not listed by the NCI CTCAE will be graded as 
displayed in Table 10.a.
Table 10.a NCI CTCAE
Grade Description
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations
only; intervention not indicated.
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting
age-appropriate instrumental activities of daily living (ADL).
3 Severe or medically significant but not immediately life-threatening;
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.
4 Life-threatening consequences; urgent intervention indicated.
5 Fatal AE; an event that results in the death of the subject.
NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.
10.2.2 Assigning Ca usality of AEs
The relationship of each AE to study med ication(s) will be assessed using the following 
categories:
Related: An AE that follows a reasonable temporal sequence from administration of a 
drug (including the course after withdrawal of the drug), or for which a causal
relationship is at least a reasonable po ssibility, ie, the relationship cannot be 
ruled out, although factors other than the drug, such as underlying diseases, 
complications, concomitant drugs and concurrent treatments, may also be Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usehould bould 
ons, hyps, hyp
ential risntial r
mergent ergen
stedstedby by
lU
c or mildor mil
n not not indincia
minimal, lnimal
opriate inpriate imm
e or medor me
spitalizatspitalizC
Lifeif-threthN
FataFatFFFo
 NationaNation:
2.2.2
The reThe r
catecateto t
TAK -510
Study ID TAK -510-1001 Page 97of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALresponsible.
Not Rel ated: An AE that does not follow a reasonable temporal sequence fro m ad ministration 
of a drug and/or tha t can reasonably be explained by other factors, such as 
underlying diseases, complicat ions, conco mitant medi cations and concurrent 
treatm ents.
10.2.3 Start Date 
The start date of the AE is the date that the first signs/symptoms were noted by  the subject and/or 
investigator.
10.2.4 End Date 
The end date of the AE is the date at which the subject recovered, the event resolved but with 
sequelae or the subject died.
10.2.5 Pattern of Adverse Event (Frequency) 
Episodi c AEs (eg, headache) or those which occur repeatedly over a pe riod of consecutive days are 
intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn –a study  medicat ion is stopped due to the particular AE.
Dose not changed –the particular AE did not require stopping a study  medication.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Not applicable –a study  medicat ion was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the subject died, dosing wi th study  medicat ion had not y et 
started or dosing wit h study  medicat ion was already  stopped before the onset of the AE.
Drug interrupted –the dose was interrupted due to the particular AE.
10.2.7 Outcome 
Recovered/reso lved –subject returned to first assessment status with respect to the AE.
Recovering/resolving –the intensit y is lowered by  one or m ore stages: the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the b aseline value; the subject died fro m a cause other 
than the particular AE with the condit ion rem aining “recovering/resolving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, signs/sympto ms or laboratory  value on the l ast day  of the observed 
study peri od has beco me worse than when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE state remaining “Not recovered/not 
resolved.”
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 98of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALRecovered/Resolved with sequelae –the subject recovered fro m an acute AE but was left wit h 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal  –an AE that is considered as the cause of d eath.
Unknown –the course of the AE cannot be fo llowed up due to hospi tal change or residence 
change at the end of the subject’s participation in the study .
10.2.8 Collection and Reporting of AEs, SAEs, AESIs, and Abnormal LFTs
10.2.8.1 Collection Period
Collect ion of AE s (ie, AEs, SAEs, AESIs, and abnormal LFTs) will commence at the time the 
subject signs the informed consent. Routine collection of AEs will cont inue until approximately 30 
days after the last dose of invest igational product. For subjects who discontinue p rior to the 
administration of study  medicati on, AEs will  be followed until the subject discont inues study 
participat ion. 
10.2.8.2 Reporting AEs
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have y ou been feeling since y our l ast visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing an 
SAE prior to the first exposure to invest igational product must be monitored un til the symptom s 
subside and any clinically relevant changes in laboratory values have returned to Baseline or there 
is a sat isfactory  explanat ion for the change. Nonserious AEs that begin prior to the first exposure 
to invest igational product, related or unrelated to the study  procedure, need not be fo llowed-up for 
the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study medicat ion 
or not, m ust be m onitored until the symptoms subside and any clinically  relevant ch anges in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the dr ug treatm ent. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and end date and time.
Pattern of AE (frequency).
Severit y/Intensi ty.
Causalit y (Invest igator’s opinio n of the causal relationship between the event and 
administra tion of  study  drug).
Action taken with study  drug.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 99of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALOutcom e of event.
Seriousness.
10.2.8.3 Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A Takeda SAE form must be co mpleted, in En glish and signed by the invest igator immediately or 
within 24 hours of first onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the eve nt is categori zed as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the study  medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 14.1.1 .
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
Reporting of SAEs that begin before first administration of investigational product will fo llow the 
same procedure for SAEs occurring on treatment.
10.2.8.3.1 SAE Follow -Up
If informat ion is not available at the time o f the first report becomes available at a later date, the 
investigator s hould complete a fo llow-up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. The site must use the eCRF to report an SAE within 
24 hours, and, only if the eCRF is unavailable, should the site send a safet y reporting form. Copies 
of any relevant data from the hospital notes (eg, ECGs, laboratory  tests, di scharge summary , 
postm ortem  resul ts) shoul d be sent to the addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of th e event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 100of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL10.2.8.4 Management of Specific AEs
10.2.8.4.1 Sinus Tachycardia
CTCAE Grade Management
CTCAE v5.0 Grade 2 sinus tachycardia 
(ie, Sy mptomatic a; nonurgent medical 
interv entio n indicated) with HR 120 and 
above at rest for at least 5 minutes with 
no phy sical exertion. Evaluate ECG for abnormalities, manage as per local guidelines and call 
the medical monitor immediately. 
Any CTCAE v5.0 Grade 3 sinus 
tachycardia (ie, urgent medical 
intervention indicated) o r Grade 4 
(life-threatening)Evaluate ECG for abnormalities, manage as per local guidelines and call 
the medical monitor immediately. 
In all subjects, discontinue further treatment with study drug.
CTCAE: Common Te rminology Criteria for Adverse Events; ECG: electrocardiogram.
a Symptoms may include dizziness, light headedness, chest pain, chest heaviness, palpitations, and shortness of breath.
If a subject complains of palpitat ions, dizziness, breathlessness, chest ti ghtness, or any  other 
symptoms suggest ive of arrhyt hmia, the subject should be advised to lie flat, and pulse and BP 
shoul d be measured and recorded, followed by a 12 -lead ECG (urgently if hypotensio n is detected; 
otherwi se as soon as i s feasible). The BP, pulse, and ECG measurements will be reviewed by the 
investigator, who will use their clinical judgment regarding further monitoring and management.
10.2.8.4.2 Low BP
If a subject develops symptoms suggest ive of hypotension or postural hypotensio n, BP should be 
assessed for evidence of hypotension, which should be managed as per local guidelines, and the 
medical mo nitor should be contacted. TAK -510 administration will be discontinued on occurrence 
of an event of CTCAE v5.0 Grade ≥3 hypotension (ie, requiring m edical intervent ion).
If systolic BP is <85 mmHg or if the subject is experiencing symptoms suggestive of postural 
hypotension after standing, the subject should be advised to lie flat, and BP and HR should be 
rechecked in that posit ion. If systo lic BP re mains <85 mmHg, a 12 -lead ECG shoul d be 
perform ed and the investigator will use their clinical judgment regarding further monitoring and 
management. 
10.2.8.4.3 Injection Site Reaction
If a subject develops a CTCAE v5.0 Grade 3 (ulceration or necrosis; severe tissue damage; need 
for operative intervent ion) or Grade 4 (life -threatening consequences; urgent intervention 
indicated), discont inue administration of TAK -510, provi de immediate treatment, and contact the 
medical mo nitor. Any inject ion site reaction assessed a s a CTCAE v5.0 Grade 2 (ie, pain, 
lipody strophy , edem a, phlebit is) shoul d be m anaged according to standard of care. Symptomat ic 
treatm ent shoul d be administered, and the invest igator shoul d contact the medical mo nitor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 101of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL10.2.8.4.4 Hypersensitivity
If anaphylaxis or other serious allergic react ions occur, TAK -510 administration will be 
discontinued immediately  and appropri ate m anagement init iated (eg, epinephrine, ant ihistamines, 
and further immediate care as necessary). 
10.2.8.5 Reporting of Abnormal LFTs
If a su bject is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN, the event should 
be recorded as an SAE and reported as per Section 10.2.8.3 . The investigator must contact the 
medical mo nitor for discussio n of the relevant subject details and possible alternat ive etio logies, 
such as acute viral hepatit is A or B or other acute liver disease. Follow -up laboratory  tests as 
described in Sect ion 9.2.9 must also be performed. 
10.2.9 Safety Reporting to Investigators, IRBs and/or IECs, and Regulatory Authorities 
The sponsor will be responsible for reporti ng all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory authorit ies, investigators and IRBs and/or 
IECs, as applicable, in accordance with nat ional regulat ions in the countries where the study  is 
conducted. Relat ive to the first awareness of the event by/or further provisio n to the sponsor or 
sponsor’s designee, SUSARs will be submitted within 7 days for fatal and life -threatening events 
and 15 days for other serious events, unless otherwise req uired by nat ional regulat ions. The 
sponsor will also prepare an expedited report for other safet y issues where these might materially 
alter the current benefit -risk assessment of an investigat ional medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal products administration or in the 
overall conduct of the study . The invest igational site al so will forward a copy  of all expedited 
reports to his or her IRB and/or IEC in accordance with national regulat ions.
11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized before database lock. This document will 
provi de further details regarding the definit ion of analysis variables and analysis methodology  to 
address all study  object ives.
A targeted data review will be conducted before database lock. This review will assess the 
accuracy  and com pleteness of the study  database, subject evaluabilit y, or appropri ateness of the 
planned statistical methods.
The impact du e to COVID -19 will be summarized and listed based on all randomized subjects, 
where appropriate.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 102of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL11.1.1 Analysis Sets
11.1.1.1 Safety Analysis Set
The safet y analysis set consists of all subjects who are randomized and receive at least 1 dose of 
study  treatm ent. Subj ects will be analyzed according to the study  treatm ent actually  received.
11.1.1.2 PK Analysis Set
The PK analysis set consists of all subjects who receive at least 1 dose of TAK -510 and have at 
least 1 m easurable postdose plasma or urine concentration for TAK -510.
11.1.1.3 Immunogenicity Analysis Set
The immunogenicit y analysis set consists of all subjects who receive at least 1 dose of study  
treatm ent and have the baseline sample and at least 1 postbaseline sample ADA assessment.
11.1.2 Analysis of Demography and Other Baseline Charac teristics
Descript ive statistics (n, mean, standard deviation, median, minimum, and maximum) will be 
provi ded for continuous demographic variables and baseline characterist ics variables (eg, age, 
height, weight, and BMI) for placebo, each TAK -510 dose l evel (Parts 1 and 2)/dose regimen 
(Part 3), and TAK -510 overall in Parts 1, 2, and 3 separately. The number and percentage of 
subjects in each class of the categorical demographic variables and baseline characterist ics 
variables (eg, gender, ethnicit y, race) will be tabulated for placebo, each TAK -510 dose l evel 
(Parts 1 and 2)/dose regimen (Part 3), and TAK -510 overall in Parts 1, 2, and 3 separately. Placebo 
data will be pooled across cohorts within each part of the study . The sam e dose l evel (Parts 1 
and2)/dose regimen (Part 3) will be pooled across cohorts within each part of the study where 
appropriate. The safet y analysis set will be used to summarize the demographics and baseline 
characterist ics. All data will be provided in by -subject list ings.
11.1.3 PK Anal ysis
The pl asma (all  parts of the study ) and urine (Parts 1 and 2 only) concentrations of TAK -510 will 
be summarized by dose level (Parts 1 and 2 only)/dose regimen (Part 3 only) at each scheduled 
sampling day/t ime within each part of the study separately, using descri ptive statist ics (n, m ean, 
standard deviat ion, geom etric mean, percent coefficient of variation [%CV], median, minimum, 
and maximum) based on the PK analysis set. The PK parameters of TAK -510 determined using a 
nonco mpart mental analysis approa ch will be summarized by dose level (Parts 1 and 2 only)/dose 
regimen (Part 3 only) of TAK -510, as appropri ate, wi thin each part of the study  separately , using 
descript ive statist ics (n, mean, standard deviat ion, geom etric mean, %CV, median, minimum, and 
maximum ) based on the PK analysis set. Dose proportionalit y may be assessed graphically  
(log-transform ed dose -norm alized C maxand AUC versus dose) and by using a power model within 
each part of the study separately as data allow; no formal statist ical co mpar isons will be conducted. 
The same dose level (Parts 1 and 2 only)/dose regimen (Part 3 only) may be pooled across cohorts 
within each part of the study  where appropriate. All data will be provided in by subject list ings.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 103of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALA populat ion PK analysis may be conducted and a more detailed description of these analyses will 
be given in a separate analysis plan. The results from these analyses will not be included in the 
CSR and may  be a standalo ne report.
11.1.4 Safety Analysis
Safety analyses will be based on the safet y analysis set. No formal statist ical tests or inference will 
be perform ed for safet y analyses. All safet y summary  analyses w ill be perform ed by  placebo, 
TAK -510 dose level (Parts 1 and 2 only)/dose regimen (Part 3 only), and TAK -510 overall wit hin 
each part of the study separately. In particular, the number and percentage of subjects with at least  
1 postdose value meet ing the s ponsor’s m arkedly  abnorm al criteria f or BP and HR will be 
provi ded. Pl acebo data will be pooled across cohorts within each part of the study. The same dose 
level (Parts 1 and 2 only)/dose regimen (Part 3 only) will be pooled across cohorts within each part
of the study  where appropriate. For Part 3 only, similar safet y summary analyses (excluding ADA 
assessments) will be performed for the single dose after washout from mult iple dose regimens o f 
TAK -510 by placebo, TAK -510 single dose level after washout, an d TAK -510 single dose overall 
after washout. All data will be provided in by subject list ings. 
11.1.4.1 AEs
The summary of treatment -emergent adverse events (TEAEs) will include the number and 
percentage of subjects with at least 1 TEAE by MedDRA System Organ Clas s and Preferred Term 
and by  placebo, each TAK -510 dose l evel (Parts 1 and 2)/dose regimen (Part 3), and TAK -510 
overall wit hin each part of the study  separately. Similar summary analyses will be provided for 
treatm ent-related TEAEs, SAEs, AESIs, and AEs le ading to permanent treatment discont inuat ion 
as well. will be For Part 3 only , similar summary  analyses of TEAEs will be performed for the 
single dose after 7 day s of washout from mult iple dose regimens o f TAK -510 by  placebo, 
TAK -510 single dose level afte r washout, and TAK -510 single dose overall after washout.
11.1.4.2 Clinical Laboratory Evaluations
Clinical laboratory  parameters will be summarized using descriptive statist ics for baseline, 
postdose, and change fro m baseline to postdose by placebo, each TAK -510 d ose level (Parts 1 
and2 only)/dose regimen (Part 3 only), and TAK -510 overall wit hin each part of the study  
separately . The number and percentage of subjects with at least 1 postdose value meeting the 
sponsor’s markedly abnormal criteria for clinical labo ratory  param eters will  be presented by  
placebo, each TAK -510 dose l evel (Parts 1 and 2 only)/dose regimen (Part 3 only), and TAK -510 
overall wit hin each part of the study  separately. For Part 3 only , similar summary  analyses of 
clinical laboratory data wil l be performed for the single dose after 7 days o f washout from mult iple 
dose regimens o f TAK -510 by  placebo, TAK -510 single dose level after washout, and TAK -510 
single dose overall after washout.
11.1.4.3 Vital Signs
Typically , BP and pulse assessments are made i n duplicate wi th an interval o f approximately  
2minutes between the 2 assessments. The invest igator can take a third BP and pulse assessment if 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 104of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALresul ts are inconsistent (as defined in Section 9.2.4 ). If the assessments are made in duplicate, the 
average value of the duplicate assessments will be used in the summary analysis. If the invest igator 
takes a thi rd BP and pul se assessment when results are inconsistent, the av erage value of the 2 
more consistent corresponding assessments (details will be provided in the statistical analysis plan ) 
will be used in the summary analysis.
Vital signs (including but not limited to BP) data will be summarized using descript ive statistics 
for baseline, postdose, and change from baseline to postdose by placebo, each TAK -510 dose leve l 
(Parts 1 and 2 only)/dose regimen (Part 3 only), and TAK -510 overall wit hin each part of the study 
separately . The number and percentage of subjects with at least 1 postdose value meeting the 
sponsor’s markedly abnormal criteria for vital signs (including by not limited to BP) will be 
presented by placebo, each TAK -510 dose l evel (Parts 1 and 2 only)/dose regimen (Part 3 only), 
and TAK -510 overall wit hin each part of the study separately. For Part 3 only, similar summary 
analyses o f vital signs data will be performed for the single dose after 7 days of washout from 
multiple dose regimens of TAK -510 by placebo, TAK -510 single dose level after washout, a nd 
TAK -510 single dose overall after washout.
All vital sign data will be listed by subject and treatment group for each part of the study .
11.1.4.4 ECG
ECG parameters (including but not limited to HR, QT/QTc, PR) will be summarized using 
descript ive statistics for baseline, postdose, and change fro m baseline to postdose by placebo, each 
TAK -510 dose level (Parts 1 and 2 only)/dose regimen (Part 3 only), and TAK -510 overall wit hin 
each part of the study  separately. The number and percentage of subjects with at least 1 postdose 
value meet ing the sponsor’s markedly abnormal criteria for ECG parameters (including but not 
limited to HR, QT/QTc, and increase from baseline in QT/QTc) will be presented by placebo, each 
TAK -510 dose level (Parts 1 and 2 only)/dose regimen (P art3 only), and TAK -510 overall wit hin 
each part of the study  separately. For Part 3 only , similar summary  analyses of ECG data will be 
perform ed for the single dose after 7 days of washout from mult iple dose regimens of TAK -510 by 
placebo, TAK -510 single dose l evel after washout, and TAK -510 single dose overall after 
washout.
ECG data will be listed by subject and treatment group for each part of the study .
11.1.4.5 Other Safety Parameters
Physical examinat ion findings will only be presented in the data list ings. 
11.1.5 Immunogenicity Analysis 
Immunogenicit y will be summarized using the immunogenicit y analysis set. The number and 
percentage of subjects in each category  of the immunogenicit y status (ADA -negat ive or 
ADA -positive, and low or high ADA t iter) will be tabulat ed by  placebo, TAK -510 dose l evel 
(Parts 1 and 2 only)/dose regimen (Part 3 only), and TAK -510 overall at scheduled time po ints 
within each part of the study  separately. The relat ionship between immunogenicit y status 
(ADA -negat ive or ADA -positive, and low or high ADA t iter) and PK, and safet y will be analyzed 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 105 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALif they are applicable. Placebo data will be pooled across cohorts within each part of the study. The 
same dose level (Parts 1 and 2 only)/dose regimen (Part 3 only) will be pooled across cohorts 
within each part of the study where appropriate. All data will be provided in by subject listings.
11.1.6 Biomark er Analysis 
Biomarker measurements will be summarized using the safety analysis set. The concentrations  
 at each time point (ie, Day -1 and ba seline [predose, Day 1]) will be summarized 
using descriptive statistics  (n, mean, standard deviation, geometric mean, %CV, median, 
minimum, and maximum) by placebo, TAK-510 dose level (Parts 1 and 2 only)/dose regimen 
(Part 3 only) within each part of the study separately. In addition, the number and percentage of 
subjects within each of the 4 categories defined by quartile (ie, 0 to <Q1, Q1 to < median, median 
to <Q3, ≥Q3) of  concentrations will be prese nted for each time  point by placebo, 
TAK-510 dose level (Parts 1 and 2 only)/dose regimen (Part 3 only) within each part of the study
separately. The change from baseline  will be summarized 
using descriptive statistics (n, mean, standard deviation, median, minimum, and maximum) by 
placebo, TAK-510 dose level (Parts 1 and 2 only)/dose regimen (Part 3 only), and TAK-510 
overall at scheduled time points within each part of the study separately. Placebo data will be 
pooled across c ohorts within each part of the study. The same dose level will be pooled across 
cohorts within each part of the study where appropriate. All data will be provided in by subject 
listings.
11.2 Interim Analysis
Safety, tolerability, and available PK data will be reviewed in a blinded manner after completion of 
each cohort in the dose escalatio n meeting and before next dose escalation stage in the study (see 
Section 6.0).
If a data-dependent internal decision is needed to inform the subsequent development of TAK- 510 
before database lock, an interim analysis may be deemed necessary. The details about situations 
when such a case occurs and associated interim an alyses will be provided in  the statistical analysis 
plan.
11.3 Determination of Sample Size
The selected sample sizes in Parts 1, 2, and 3 of the study are considered sufficient for evaluation 
of safety and tolerability of TAK-510 in healthy subjects. No formal statist ical hypothesis testing 
is planned in Parts 1, 2, or 3. Therefore, no formal power calculations were performed in the 
determination of the sample size for this study.
12.0 QUALITY CONTROL AND QUALITY ASSURANCE
12.1 Study-Site Monitoring Visits
Monitoring visits to the study site will be mad e periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents will be reviewed for verification of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. Property of Takeda: For Non-Commercial Use Only and Subjecdian, minian, m
gimen (gimen 
e studytudy sy
The samhe sa
opripriate. ate
data widata w
meetmeet inin
l decisiol decis
n interiminteri
urs and urs an
erminarmin
cted samcted sa
etety y and an
planned anne
determietermt to the Applicable Terms of Usentrationratio
e summe sum
medianmedia
y)/dose )/dos
ber and per and
, Q1 to Q1 to 
r each teach t i
yy) wi) wiyy thtiiii
121ect t
TAK -510
Study ID TAK -510-1001 Page 106of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALThe invest igator and study site guarantee access to source documents by the sponsor or its 
designee (CRO) and by the IRB and/or IEC. In the event a monitor cannot visit the site in a timely 
manner, alternat ive monitoring approaches, such as remote source verificat ion or telephone 
contact, may be used to ensure data qualit y and int egrity and maintain pat ient safet y.
All aspects of the study  and i ts docum entati on will be subject to review by the sponsor or the 
sponsor’s designee (as long as blinding is not jeopardi zed), including but not limited to the 
Invest igator’s Binder, study  drug, subj ect m edical records, informed consent documentation, and 
review of eCRFs and associated source documents. It is important that the invest igator and other 
study  personnel are available during the monitoring visits and that sufficient time is devoted to the 
process.
12.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study  subjects. Should othe r unexpected circumstances arise that have a 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB and/or IEC, as required) for medical and safet y assessments.
Significant deviat ions include, bu t are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. 
12.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any  other facili ty used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the sponsor should be notified 
immediately . The investi gator guarantees a ccess for qualit y assurance auditors to all study  
docum ents as described in Sect ion 12.1.
13.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declarat ion of Helsinki, 
and the ICH Harmonised Tripartite Guideline for GCP. Each invest igator will con duct the study  
according to applicable local or regional regulatory requirements and align his or her conduct in 
accordance with the “Responsibilit ies of the Investigator” that are listed in Appendix A. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 107of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL13.1 IRB and/or IEC Approval
IRBs and/or IECs must be const ituted according to the applicable state and federal/local 
requi rements of each participating region. The sponsor or designee will require documentation 
noting all names and tit les of members who make up the respect ive IRB and/or IEC. If any 
member of the IRB and/or IEC has direct participatio n in this study, written notificat ion regarding 
his or her abstinence fro m vo ting must also be obtained. Those Americas sites unwilling to provide 
names and t itles of all members due to privacy and co nflict of interest concerns should instead 
provi de a Federal Wide Assurance Number or comparable number assigned by the Department of 
Health and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB 
and/or IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a 
copy  of the informed consent form, and, if applicable, subject recruit ment materials and/or 
advert isements and other documents required by all applicable laws and regul ations, m ust be 
submitted to a central or local IRB and/or IEC for approval. The IRB’s and/or IEC’s written 
approval  of the protocol  and subject informed consent must be obtained and submitted to the 
sponsor or designee before commencement of the stu dy (ie, before shipment of the 
sponsor -supplied drug or study -specific screening activit y). The IRB and/or IEC approval must 
refer to the study  by exact protocol  title, number, and versio n date; ident ify versio ns of other 
docum ents (eg, informed consent fo rm) reviewed; and state the approval date. The sponsor will 
ship drug/notify  site once the sponsor has confirmed the adequacy  of site regul atory  
docum entati on and, when applicable, the sponsor has received permissio n from competent 
authori ty to begin the s tudy. Unt il the site receives drug/notificat ion no protocol activit ies, 
including screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB and/or IEC. This may 
include notificat ion to the IRB and/or IEC regarding proto col amendments, updates to the 
inform ed consent form , recrui tment m aterials intended for viewing by subjects, local safet y 
reporting requirements, reports and updates regarding the ongoing review of the study at intervals 
specified by the respective IRB an d/or IEC, and submissio n of the invest igator’s final status report 
to IRB and/or IEC. All IRB and IEC approvals and relevant documentation for these items must be 
provi ded to the sponsor or its designee.
Subject incentives should not exert undue influence for parti cipat ion. Payments to subjects must 
be approved by the IRB and/or IEC and sponsor.
13.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declarat ion of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 108of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALdate informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB and/or IEC approval of the 
inform ed consent form  and, if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB and/or IEC and the sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by  the IRB and/or IEC. In the event the subject is not capable of 
rendering adequ ate wri tten informed consent, then the subject’s legally  acceptable representative 
may provide such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given a mple opportunit y to: 
(1) inquire about details o f the study, and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informe d consent form  and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and prior to subject entering
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if ap plicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent f orm, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
Inform edconsent for optional DNA sample co llectio n and analysis will be co llected in a separate 
section of the study  informed consent form. Subjects who consented and provided a DNA sample 
can withdraw their consent for DNA sample analysis and request disposal of a stored sample at any 
time pri or to analysis. Notify  sponsor of consent wit hdrawal.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 109of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL13.3 Subject Confidentiality
The sponsor and designees affirm and uphol d the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study ,a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monito r or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to revie w the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
andautopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 13.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
13.4 Publication, Disclosure, and Clinical Study Registration Policy
13.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and inf ormation 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentatio ns must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Study Registrati on 
In order to ensure that information on clinical studies reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register all 
intervent ional clinical studies it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 110of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALcontact informat ion, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone numbe r to the callers request ing study  
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the study . The invest igative sites are encouraged to handle the study 
inquiries according to their esta blished subject screening process. If the caller asks addit ional 
questions bey ond the topic of study  enro llment, th ey shoul d be referred to the sponsor.
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
spon sor wi th a wri tten noti ce request ing that their informat ion not be listed on the registry  site.
13.4.3 Clinical Study Results Disclosure 
Takeda will post the results of clinical studies on ClinicalTrials.gov or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
13.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk of  injury  to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponso r’s designee.
14.0 ADMINISTRATIVE AND REFERENCE INFORMATION
14.1 Administrative Information
14.1.1 Study Contact Information 
Study  contact numbers can be found in the study manual, the communication plan, or other similar 
docum ents provi ded to the si te. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 111of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL14.1.2 INVESTIGATOR AGRE EMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert and any  other product information provided by  the sponsor. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Council for Harmonisat ion of Technical Requirem ents f or Pharm aceut icals for
Hum an Use, E6(R2) Good Clinical Pract ice: Consolidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and
regul ations.
Regulatory  requi rements for reporting serious adverse even ts defined in Sect ion10.2.9 of this
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 112of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL14.1.3 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Study -Related Responsibilit ies template. The vendors i dentified for specific study -related
activit ies will perform these act ivities in full or in partnership wi th the sponsor.
14.1.4 List of Abbreviations
ADA antidrug antibody
AE adverse event
AESI adverse event of special interest
Aet amount of drug excreted in urine from time 0 to time t
Aet1-t2 amount of drug excreted in urine from time 1 to time 2
Aeτ amount of drug excreted in urine during a dosing interval (τ) at steady state
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC area under the plasma concentration -time curve
AUC ∞ area under the plasma concentration -time curve from time 0 to infinity
AUC last area under the plasma concentration -time curve from time 0 to time of the last 
quantifiable concentration
AUC τ area under the plasma concentration -time curve during a dos ing interval, where tau (τ) is 
the length of the dosing interval
AV atrioventricular
BMI body mass index
BP blood pressure
bpm beats per minute
CL/F apparent clearance after extravascular administration, calculated using the observed value 
of the last quantifiable concentration
CL R renal clearance
Cmax maximum observed plasma concentration
COVID -19 coronavirus disease 2019
CRO contract research organization
CSR clinical study report
CTCAE Common Terminology Criteria for Adverse Events
Ctrough observed plasma concentration at the end of a dosing interval
CV coefficient of variation
ECG electrocardiogram
eCRF electronic case report form
FDA Food and Drug Administration
fe,t fraction of administered dose of drug excreted from urine from time 0 to time t
FIH first-in-human
FSH follicle -stimulating hormone
GCP Good Clinical Practice
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 113 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALGLP Good Laboratory Practice
HED human equivalent dose
HR heart rate
ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals 
for Human Use
IEC independent ethics committee
IRB institutional review boardLFT liver function test
MedDRA Medical Dictionary for Regulatory Activities
MRD multiple rising dose
NCI National Cancer Institute
NOAEL no-observed-adverse-effect level
NOEL no-observed-effect level
PPB plasma protein binding
PK pharmacokinetic(s)
QTcF QT interval with Fridericia correction method
Rac(AUC) accumulation ratio based on AUC τ
Rac(Cmax) accumulation ratio based on C max
RBC red blood cellSAE serious adverse event
SC subcutaneous(ly)
SRD single rising dose
t
1/2z terminal disposition phase hal f-life
tmax time of first occurrence of C max
TQT thorough QT
ULN upper limit of normal
Vz/F apparent volume of distribution during the terminal disposition phase after extravascular 
administration
WBC white blood cell
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UsePharmacharm
rrection rectio
n AUCAUC
ed on Cd on 
eventvent
us(ly)(ly)
sing dosing do
minal dispminal dis
me of fie of 
thorouthoro
up
TAK -510
Study ID TAK -510-1001 Page 114of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL15.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, m edical history , and concurrent conditions will be coded using the Medical Dictionary  for 
Regulatory  Activities (MedDRA). Drugs will be coded using the World Heal th Organizat ion Drug 
Dictionary.
15.1 Case Report Forms (Electronic and Paper)
The sponsor or its designee will supply investigative sites with access to eCRFs. The sponsor will 
make arrangements to train appropriate site staff in the use of the eCRF. These for ms are used to 
transmit the informat ion collected in the performance o f this study  to the sponsor and regulatory  
authori ties. eCRFs must be completed in English. Data are transcribed direct ly onto eCRFs.
After complet ion of the entry process, computer logi c checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d addi tionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of t he clinical study database, any change of, modificat ion of, or addit ion to the data 
on the eCRFs should be made by the investigator with use of change and modificat ion records of 
the eCRFs. The principal investigator must review the data change for complet eness and accuracy, 
and must sign and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital re
cords pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
15.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed a nd dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 115 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALdocumentation printed on degradable thermal sensitive paper should be photocopied by the site 
and filed with the original in the subject’s char t to ensure long-term legibility. Furthermore, 
ICH E6(R2) Section 5.5.11 requires the investigator to retain essential documents specified in ICH 
E6(R2) (Section 8) until at least 2 years after the last approval of a marketing application for a 
specified drug indication being investigated or, if an application is not approved, until at least 
2 years after the investigation is discontinued and regulatory authorities are notified. In addition, 
ICH E6(R2) Section 5.5.11 states that the study records should be retained until an amount of time 
specified by applicable regulatory requirements or for a time specified in the Clinical Study Site 
Agreement between the investigator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator and the head of the institution should contact and receive written approval from the 
sponsor before disposing of any such documents.
16.0 REFERENCES
2. Wang S, Oestricker LZ, Wallendorf MJ, Sterl K, Dunai J, Kilpatrick CR, et al. Cholinergic 
signaling mediates the effects of xenin-25 on s ecretion of pancreatic polypeptide but not 
insulin or glucagon in humans with impaired glucose tolerance. PLoS One 
2018;13(2):e0192441.
Property of Takeda: For Non-Commercial Use Only an K, DunK, Du
on secreon secre
aired glired gject to the Applicable Terms of UseH 
a 
east ast 
additaddit ioi
mount omount o
ical Stucal St
on recorn reco
written aptten
and Subje
perty of Takeda: For Non-Commercial U
TAK-510
Study ID TAK-510-1001 Page 116 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIAL10. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials
for Therapeutics in Adult Healthy Volunteers. US Dept of Health and Human Services, Food
and Drug Administration, Center for Drug Evaluation and Research. 06 July 2005. Publication
No. 5541.
13. ICH Harmonised Tripartite Guideline: Guidance on Nonclinical Safety Studies for the
Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2).
International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceut icals for Human Use. 11 June 2009. Publication No. M3(R2).
14. Guidance for Industry: Safety Testing of Drug Metabolites. U.S. Department of Health and
Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
(CDER). March 2020 Revision 2.
15. Abdullah N, Beg M, Soares D, Dittman JS, McGraw TE. Downregulation of a GPCR by
beta-Arrestin2-mediated switch from an endosomal to a TGN recycling pathway. Cell Rep
2016;17(11):2966-78.
Property of Takeda: For Non-Commercial Use Only and Subjenclinicaclinic
uthorizauthoriz
chnical hnica
 PublicPubl
Drug Merug Me
nistratiostrati
Dittman ttma
ch from h from
rty of Takeda: For Non-Commble Terms orialsals
es, Foodes, Foo
PublicaublicUseof Us
ject to the Applicab
TAK -510
Study ID TAK -510-1001 Page 117of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL17.0 APPENDICES
Appendix AResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on inv estigators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form  FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
study -related duti es and funct ions, the invest igator/inst itution shoul d ensure that this 
individual or party  is qualified to perform those study -related duti es and functi ons and shoul d 
implement procedures to ensure the integrity  of the study -related duti es and funct ions 
perfor med and any data generated.
4.Ensure that study  related procedures, including study  specific (nonrouti ne/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies /authori ties.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regu latory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
8.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
9. Obtain valid informed con sent f rom each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, t hen the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital recor ds, laboratory  resul ts, etc, and maintain these data for a minimum o f 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 118of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator sho uld 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
11.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
12.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
13.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 119of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALAppendix BElements of the Subject Informed Consent
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When ther e is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any medi cal treatments are available if injury occurs and, if so, 
what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to th e subject for participat ing in the study.
18.An explanat ion of whom to contact for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
19.A statem ent that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefit s to whi ch the subject otherwise is ent itled, and that the subject or the subject’s 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 120of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALlegally acceptable representative may discont inue participa tion at any  time wi thout penal ty or 
loss of benefit s to whi ch the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.A statement that results of DNA a nalysis will not be disclo sed to an individual, unless 
prevailing laws require the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her co ntained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of condu cting the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assist ing Takeda, its affiliates, and licens ing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and y our name will not be di sclosed outsi de the clinic unless required by l aw;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and effect iveness o f the study  medicat ion(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawa l from the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 121of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL25.Male subje cts m ust use highly effect ive contraceptio n (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study  and f or 5 half -lives 
after the last dose of study drug. If the partner of the subject is found to be pre gnant during the 
study , the investigator will offer the subject the choice to receive unblinded treatment 
inform ation. 
26.A statement that clinical study  informat ion from this study  will be publicly disclo sed in a 
publicly  accessible website, such as Clinica lTrials.gov.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 122of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALAppendix CInvestigator Consent to the Use of Personal Information 
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informa tion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondenc e, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study .
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical study  registri es, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 123of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALAppendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the study , and for 5 half -lives after 
last dose of study  drug, nonsterilized** male subjects who are sexually  active wi th a female 
partner of childbearing poten tial* must use barri er contracepti on (eg, condom  with spermicidal 
cream  or jelly). In addit ion, they  must be advised not to donate sperm during this period. Females 
of childbearing potential who are partners of male subjects are also advised to use addit ional 
contraception as shown in the list containing highly  effect ive/effect ive contraception below.
Definitions and Procedures for Contraception and Pregnancy Avoidance
The follow ing definitions apply for contraception and pregnancy avoidance procedures.
* Awom an is considered a woman of childbearing potential, ie, fert ile, fo llowing menarche and 
until becoming postmenopausal unless permanent ly sterile. Permanent sterilizat ion methods 
include hysterectomy, bilateral tubal ligat ion, bilateral salpingectomy, a nd bilateral oophorectomy. 
A postm enopausal  state is defined as no menses for 12 months without an alternat ive medical 
cause. A high FSH level in the postmenopausal range (FSH >40 IU/L) may be used to confirm a 
postm enopausal state in y ounger women (eg, th ose aged <45 y ears) or wom en who are not using 
horm onal contracepti on or horm onal replacement therapy. However, in the absence of 12 months 
of amenorrhea, a single FSH measurement is insufficient.
** No restrict ions are required for a vasectomized male sub ject provided the subject is at least 
1year after bilateral vasectomy. A male subject whose vasectomy procedure was performed less 
than 1 y ear before the first dose of study  drug m ust follow the same restrict ions as a 
nonvasectomized man.
The follow ing pr ocedures apply for contraception and pregnancy avoidance.
1.Highly effect ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correct ly)”. In this study, where medications and devices containing hormones are 
included/excluded, the only acceptable methods of contraception are: 
Non-Hormonal Methods: 
–IUD (Intrauterine device).
–Bilateral tubal occlusio n.
–Vasectomized partner (provided tha t partner i s the sole sexual partner of the study  
participant and that the vasectomized partner has received medical assessment of the 
surgi cal success ).
Horm onal Methods: Horm onal contracepti on m ay be suscept ible to interaction with the 
investigat ive co mpound, com parator, concomitant medicat ions, which may reduce the 
efficacy  of the contracepti on method.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 124of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL–Combined (estrogen and progestogen) hormonal contraception associated with 
inhibit ion of ovulation initiated at least 3 months prior to the first dose of study  drug 
OR combined with a barrier method (male condom, female condo m or diaphragm) if 
for shorter durati on unt il she has been on contraceptive for 3 months;
Oral.
Intravaginal (eg, ring).
Transdermal.
–Progestogen -only hormonal contracepti on associ ated with inhibit ion of ovulation 
initiated at least 3 months prior to the first dose of study drug OR combined with a 
barrier method (male condo m, female condo m or diaphragm) if shorter till she has bee n 
on contraceptive for 3 months;
Oral.
Injectable.
Implant able.
2.If genotoxicit y/teratogenicit y/embry otoxi city is unlikely  to be caused by  the investi gational 
drug, com parator, background therapy  or standard of care medications,effect ive methods of 
contraception (there may  be a hi gher than 1% failure rate) are: 
Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams PLUS male condo m).
Progestogen only hormonal contraception, where inhibit ion of ovulat ion is not the primary 
mode of act ion PLUS condom wit h or without spermicide.
3.Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/sponge wi thout spermicide and wit hout condom .
Sexual abst inence is NOT an acceptable method of contraception.
4.Subjects will be provided with information on highly effect ive/effect ive methods of 
contraception as part of the subject informed co nsent process and will be asked to sign a 
consent form stating that they  understand the requirements for avoidance of pregnancy, 
donati on of  ova, and sperm donat ion during the course of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 125of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIAL5.During the course of the study, regular serum hCG (human ch orionic gonadotropin) pregnancy 
tests will be performed for female subjects, and all subjects (male and female) will receive 
continued guidance with respect to the avo idance of pregnancy and sperm donat ion as part of 
the study  procedures. Such guidance sho uld include a reminder of the fo llowing:
a)contraceptive requirements of the study
b)reasons for use of barrier methods (ie, condom) in males with pregnant partners
c)assessment of subject compliance through questions such as
i.Have you used the contraception cons istent ly and correctly since the last visit ?
ii.Have y ou forgotten to use contraception since the last visit ?
iii.Are y our menses l ate (even in wom en wi th irregular or infrequent menstrual cy cles a 
pregnancy test must be performed if the answer is “yes”)
iv.Is ther e a chance y ou coul d be pregnant ?
Pregnancy
Women of childbearing potential will not be included in this study .
If any subject is found to be pregnant during the study , she shoul d be wi thdrawn and any  
sponsor -supplied drug should be immediately discontinue d. In addi tion, any pregnancies in the 
partner of a male subject during the study  or for 5 half- lives after the l ast dose should also be 
recorded fo llowing authori zation from the subject’s partner. 
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment informat ion, the individual blind should be broken by the invest igator. 
If the female subject and/or female partner of a male subject agrees to the primary care physician 
being informed, the invest igator should notify the primary care physician that the female 
subject/female partner of the subject was participating in a clinical study  at the time she became 
pregnant and provide details o f the study  drug the subject received (blinded or unblinded, as 
applicable).
All pregnancies, including female partners of male subjects, in subjects on active study  drug 
(including co mparator, if applicable) will b e followed up to final outcome, using the pregnancy  
form. Pregnancies will remain blinded to the study team. The outcome, including any  premature 
termination, must be reported to the sponsor. An evaluat ion after the birth o f the child will also be 
conducte d.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 126of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALAppendix EProtocol History
Date Amendment NumberAmendment Type (for regional 
Europe purposes only) Region
21April 2022 Amendment 3 Substantial Global
02 September 2021 Amendment 2 Substantial Global
19 May  2021 Amendment 1 Substantial Global
02 December 2020 Initial protocol Not applicable Global
Protocol Amendment 2 Summary and Rationale:
This sect ion describes the changes in reference to the protocol incorporating Amendment 2. The 
primary  reasons for thi s amendment are to: 
1.Add serum sampling for measurement of creatine kinase levels.
2.Add at l east 24 hours of continuous telemetry  monitorin g before the first dose.
3.Include addit ional guidance for the investigator regarding vital sign assessments collected 
before dosi ng.
4.Specify  that only  serum  electroly tes (sodi um, potassium , chloride, and carbon dio xide) are 
measured at the 4 -hour postdose t ime po int on Day 1.
5.Add co llection of a blood sample for DNA at discharge or at early terminat ion in all study  
parts. 
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affect ing the conduct of the study  are includ ed for clarificati on and administrati ve purposes only.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 127of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 2
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
1. Section 3.1 Part 1 for SRD Cohorts 
1 to 
Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2
Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3 Section 
3.3.2 Part 3 Screening Through 
Day 1 Assessments
Section 9.2.6.2 TelemetryTable 3.a, Table 3.b, Table 3.c, 
Table 3.f, Table 3.g
Added at least 24 hours of 
continuous telemetry monitoring 
before the first dose of TAK -510 or 
placebo. 
Added predose telemetry 
extractions time -matched to 
extractions on Day 1. 
Section 9.2.6.2 Telemetry
Changed “approximately 2 hours 
before dosing through to 
approximately 24 hours postdose” 
to “at least 24 hours before dosing 
and at least 24 hours postdose” of 
cardiac monitoring.
Revised “23.5 hours of continuous 
cardiac monitoring” to “48 hours of 
cardiac monitoring (24 hours 
predose and 24 hours postdose).”To extend baseline telemetry 
measurements to a period of 
at least 24 hours before 
dosing to aid in evaluation of 
any rhythm findings 
following dosing. 
To add predose telemetry 
extraction time points to 
support future 
concentration -QT analysis. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 128of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 2
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
2. Section 3.1 Part 1 for SRD Cohorts 
1 to 
Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2
Section 3.2.2 Part 2 Scree ning 
Through Day 1 Assessments 
Section 3.2.3 Part 2 Days 2 to 4 
Assessments
Section 3.2.4 Part 2 Day 5 Through 
Day 9 Assessments, Follow -Up, 
and Early Termination
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3
Section 3.3.2 Part 3 Screening
Through Day 1 Assessments
Section 3.3.3 Part 3 Days 2 to 6 
Assessments
Section 3.3.4 Part 3 Day 7 and Day 
8 Assessments
Section 3.3.5 Part 3 Day 9 Through 
Day 15 Assessments, Follow -Up, 
and Early Termination 
Section 9.2.6.2 TelemetryTable 3.a, Table 3.b, Table 3.c, 
Table 3.d, Table 3.e, Table 3.f, 
Table 3.g, Table 3.h, Table 3.i, 
Table 3.j
Clarified that telemetry is 
electrocardiogram 12 -lead 
telemetry.Clarification
3. Section 3.1 Part 1 for SRD Cohorts 
1 to Table 3.a
Rem oved X indicating telemetry 
extraction from the Day 1 Hour 0 
time point in Part 1. To remove an extraction time 
point that is redundant with 
the predose extraction on 
Day 1.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 129of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 2
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
4. Section 3.1 Part 1 for SRD Cohorts 
1 to 
Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2
Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments
Section 3.2.4 Part 2 Day 5 Through 
Day 9 Assessments, Follow -Up, 
and Early Termination
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3
Section 3.3.2 Part 3 Screening 
Through Day 1 Asses sments
Section 3.3.4 Part 3 Day 7 and Day 
8 Assessments
Section 3.3.5 Part 3 Day 9 Through 
Day 15 Assessments, Follow -Up, 
and Early Termination
Section 9.2.9.2 ChemistryTable 3.a, Table 3.b, Table 3.c, 
Table 3.e, Table 3.f, Table 3.g, 
Table 3.i, Table 3.j
Added serum sample collection of 
creatine kinase (CK) at pre -and 
postdose time points on Day 1, at 
discharge, and at early termination.
Added footnote to allow for 
additional serum samples for CK at 
the investigator’s discretion if CK 
is elevated in an i ndividual subject 
after dosing, and to note that the 
medical monitor will be updated 
regularly  on any  findings of 
elevated CK and plans for 
continued monitoring.To enable assessment of 
potential changes in CK 
levels after TAK -510 dosing 
and to evaluate an y 
association with events of 
myalgia.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 130of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 2
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
5. Section 3.1 Part 1 for SRD Cohorts 
1 to 12
Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2
Section 3.2.4 Part 2 Day 5 Through 
Day 9 Assessments, Follow -Up, 
and Early Termination
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3
Section 3.3.4 Part 3 Day 7 and Day 
8 Assessments
Section 3.3.5 Part 3 Day 9 Through 
Day 15 Assessments, Follow -Up, 
and Early Termination
Section 6.1.2 Part 1: SRD Cohorts 
1 to 12
Section 6.1.3 Part 2: MRD Co horts 
13 to 17
Section 6.1.4 Part 3: Dose Titration 
and Redosing Cohorts 18 to 20
Table 9.a Primary Specimen 
Collections
Section 9.2.10.4 DNA 
MeasurementsTable 3.a, Table 3.b, Table 3.e, 
Table 3.f, Table 3.i, Table 3.j
Added collection of optional blood 
samples for DNA at discharge or at 
early  termination in all study parts.
Revised text to indicate that if 
subjects have provided consent for 
the optional DNA collection, both 
buccal swabs and blood samples 
should be collected.
Table 3.f
Rem oved statement th at only 
1DNA sample will be collected 
per subject from the footnote.Inclusion of optional blood 
samples for DNA 
sequencing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 131of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 2
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
6. Section 3.1 Part 1 for SRD Cohorts 
1 to 12
Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2
Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3
Section 3.3.2 Part 3 Screening 
Through Day 1 Assessments
Section 6.1.2 Part 1: SRD Cohorts 
1 to 12
Section 6.1.3 Part 2: MRD Cohorts 
13 to 17
Section 6.1.4 Part 3: Dose Titration 
and Redosing Cohorts 18 to 20
Section 9.3.1 Part 1 (SRD)
Section 9.3.2 Part 2 (MRD)
Section 9.3.3 Part 3 (Dose Titration 
and Redosing)Rem oved the option to admit 
subjects to the site on Day -1 if the 
Day -2 assessments can be 
performed on Day -1.To specify that subjects must 
be admitted to the site on Day 
-2 to allow for at least 24 
hours of continuous 
telemetry monitoring before 
the first dose of study drug.
7. Section 3.1 Part 1 for SRD Cohorts 
1 to 12
Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments
Section 3.3.2 Part 3 Screening 
Through Day 1 AssessmentsTable 3.a, Table 3.c, Table 3.g
Revised footnote for safety 
laborato ry assessments at the 
4-hour time points to specify that 
only serum chemistry to measur e 
electroly tes (sodium, potassium, 
chloride, and carbon dioxide) 
should be performed. To clarify the footnote by 
stating the measurements to 
be performed at the 4 -hour 
time points and removing the 
list of excluded 
measurements. 
8. Section 3.2.2 Part 2 S creening 
Through Day 1 Assessments
Section 3.2.3 Part 2 Days 2 to 4 
AssessmentsTable 3.c, Table 3.d
Rem oved footnote for samples for 
pharmacokinetics and metabolite 
identification stating that the 
24-hour sample o n Day 1 is the 
same as the predose sample on Day 
2.To remove redundancy with 
the footnote for the 24 -hour 
columns.
9. Section 4.3 Benefit/Risk Profile Updated blood sampling volume 
totals for each study part.To reflect the increase in 
blood sampling volume with 
the addition of sampling for 
DNA and CK.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 132of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 2
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
10. Section 6.1.2 Part 1: SRD Cohorts 
1 to 12
Section 6.1.3 Part 2: MRD Cohorts 
13 to 17
Section 6.1.4 Part 3: Dose Titration 
and Redosing Cohorts 18 to 20
Section 1.0 STUDY SUMMARYRem oved the phrase “due to 
reasons unrelated to safety” in 
statem ent that the approximate 
subject number accounts for 
potential replacement of subjects 
who withdraw.
Rem oved “for reasons unrelated to 
safety” from the statement 
describing replacement of subjects 
at the discretion of the sponsor 
after discussion with inve stigator. To align with language with 
Section 7.7, Subject 
Replacement, allowing 
replacement of subjects as 
appropriate following 
discussion between the 
investigator and sponsor.
11. Section 6.2.2 Criteria for 
Premature Termination or 
Suspension of the StudyAdded language “at rest while 
semirecumbent.”To clarify the stopping 
criterion related to sinus 
tachycardia.
12. Section 9.1.1.1 Assignment of 
Screening and Randomization 
NumbersAdded statem ent that rescreening 
of subjects will be considered on a 
case-by-case basis by the sponsor. To ensure that a discussion 
with the sponsor occurs 
before a subject is 
rescreened.
13. Section 9.2.4 Vital Signs Added additional guidance for the 
investigator regarding vital sign 
assessments collected before each 
dose.To allow for the 
investigator’s clinical 
assessment of vital signs 
before dosing on subsequent 
dosing days and to provide a 
window for discussion on a 
case-by-case basis between 
the investigator and the 
medical monitor.
14. Section 9.2.10.4.1 Buccal 
Epithelial Cells Sample and Blood 
Sample for DNAAdded statement that DNA 
sequencing analysis will not be 
reported in the clinical study 
report. To clarify the planned 
reporting approach for DNA 
analy sis. 
15. Section 12.1 Study -Site 
Monitoring VisitsAdded a statement that alternative 
monitoring approaches may be 
used in the event a monitor cannot 
visit the site in a timely manner.To allow remot e source data 
verification in extenuating 
circumstances.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 133of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 1 Summary and Rationale:
This sect ion describes the changes in reference to the protocol incorporating Amendment 1. The 
primary  reasons for thi s amendment are to: 
1.Modify exclusio n criteria for vital signs (including orthostatic assessments of heart rate [HR] 
and blood pressure [BP]). In particular, more specific criteria are implemented to account for 
intrasubject variabilit y with multiple Day  -1 assessments that impact subject eligibilit y for 
rando mizat ion.
2.Revise vital sign assessment and monitoring procedures (including orthostatic assessments of 
HR and BP).
3.Update the schedule of assessment tables to correct discrepancies.
4.Provi de cl arificat ion for some of the protocol language.
5.Provi de language in case the study  is affected by  the coronavi rus disease 2019 (COVID -19) 
pandemic.
In thi s amendment, minor grammat ical, editorial, formatting, and administrative changes not 
affect ing the conduct of the study  are included for cl arificati on and administrati ve purposes only.
Protocol Amendment 1
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
1 Section 2.0 STUDY SCHEMATIC
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3Figure 2.a 
Updated schematic to add a 
footnote for washout period.
Table 3.f, Table 3.j
Added text to footnote b (Table 3.f) 
and footnote a (Table 3.j) 
indicating t hat the duration of 
washout period may be shortened 
or lengthened in Cohorts 19 and 20.Added a footnote to reflect 
the flexibility of the washout 
period in Part 3 as previousl y 
detailed in the body of the 
protocol.
2 Section 3.1 Part 1 for SRD Cohorts 
1 to 12
Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments 
Section 3.3.2 Part 3 Screening 
Through Day 1 Assessments Tables 3.a, 3.c, 3.g 
Added a footnote to indicate that 
the 24 -hour sample on a given day 
is the same as the predose sample 
on the next day.To clarify that the 24 -hour 
measurements are the same 
as the next day predose 
measurements for vital signs. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK-510
Study ID TAK-510-1001 Page 134 of 137Protocol Incorporating Amendment No. 3 21 April 2022
CONFIDENTIALProtocol Amendment 1
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
3 Section 3.1 Part 1 for SRD Cohorts 
1 to 12
Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2 
Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments 
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3 
Section 3.3.2 Part 3 Screening 
Through Day 1 Assessments
Section 6.1.2 Part 1: SRD Cohorts 
1 to 12
Section 6.1.3 Part 2: MRD Cohorts 
13 to 17 
Section 6.1.4 Part 3: Dose Titration 
and Redosing Cohorts 18 to 20
Section 11.1.6 Biomarker AnalysisTable 3.a, 3.b, 3.c, 3.f, 3.g
For plasma sample for 
glucose-dependent insulinotropic polypeptide moved from collection at screening to collection at Day -1 Time 0 and updated the corresponding footnote and text accordingly.Modify timing of sample 
from screening to Day -1 for administrative and feasibility purposes.
4 Section 3.2 Part 2 for MRD 
Cohorts 13 to 17: Screening Through Day 9, Follow-Up, and Early Termination
Section 3.3 Part 3 for Dose 
Titration and Redosing Cohorts 18 
to 20: Screening Through Day 15, 
Follow-Up, and Early TerminationAdded a level 3 heading (Section 
3.2.1 and 3.3.1) to denote that Table 3.b is the overall schedule of events for Part 2 cohorts and Table 3.f is the overall schedule of events for Part 3.To clarify that da
y-by-day
schedules of events is preceded by an overall assessment table for Parts 2 and 3.
5 Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2
Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3
Section 3.3.2 Part 3 Screening 
Through Day 1 AssessmentsTable 3.b, Table 3.c, Table 3.f, 
Table 3.g
Removed X at Day -2 for BP and 
pulse (vital signs) and for standing BP and pulse.For consistency with tables 
in Part 1 SRD.
6 Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2
Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3 Table 3.b, 3.f, 
Changed individual “X”s to 
“X---continuous---X” as electrocardiogram (ECG) 
telemetry is a continuous reading.For consistency with ECG 
telemetry measurements with other tables.ffffofooo
ample ample 
o Day Day -1
e and feaand m
lth
p, and and 
r Dose Dose 
osing Coing C
ng Througg Thr
and Earland EaAddA
3lllUal
3.2.1 Ov2.1 O
y ProceduProced
ection 3.ction 
ThrougThrou
SecSe
SrN
eTak
eerpe
TAK -510
Study ID TAK -510-1001 Page 135of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 1
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
7 Section 3.2.1 Overall Schedule of 
Study Procedures for Part 2Table 3.b Shifted urine sample for 
pharmacokinetic (PK) from Day 7 
to Days 5 and 6.For consistency between 
overall schedule of 
assessments (SOA) for Part 2 
and the SOA detailing the 
individual day.
8 Section 3.2.2 Part 2 Screening 
Through Day 1 Assessments 
Section 3.3.2 Part 3 Screening 
Through Day 1 Assessments Table 3.c, 3.g
Changed ECG telemetry spanning 
from Day -1 through Day 1, to only 
Day 1.For consistency with other 
tables and telemetry 
procedure outline d in 
protocol.
9 Section 3.3.1 Overall Schedule of 
Study Procedures for Part 3
Section 6.1.4 Part 3: Dose Titration 
and Redosing Cohorts 18 to 20Table 3.f
Shifted Day 15 DNA sample to 
Day 8 (discharge) and modified 
footnote ‘m’ indicating that only 1 
DNA sample will be collected per 
subject.For consistency with other 
tables.
10 Section 3.3.2 Part 3 Screening 
Through Day 1 Assessments
Section 3.3.5 Part 3 Day 9 Through 
Day 15 Assessments, Follow -Up, 
and Early Termination Table 3.c, 3.g, 3.j
Rem oved glucose finger stick at 
Day -2 and Day -1 Hour 3; and Day 
13.Corrected errors on glucose 
finger sticks on Day -2 and 
Day -1 in this SOA. Now is 
consistent with other tables 
in the study.
11 Section 3.3.4 Part 3 Day 7 and Day 
8 AssessmentsTable 3.i
Adde d row for 12 -lead ECG at Day 
8 (discharge).Corrected error.
12 Section 7.1 Inclusion Criteria
Section 9.4.2 Women of 
Nonchildbearing Potential
Appendix D Pregnancy and 
ContraceptionAdded bilateral tubal ligation and 
bilateral salpingectomy to 
Inclusion Criteria 7.To include history of 
bilateral tubal ligation and 
bilateral salpingectomy as 
meeting criterion for surgical 
sterility for eligibility of 
female subjects.
13 Section 7.2 Exclusion Criteria
Section 1.0 STUDY SUMMARYModified exclusion criteria 
(#15-18) for semirecumbent blood 
pressure, heart rate, orthostatic 
hypotension, and orthostatic 
tachycardia.To control for intrasubject 
variability observed in vital 
signs in healthy subjects, in 
particular with multiple 
Day -1 time -matched 
assessments. R epeat 
measurements and flexibility 
for borderline values now 
detailed for orthostatic vital 
signs to account for 
variability while maintaining 
vital sign criteria for 
eligibility and dosing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 136of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 1
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
14 Section 7.2 Exclusion Criteria
Section 7.5 Criteria for 
Disco ntinuation or Withdrawal of a 
Subject
Section 11.1 Statistical and 
Analy tical PlansAdded Exclusion Criteria 19 for 
subjects who are excluded due to 
current coronavirus disease 2019 
(COVID -19) infection.
Added language for subject 
withdrawal for reasons re lated to 
COVID -19 pandemic.
Added language in case of impact 
in analysis due to COVID -19.Due to the COVID -19 
pandemic, language was 
added to exclusion criteria, 
subject withdrawal, and 
analy sis sections.
15 Section 9.2.4 Vital Signs
Section 3.0 SCHEDULE OF 
STUDY PROCEDURESModified vital signs procedures 
and updated relevant footnotes in 
SOAs for consistency.Modified to include 
procedures for repeat vital 
sign measurements detailed 
in exclusion criteria and how 
to report the repeat 
measurements .
16 Section 9.2.6 ECG Procedure Modified semirecumbent time 
from 10 minutes to 5 minutes.Required rest period before 
ECG extractions shortened 
for feasibility while 
maintaining quality of 
extractions.
17 Section 11.1.3 PK Analysis Added language for population PK 
analy sis.To better clarify possible 
additional PK analyses.
18 Section 10.2.8.4.1 Sinus 
TachycardiaModified language in sinus 
tachycardia management 
procedures. To clarify the language for 
management of a subject 
with sy mptoms suggestive of 
arrhy thmia. Removed 
language referring to 
management of grade 2 sinus 
tachycardia from this 
paragraph because the 
management of grade 2 sinus 
tachycardia is detailed in the 
existing table in Section 
10.2.8.4.1.
19 Appendix D Pregnancy and 
ContraceptionRem ove bullet for “true sexual 
abstinence” as a method of 
contraception.Rem oved language to fix 
discrepancy as sexual 
abstinence is not an 
acceptable method of 
contraception in this study.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
TAK -510
Study ID TAK -510-1001 Page 137of 137
Protocol Incorporating Amendment No. 3 21April 2022
CONFIDENTIALProtocol Amendment 1
Summary of Changes Since the Last Version of the Approved Protocol
Change 
NumberSections Affected by Change Description of Each Change and Rationale
Location Description Rationale 
20 Appendix D Pregnancy and 
ContraceptionRem ove urine hCG test. Serum samples will be 
collected for hCG to align 
with the schedule of 
assessments.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
  ELECTRONIC SIGNATURES
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
GFIF䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢵䢢䣶䣱䢢䣃䢢䣔䣣䣰䣦䣱䣯䣫䣼䣧䣦䢮䢢䣆䣱䣷䣤䣮䣧䢯䣄䣮䣫䣰䣦䢮䢢䣒䣮䣣䣥䣧䣤䣱䢯䣅䣱䣰䣶䣴䣱䣮䣮䣧䣦䢮䢢 䣒䣪䣣䣵䣧䢢䢳䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣶䣪䣧䢢䣕䣣䣨䣧䣶䣻䢮
䣖䣱䣮䣧䣴䣣䣤䣫䣮䣫䣶䣻䢮䢢䣣䣰䣦䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䣖䣃䣍䢯䢷䢳䢲䢢䣫䣰䢢䣊䣧䣣䣮䣶䣪䣻䢢䣕䣷䣤䣬䣧䣥 䣶䣵
&OLQLFDO3KDUPDFRORJ\$SSURYDO $SU87&
%LRVWDWLVWLFV$SSURYDO $SU87&
3KDUPDFRYLJLODQFH$SSURYDO $SU87&
&OLQLFDO6FLHQFH$SSURYDO $SU87&
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

$SUSU
$S